,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,33,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
13,35,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
14,37,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
15,39,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
16,41,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
17,43,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
18,45,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
19,47,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
20,49,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
21,53,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
22,55,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
23,59,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
24,67,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
25,71,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
26,73,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
27,77,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
28,79,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
29,81,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
30,83,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
31,87,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
32,91,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
33,93,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
34,95,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
35,97,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
36,99,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
37,101,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
38,107,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
39,109,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
40,113,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
41,115,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
42,119,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
43,121,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
44,123,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
45,125,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
46,131,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
47,137,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
48,139,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
49,141,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
50,143,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
51,145,1,1,,68760,2153,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
52,155,1,1,,68760,2153,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
53,157,1,1,,68760,2153,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
54,161,1,1,,68760,2153,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
55,165,1,1,,68760,2153,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
56,167,1,1,,68760,2153,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
57,175,1,1,,68760,2153,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
58,180,1,1,,68760,2153,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
59,228,1,1,,68760,2153,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
60,248,1,1,,68760,2153,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
61,328,1,1,,68760,2153,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
62,342,1,1,,68760,2153,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
63,357,2,1,,855679,2153,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
64,361,1,2,,855679,2153,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
65,364,1,3,,855679,2153,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
66,368,2,3,,855679,2153,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
67,371,1,1,,855679,2153,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
68,373,1,4,,855679,2153,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
69,374,2,3,,855679,2153,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
70,375,2,3,,855679,2153,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
71,411,2,1,,855679,2153,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
72,421,1,3,,17389715,2153,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
73,422,1,5,,855679,2153,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
74,425,3,2,,855679,2153,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
75,426,1,2,,17389715,2153,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
76,427,1,1,,17389715,2153,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
77,429,1,5,,855679,2153,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
78,429,1,5,,855679,2153,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
79,430,2,4,,855679,2153,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
80,431,2,4,,855679,2153,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
81,432,2,4,,855679,2153,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
82,433,1,1,,17389715,2153,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
83,434,1,2,,17389715,2153,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
84,435,1,2,,17389715,2153,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
85,436,2,1,,855679,2153,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
86,438,1,4,,855679,2153,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
87,440,3,3,,855679,2153,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
88,441,3,3,,855679,2153,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
89,444,1,1,,855679,2153,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
90,445,3,1,,17389715,2153,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
91,446,1,1,,855679,2153,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
92,449,1,5,,855679,2153,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
93,450,1,2,,855679,2153,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
94,453,2,2,,855679,2153,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
95,454,1,7,,855679,2153,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
96,455,1,7,,855679,2153,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
97,456,1,7,,855679,2153,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
98,457,1,7,,855679,2153,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
99,460,2,2,,855679,2153,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
100,483,1,6,,855679,2153,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
101,485,1,8,,855679,2153,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
102,487,1,2,,855679,2153,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
103,488,2,1,,855679,2153,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
104,501,2,2,,855679,2153,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
105,518,2,6,,855679,2153,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
106,521,2,5,,855679,2153,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
107,522,1,2,,855679,2153,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
108,524,1,3,,855679,2153,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
109,525,1,3,,855679,2153,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
110,527,3,1,,855679,2153,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
111,528,1,4,,855679,2153,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
112,529,1,4,,855679,2153,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
113,530,1,1,,17389715,2153,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
114,538,2,2,,855679,2153,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
115,539,1,2,,855679,2153,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
116,540,1,1,,17389715,2153,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
117,541,1,1,,17389715,2153,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
118,542,1,1,,17389715,2153,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
119,543,1,1,,17389715,2153,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
120,544,2,1,,17389715,2153,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
121,545,1,1,,17389715,2153,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
122,546,1,1,,17389715,2153,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
123,552,1,3,,855679,2153,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
124,555,1,2,,855679,2153,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
125,556,1,3,,855679,2153,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
126,559,2,2,,855679,2153,Inactive,147728.0,,,,RNA polymerase,Screening,,
127,560,1,2,,855679,2153,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
128,561,1,3,,855679,2153,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
129,565,1,4,,855679,2153,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
130,567,1,4,,855679,2153,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
131,568,1,7,,855679,2153,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
132,568,1,7,,855679,2153,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
133,570,1,4,,855679,2153,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
134,571,1,4,,855679,2153,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
135,572,1,5,,855679,2153,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
136,573,1,4,,855679,2153,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
137,574,1,3,,855679,2153,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
138,575,1,4,,855679,2153,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
139,576,1,2,,855679,2153,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
140,577,1,1,,855679,2153,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
141,580,1,5,,855679,2153,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
142,581,2,2,,855679,2153,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
143,583,2,6,,855679,2153,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
144,584,1,3,,17389715,2153,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
145,585,1,4,,17389715,2153,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
146,587,1,5,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
147,588,1,4,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
148,589,1,3,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
149,590,1,3,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
150,591,1,4,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
151,592,1,6,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
152,593,1,4,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
153,594,1,4,,855679,2153,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
154,595,1,3,,17389715,2153,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
155,596,1,2,,17389715,2153,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
156,597,1,3,,855679,2153,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
157,598,1,4,,855679,2153,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
158,601,1,4,,855679,2153,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
159,602,1,4,,855679,2153,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
160,603,1,2,,17389715,2153,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
161,604,1,3,,855679,2153,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
162,605,1,2,,17389715,2153,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
163,606,1,3,,855679,2153,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
164,606,1,3,,855679,2153,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
165,608,1,6,,11537637,2153,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
166,609,1,2,,855679,2153,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
167,614,1,6,,855679,2153,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
168,615,1,6,,855679,2153,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
169,618,2,6,,855679,2153,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
170,620,2,5,,855679,2153,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
171,622,1,2,,855679,2153,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
172,623,1,3,,855679,2153,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
173,624,1,2,,855679,2153,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
174,625,1,2,,855679,2153,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
175,626,1,3,,855679,2153,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
176,628,2,4,,855679,2153,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
177,629,1,3,,855679,2153,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
178,630,1,1,,855679,2153,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
179,631,1,4,,855679,2153,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
180,631,1,4,,855679,2153,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
181,633,1,3,,855679,2153,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
182,636,1,4,,855679,2153,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
183,637,1,4,,855679,2153,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
184,639,1,2,,855679,2153,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
185,641,1,4,,855679,2153,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
186,645,1,4,,855679,2153,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
187,648,1,3,,855679,2153,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
188,654,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
189,655,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
190,656,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
191,657,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
192,658,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
193,659,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
194,660,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
195,661,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
196,662,1,1,,17389715,2153,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
197,663,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
198,664,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
199,665,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
200,666,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
201,667,1,1,,17389715,2153,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
202,680,1,10,,855679,2153,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
203,684,1,12,,855679,2153,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
204,686,1,1,,855679,2153,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
205,687,1,17,,855679,2153,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
206,701,1,17,,855679,2153,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
207,708,1,4,,855679,2153,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
208,709,1,2,,855679,2153,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
209,719,1,3,,855679,2153,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
210,731,1,5,,855679,2153,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
211,731,1,5,,855679,2153,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
212,746,1,1,,855679,2153,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
213,750,1,3,,855679,2153,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
214,751,1,3,,855679,2153,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
215,757,1,4,,855679,2153,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
216,758,1,4,,855679,2153,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
217,759,1,4,,855679,2153,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
218,760,1,4,,855679,2153,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
219,761,1,4,,855679,2153,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
220,764,1,4,,855679,2153,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
221,770,1,1,,855679,2153,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
222,771,1,2,,855679,2153,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
223,772,1,2,,855679,2153,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
224,774,1,2,,855679,2153,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
225,775,1,3,,855679,2153,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
226,781,1,1,,855679,2153,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
227,782,1,2,,855679,2153,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
228,782,1,2,,855679,2153,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
229,784,1,4,,855679,2153,Inactive,55584151.0,2629.0,,,Primary Cell Based High Throughput Screening Assay for Enhancers of Beta-Glucosidase Activity,Screening,,
230,793,1,2,,855679,2153,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
231,795,1,1,,855679,2153,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
232,797,1,1,,855679,2153,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
233,798,2,12,,855679,2153,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
234,799,1,5,,855679,2153,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
235,800,2,11,,855679,2153,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
236,803,1,4,,855679,2153,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
237,804,1,3,,855679,2153,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
238,813,1,4,,855679,2153,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
239,817,1,1,,855679,2153,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
240,818,1,2,,855679,2153,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
241,827,1,2,,855679,2153,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
242,828,1,5,,855679,2153,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
243,834,1,3,,855679,2153,Inactive,,,,,C. albicans biofilm killing,Screening,,
244,841,1,1,,855679,2153,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
245,847,1,2,,855679,2153,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
246,861,1,1,,855679,2153,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
247,862,1,2,,855679,2153,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
248,868,1,3,,855679,2153,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
249,871,1,2,,855679,2153,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
250,873,1,13,,855679,2153,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
251,875,1,2,,855679,2153,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
252,875,1,2,,17389715,2153,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
253,878,1,2,,855679,2153,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
254,880,2,1,,855679,2153,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
255,880,2,1,,855679,2153,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
256,880,2,1,,17389715,2153,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
257,880,2,1,,17389715,2153,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
258,880,2,1,,26746955,2153,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
259,880,2,1,,26746955,2153,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
260,880,2,1,,26751482,2153,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
261,880,2,1,,26751482,2153,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
262,880,2,1,,29215004,2153,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
263,880,2,1,,29215004,2153,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
264,880,2,1,,50103997,2153,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
265,880,2,1,,50103997,2153,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
266,880,2,1,,50103998,2153,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
267,880,2,1,,50103998,2153,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
268,881,2,2,,855679,2153,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
269,881,2,2,,17389715,2153,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
270,881,2,2,,26751482,2153,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
271,884,1,2,,855679,2153,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
272,884,1,2,,17389715,2153,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
273,885,1,2,,855679,2153,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
274,885,1,2,,17389715,2153,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
275,886,1,2,,17389715,2153,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
276,886,1,2,,17389715,2153,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
277,887,1,2,,855679,2153,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
278,887,1,2,,17389715,2153,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
279,889,1,3,,855679,2153,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
280,889,1,3,,17389715,2153,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
281,892,1,2,,855679,2153,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
282,892,1,2,,17389715,2153,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
283,893,1,2,,855679,2153,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
284,893,1,2,,855679,2153,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
285,893,1,2,,17389715,2153,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
286,893,1,2,,17389715,2153,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
287,894,2,1,,855679,2153,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
288,894,2,1,,17389715,2153,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
289,894,2,1,,26746955,2153,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
290,894,2,1,,26751482,2153,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
291,898,1,1,,855679,2153,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
292,900,1,3,,855679,2153,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
293,900,1,3,,17389715,2153,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
294,902,1,2,,855679,2153,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
295,902,1,2,,17389715,2153,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
296,910,1,2,,855679,2153,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
297,912,1,2,,17389715,2153,Inconclusive,21392848.0,,0.7943,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
298,914,1,3,,855679,2153,Inconclusive,32879895.0,3091.0,3.1623,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
299,915,1,3,,855679,2153,Inconclusive,32879895.0,3091.0,3.1623,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
300,920,1,2,,855679,2153,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
301,921,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
302,923,1,2,,855679,2153,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
303,923,1,2,,17389715,2153,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
304,924,1,2,,855679,2153,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
305,924,1,2,,17389715,2153,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
306,925,1,2,,17389715,2153,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
307,926,1,2,,17389715,2153,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
308,927,1,3,,855679,2153,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
309,930,1,2,,855679,2153,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
310,932,1,4,,855679,2153,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
311,938,1,2,,17389715,2153,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
312,940,1,2,,855679,2153,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
313,940,1,2,,26611941,2153,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
314,946,1,2,,17389715,2153,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
315,947,1,2,,17389715,2153,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
316,948,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
317,950,1,1,,855679,2153,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
318,951,1,1,,855679,2153,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
319,952,1,1,,855679,2153,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
320,955,1,2,,17389715,2153,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
321,960,1,2,,17389715,2153,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
322,961,1,2,,17389715,2153,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
323,962,1,2,,17389715,2153,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
324,963,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
325,964,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
326,965,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
327,966,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
328,967,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
329,968,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
330,969,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
331,970,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
332,971,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
333,972,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
334,973,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
335,974,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
336,975,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
337,976,1,2,,17389715,2153,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-025,Confirmatory,,
338,977,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
339,978,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
340,979,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
341,980,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
342,981,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
343,982,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
344,983,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
345,984,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
346,985,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
347,986,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
348,987,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
349,988,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
350,989,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
351,993,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
352,994,1,2,,17389715,2153,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
353,995,1,2,,855679,2153,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
354,995,1,2,,17389715,2153,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
355,999,1,1,,46487916,2153,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
356,1001,2,2,,855679,2153,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
357,1004,1,1,,46487916,2153,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
358,1006,1,6,,855679,2153,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
359,1007,1,1,,855679,2153,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
360,1008,1,2,,855679,2153,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
361,1009,1,2,,855679,2153,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
362,1012,1,4,,855679,2153,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
363,1016,1,4,,855679,2153,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
364,1018,2,5,,855679,2153,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
365,1019,1,4,,855679,2153,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
366,1020,1,5,,855679,2153,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
367,1021,1,1,,855679,2153,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
368,1022,1,1,,855679,2153,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
369,1027,1,3,,855679,2153,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
370,1030,2,1,,855679,2153,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
371,1030,2,1,,17389715,2153,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
372,1030,2,1,,26746955,2153,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
373,1030,2,1,,26751482,2153,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
374,1030,2,1,,50103997,2153,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
375,1030,2,1,,50103998,2153,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
376,1032,1,2,,855679,2153,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
377,1032,1,2,,855679,2153,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
378,1033,2,2,,11537637,2153,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
379,1040,1,2,,855679,2153,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
380,1046,1,6,,855679,2153,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
381,1048,1,1,,855679,2153,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
382,1048,1,1,,855679,2153,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
383,1049,1,1,,855679,2153,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
384,1049,1,1,,855679,2153,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
385,1051,1,1,,855679,2153,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
386,1051,1,1,,855679,2153,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
387,1063,1,1,,855679,2153,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
388,1066,1,2,,855679,2153,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
389,1085,1,1,,855679,2153,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
390,1135,1,3,,855679,2153,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
391,1136,1,3,,855679,2153,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
392,1189,1,5,,48414525,2153,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
393,1194,1,3,,48414525,2153,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
394,1195,1,2,,48416606,2153,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
395,1199,1,3,,48414525,2153,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
396,1203,1,3,,855679,2153,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
397,1205,1,4,,48414525,2153,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
398,1208,1,3,,48414525,2153,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
399,1209,2,2,,855679,2153,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
400,1214,1,4,,855679,2153,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
401,1216,1,5,,855679,2153,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
402,1217,1,4,,855679,2153,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
403,1220,2,2,,855679,2153,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
404,1222,1,6,,855679,2153,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
405,1229,1,3,,855679,2153,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
406,1235,1,2,,855679,2153,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
407,1236,1,1,,855679,2153,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
408,1239,1,3,,855679,2153,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
409,1239,1,3,,855679,2153,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
410,1242,1,1,,855679,2153,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
411,1251,1,1,,855679,2153,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
412,1273,1,1,,855679,2153,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
413,1274,1,2,,855679,2153,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
414,1276,1,1,,855679,2153,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
415,1285,1,1,,855679,2153,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
416,1296,1,1,,855679,2153,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
417,1304,1,2,,855679,2153,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
418,1321,1,2,,855679,2153,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
419,1325,1,2,,855679,2153,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
420,1326,1,4,,855679,2153,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
421,1332,1,1,,49698738,2153,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
422,1359,1,4,,855679,2153,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
423,1362,1,2,,855679,2153,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
424,1376,1,2,,855679,2153,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
425,1377,1,1,,855679,2153,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
426,1379,1,2,,855679,2153,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
427,1379,1,2,,26746955,2153,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
428,1379,1,2,,26751482,2153,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
429,1381,1,1,,855679,2153,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
430,1385,2,2,,855679,2153,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
431,1415,1,2,,855679,2153,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
432,1415,1,2,,855679,2153,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
433,1416,1,2,,855679,2153,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
434,1422,1,1,,855679,2153,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
435,1422,1,1,,26611941,2153,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
436,1423,1,2,,855679,2153,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
437,1423,1,2,,855679,2153,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
438,1424,1,1,,855679,2153,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
439,1430,1,1,,855679,2153,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
440,1434,2,3,,855679,2153,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
441,1434,2,3,,855679,2153,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
442,1439,1,1,,855679,2153,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
443,1439,1,1,,855679,2153,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
444,1440,1,1,,855679,2153,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
445,1440,1,1,,855679,2153,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
446,1441,1,1,,855679,2153,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
447,1441,1,1,,855679,2153,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
448,1443,1,3,,855679,2153,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
449,1445,1,1,,855679,2153,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
450,1446,1,3,,855679,2153,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
451,1448,1,3,,855679,2153,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
452,1452,1,1,,855679,2153,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
453,1452,1,1,,17389715,2153,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
454,1452,1,1,,26751482,2153,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
455,1454,1,1,,855679,2153,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
456,1454,1,1,,26746955,2153,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
457,1456,1,1,,855679,2153,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
458,1457,1,1,,855679,2153,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
459,1457,1,1,,17389715,2153,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
460,1457,1,1,,26746955,2153,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
461,1457,1,1,,26751482,2153,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
462,1457,1,1,,50103997,2153,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
463,1457,1,1,,50103998,2153,Inactive,44888968.0,83523.0,7.9433,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
464,1458,1,1,,855679,2153,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
465,1458,1,1,,17389715,2153,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
466,1458,1,1,,26746955,2153,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
467,1458,1,1,,50103997,2153,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
468,1458,1,1,,50103998,2153,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
469,1460,1,3,,855679,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
470,1460,1,3,,26746955,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
471,1460,1,3,,26751482,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
472,1460,1,3,,50103997,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
473,1460,1,3,,50103998,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
474,1461,1,2,,855679,2153,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
475,1463,1,1,,855679,2153,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
476,1463,1,1,,26746955,2153,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
477,1463,1,1,,26751482,2153,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
478,1463,1,1,,50103997,2153,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
479,1463,1,1,,50103998,2153,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
480,1465,1,1,,855679,2153,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
481,1466,1,2,,855679,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
482,1467,1,3,,855679,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
483,1467,1,3,,26746955,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
484,1467,1,3,,26751482,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
485,1468,1,1,,855679,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
486,1468,1,1,,26746955,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
487,1468,1,1,,26751482,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
488,1468,1,1,,50103997,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
489,1468,1,1,,50103998,2153,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
490,1469,1,1,,855679,2153,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
491,1469,1,1,,17389715,2153,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
492,1469,1,1,,26746955,2153,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
493,1469,1,1,,26751482,2153,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
494,1469,1,1,,29215004,2153,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
495,1469,1,1,,50103997,2153,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
496,1469,1,1,,50103998,2153,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
497,1471,2,1,,17389715,2153,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
498,1471,2,1,,26746955,2153,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
499,1471,2,1,,26751482,2153,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
500,1471,2,1,,29215004,2153,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
501,1471,2,1,,50103997,2153,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
502,1471,2,1,,50103998,2153,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
503,1476,2,1,,855679,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
504,1476,2,1,,17389715,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
505,1476,2,1,,26746955,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
506,1476,2,1,,26751482,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
507,1477,1,1,,855679,2153,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
508,1477,1,1,,17389715,2153,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
509,1477,1,1,,26746955,2153,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
510,1477,1,1,,26751482,2153,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
511,1477,1,1,,50103997,2153,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
512,1477,1,1,,50103998,2153,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
513,1478,2,1,,855679,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
514,1478,2,1,,17389715,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
515,1478,2,1,,26746955,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
516,1478,2,1,,26751482,2153,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
517,1479,1,2,,855679,2153,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
518,1479,1,2,,17389715,2153,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
519,1479,1,2,,26746955,2153,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
520,1479,1,2,,26751482,2153,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
521,1479,1,2,,29215004,2153,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
522,1479,1,2,,50103997,2153,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
523,1479,1,2,,50103998,2153,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
524,1481,1,2,,855679,2153,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
525,1486,1,3,,855679,2153,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
526,1487,1,1,,855679,2153,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
527,1487,1,1,,29215004,2153,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
528,1490,2,1,,855679,2153,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
529,1490,2,1,,26746955,2153,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
530,1490,2,1,,26751482,2153,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
531,1490,2,1,,29215004,2153,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
532,1490,2,1,,50103997,2153,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
533,1490,2,1,,50103998,2153,Active,10954339.0,,56.2341,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
534,1496,1,4,,855679,2153,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
535,1496,1,4,,855679,2153,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
536,1509,1,2,,855679,2153,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
537,1510,1,3,,855679,2153,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
538,1511,1,3,,855679,2153,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
539,1515,1,2,,855679,2153,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
540,1519,1,3,,26746955,2153,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
541,1527,1,3,,855679,2153,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
542,1529,1,1,,855679,2153,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
543,1530,1,1,,855679,2153,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
544,1531,1,1,,855679,2153,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
545,1532,1,1,,855679,2153,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
546,1549,1,2,,11537637,2153,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
547,1552,1,3,,11537637,2153,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
548,1554,1,1,,855679,2153,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
549,1556,1,4,,855679,2153,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
550,1565,2,2,,855679,2153,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
551,1566,2,3,,855679,2153,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
552,1578,3,2,,855679,2153,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
553,1580,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
554,1581,1,1,,8149549,2153,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
555,1582,1,1,,8149549,2153,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
556,1583,1,1,,8149549,2153,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
557,1584,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
558,1585,1,1,,8149549,2153,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
559,1586,1,1,,8149549,2153,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
560,1587,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
561,1588,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
562,1589,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
563,1590,1,1,,8149549,2153,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
564,1593,1,1,,8149549,2153,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
565,1594,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
566,1595,1,1,,8149549,2153,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
567,1596,1,1,,8149549,2153,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
568,1597,1,1,,8149549,2153,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
569,1598,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
570,1599,1,1,,8149549,2153,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
571,1600,1,1,,8149549,2153,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
572,1601,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
573,1602,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
574,1603,1,1,,8149549,2153,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
575,1604,1,1,,8149549,2153,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
576,1605,1,1,,8149549,2153,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
577,1606,1,1,,8149549,2153,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
578,1607,1,1,,8149549,2153,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
579,1608,1,1,,8149549,2153,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
580,1609,1,1,,8149549,2153,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
581,1610,1,1,,8149549,2153,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
582,1611,1,1,,8149549,2153,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
583,1612,1,1,,8149549,2153,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
584,1613,1,1,,8149549,2153,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
585,1614,1,1,,8149549,2153,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
586,1616,1,1,,8149549,2153,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
587,1619,1,2,,855679,2153,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
588,1621,1,2,,855679,2153,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
589,1626,1,2,,855679,2153,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
590,1631,3,1,,855679,2153,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
591,1634,3,1,,855679,2153,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
592,1637,1,2,,11537637,2153,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
593,1648,1,2,,11537637,2153,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
594,1654,2,2,,855679,2153,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
595,1656,2,2,,855679,2153,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
596,1662,1,2,,855679,2153,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
597,1663,1,2,,855679,2153,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
598,1672,1,3,,855679,2153,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
599,1688,1,1,,855679,2153,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
600,1688,1,1,,29215004,2153,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
601,1700,1,2,,855679,2153,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
602,1706,1,2,,855679,2153,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
603,1721,1,2,,855679,2153,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
604,1722,1,2,,855679,2153,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
605,1766,1,1,,855679,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
606,1766,1,1,,855679,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
607,1766,1,1,,26746955,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
608,1766,1,1,,26746955,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
609,1766,1,1,,26751482,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
610,1766,1,1,,26751482,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
611,1766,1,1,,29215004,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
612,1766,1,1,,29215004,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
613,1768,1,1,,855679,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
614,1768,1,1,,855679,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
615,1768,1,1,,26746955,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
616,1768,1,1,,26746955,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
617,1768,1,1,,26751482,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
618,1768,1,1,,26751482,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
619,1768,1,1,,29215004,2153,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
620,1768,1,1,,29215004,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
621,1775,1,2,,855679,2153,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
622,1776,1,2,,855679,2153,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
623,1777,3,2,,855679,2153,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
624,1778,3,3,,855679,2153,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
625,1779,2,2,,855679,2153,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
626,1789,1,2,,855679,2153,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
627,1800,1,2,,855679,2153,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
628,1811,3,2,,46393768,2153,Active,78101195.0,,,,Experimentally measured binding affinity data derived from PDB,Other,,
629,1813,1,2,,855679,2153,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
630,1814,1,2,,855679,2153,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
631,1817,2,2,,855679,2153,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
632,1822,1,3,,855679,2153,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
633,1825,1,1,,855679,2153,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
634,1832,2,1,,855679,2153,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
635,1845,1,2,,855679,2153,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
636,1850,2,1,,855679,2153,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
637,1861,2,1,,855679,2153,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
638,1862,1,4,,855679,2153,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
639,1863,2,1,,855679,2153,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
640,1865,1,1,,855679,2153,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
641,1865,1,1,,26746955,2153,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
642,1865,1,1,,26751482,2153,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
643,1865,1,1,,50103997,2153,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
644,1865,1,1,,50103998,2153,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
645,1867,1,4,,855679,2153,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
646,1868,1,4,,855679,2153,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
647,1870,1,4,,855679,2153,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
648,1873,1,4,,855679,2153,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
649,1875,2,1,,855679,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
650,1885,2,1,,855679,2153,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
651,1887,1,4,,855679,2153,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
652,1899,1,3,,855679,2153,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
653,1903,2,3,,855679,2153,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
654,1906,1,3,,855679,2153,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
655,1910,1,2,,855679,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
656,1947,1,2,,855679,2153,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
657,1948,1,1,,17389715,2153,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
658,1948,1,1,,26746955,2153,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
659,1948,1,1,,26751482,2153,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
660,1950,1,3,,855679,2153,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
661,1956,1,1,,855679,2153,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
662,1961,2,2,,855679,2153,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
663,1962,1,2,,855679,2153,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
664,1974,1,2,,855679,2153,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
665,1984,1,3,,855679,2153,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
666,1986,1,2,,855679,2153,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
667,1987,1,2,,855679,2153,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
668,1996,2,2,,855679,2153,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
669,2006,3,2,,855679,2153,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
670,2006,3,2,,855679,2153,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
671,2006,3,2,,855679,2153,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
672,2012,3,2,,855679,2153,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
673,2013,2,2,,855679,2153,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
674,2014,3,2,,855679,2153,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
675,2016,1,3,,855679,2153,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
676,2023,1,3,,855679,2153,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
677,2025,1,3,,855679,2153,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
678,2029,1,3,,855679,2153,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
679,2052,2,1,,855679,2153,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
680,2057,1,2,,855679,2153,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
681,2058,3,2,,855679,2153,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
682,2061,1,2,,85209331,2153,Active,,,,,Ligands of nucleotide-like (Class A) GPCRs,Other,,
683,2066,1,4,,855679,2153,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
684,2071,2,2,,855679,2153,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
685,2073,2,3,,855679,2153,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
686,2073,2,3,,855679,2153,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
687,2094,1,2,,855679,2153,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
688,2094,1,2,,855679,2153,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
689,2094,1,2,,855679,2153,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
690,2097,1,2,,855679,2153,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
691,2098,1,1,,855679,2153,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
692,2099,1,1,,855679,2153,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
693,2100,1,1,,855679,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
694,2101,1,1,,855679,2153,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
695,2101,1,1,,17389715,2153,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
696,2101,1,1,,26746955,2153,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
697,2101,1,1,,26751482,2153,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
698,2101,1,1,,50103997,2153,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
699,2101,1,1,,50103998,2153,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
700,2107,1,1,,855679,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
701,2107,1,1,,17389715,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
702,2107,1,1,,26746955,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
703,2107,1,1,,26751482,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
704,2107,1,1,,50103997,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
705,2107,1,1,,50103998,2153,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
706,2112,1,1,,855679,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
707,2112,1,1,,17389715,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
708,2112,1,1,,26746955,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
709,2112,1,1,,26751482,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
710,2112,1,1,,50103997,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
711,2112,1,1,,50103998,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
712,2120,1,1,,17389715,2153,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
713,2129,1,2,,855679,2153,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
714,2130,1,3,,855679,2153,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
715,2147,1,1,,855679,2153,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
716,2147,1,1,,26746955,2153,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
717,2156,2,2,,855679,2153,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
718,2174,1,3,,855679,2153,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
719,2177,1,3,,855679,2153,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
720,2205,1,1,,855679,2153,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
721,2216,1,3,,855679,2153,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
722,2221,1,2,,855679,2153,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
723,2227,1,2,,855679,2153,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
724,2234,1,2,,855679,2153,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
725,2235,1,2,,855679,2153,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
726,2237,1,2,,855679,2153,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
727,2239,1,2,,855679,2153,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
728,2240,1,1,,85787353,2153,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
729,2240,1,1,,85789579,2153,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
730,2241,1,1,,85787353,2153,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
731,2241,1,1,,85789579,2153,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
732,2242,1,1,,855679,2153,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
733,2247,1,2,,855679,2153,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
734,2275,1,1,,85787353,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
735,2275,1,1,,85789579,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
736,2280,2,3,,855679,2153,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
737,2288,1,1,,855679,2153,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
738,2289,1,1,,855679,2153,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
739,2300,1,3,,855679,2153,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
740,2313,1,1,,85787353,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
741,2313,1,1,,85789579,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
742,2314,1,2,,855679,2153,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
743,2314,1,2,,855679,2153,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
744,2315,1,2,,855679,2153,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
745,2315,1,2,,855679,2153,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
746,2316,1,1,,85787353,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
747,2322,1,1,,85787353,2153,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
748,2322,1,1,,85789579,2153,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
749,2326,1,1,,855679,2153,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
750,2330,1,1,,85787353,2153,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
751,2330,1,1,,85789579,2153,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
752,2380,1,2,,855679,2153,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
753,2391,1,1,,855679,2153,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
754,2417,1,1,,855679,2153,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
755,2435,1,2,,855679,2153,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
756,2445,1,2,,855679,2153,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
757,2451,1,2,,855679,2153,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
758,2451,1,2,,26746955,2153,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
759,2451,1,2,,26751482,2153,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
760,2462,1,1,,855679,2153,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
761,2462,1,1,,855679,2153,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
762,2472,1,2,,855679,2153,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
763,2472,1,2,,26746955,2153,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
764,2472,1,2,,26751482,2153,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
765,2517,2,1,,855679,2153,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
766,2517,2,1,,17389715,2153,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
767,2517,2,1,,26746955,2153,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
768,2517,2,1,,26751482,2153,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
769,2517,2,1,,50103997,2153,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
770,2517,2,1,,50103998,2153,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
771,2517,2,1,,124886783,2153,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
772,2520,1,4,,855679,2153,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
773,2521,1,3,,855679,2153,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
774,2523,1,1,,855679,2153,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
775,2524,1,2,,855679,2153,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
776,2528,1,2,,855679,2153,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
777,2528,1,2,,26746955,2153,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
778,2528,1,2,,26751482,2153,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
779,2528,1,2,,29215004,2153,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
780,2540,1,2,,855679,2153,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
781,2544,1,2,,855679,2153,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
782,2546,1,1,,855679,2153,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
783,2546,1,1,,17389715,2153,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
784,2546,1,1,,26746955,2153,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
785,2546,1,1,,26751482,2153,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
786,2546,1,1,,29215004,2153,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
787,2549,1,1,,855679,2153,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
788,2549,1,1,,17389715,2153,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
789,2549,1,1,,26746955,2153,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
790,2549,1,1,,26751482,2153,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
791,2549,1,1,,50103997,2153,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
792,2549,1,1,,50103998,2153,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
793,2550,1,3,,855679,2153,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
794,2551,1,1,,855679,2153,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
795,2551,1,1,,17389715,2153,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
796,2551,1,1,,26746955,2153,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
797,2551,1,1,,26751482,2153,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
798,2551,1,1,,29215004,2153,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
799,2553,1,2,,855679,2153,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
800,2557,1,3,,855679,2153,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
801,2563,1,1,,855679,2153,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
802,2599,1,2,,855679,2153,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
803,2606,1,2,,855679,2153,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
804,2629,1,1,,855679,2153,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
805,2629,1,1,,56463437,2153,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
806,2642,1,2,,855679,2153,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
807,2648,1,2,,855679,2153,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
808,2650,2,1,,855679,2153,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
809,2660,1,1,,90341676,2153,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
810,2661,1,1,,855679,2153,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
811,2662,2,1,,855679,2153,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
812,2666,1,1,,90341676,2153,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
813,2667,1,1,,90341676,2153,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
814,2668,1,1,,90341676,2153,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
815,2674,1,1,,855679,2153,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
816,2675,1,1,,855679,2153,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
817,2676,1,2,,855679,2153,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
818,2685,1,1,,855679,2153,Inconclusive,,,18.3564,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
819,2690,1,2,,855679,2153,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
820,2706,1,1,,855679,2153,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
821,2716,1,1,,855679,2153,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
822,2716,1,1,,56463437,2153,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
823,2717,1,2,,855679,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
824,2718,1,1,,855679,2153,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
825,2732,1,1,,855679,2153,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
826,2751,2,2,,855679,2153,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
827,2796,1,4,,855679,2153,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
828,2797,1,2,,855679,2153,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
829,2805,2,2,,855679,2153,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
830,2806,2,2,,855679,2153,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
831,2825,1,2,,855679,2153,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
832,7690,7,1,,103520217,2153,Active,8928539.0,25369.0,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Other,12139454.0,
833,7695,6,7,,103520217,2153,Active,341940164.0,11541.0,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Other,12139454.0,
834,7783,3,4,,103520217,2153,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
835,8002,5,2,,103520217,2153,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
836,16333,3,4,,103520217,2153,Unspecified,,,,,Delta logD (pH 6.5),Other,8632421.0,
837,16334,3,5,,103520217,2153,Unspecified,,,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",Other,8632421.0,
838,19262,5,1,,103520217,2153,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
839,19419,3,4,,103520217,2153,Unspecified,,,,,Partition coefficient (logD7.4),Other,9544199.0,
840,20050,3,3,,103520217,2153,Unspecified,,,,,Human absorption A (%),Other,9544199.0,
841,21269,3,3,,103520217,2153,Unspecified,,,,,In vitro intestinal permeability in rats,Other,2657067.0,
842,21849,7,1,,103520217,2153,Unspecified,,,,,In vitro clearance in dog in 1000000 cells,Other,10602692.0,
843,21851,7,1,,103520217,2153,Unspecified,,,,,In vitro clearance in human in 1000000 cells,Other,10602692.0,
844,21852,7,1,,103520217,2153,Unspecified,,,,,In vitro clearance in rat in 1000000 cells,Other,10602692.0,
845,21853,6,2,,103520217,2153,Unspecified,,,,,In vivo clearance in dog,Other,10602692.0,
846,21856,6,2,,103520217,2153,Unspecified,,,,,In vivo clearance in human,Other,10602692.0,
847,21858,6,2,,103520217,2153,Unspecified,,,,,In vivo clearance in rat,Other,10602692.0,
848,22293,4,4,,103520217,2153,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
849,24457,3,4,,103520217,2153,Unspecified,,,,,"Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for K+ excretion.",Other,1992150.0,
850,24458,3,4,,103520217,2153,Unspecified,,,,,"Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for Na+ excretion.",Other,1992150.0,
851,24459,3,4,,103520217,2153,Unspecified,,,,,"Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for urine volume.",Other,1992150.0,
852,26304,4,4,,103520217,2153,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
853,26380,3,3,,103520217,2153,Inconclusive,,,,,Dissociation constant (pKa),Other,14971904.0,
854,28659,4,1,,103520217,2153,Unspecified,,,,,Ability to solubilize benzo(a)pyrene in water was reported by Weil-Malherbe.,Other,11741482.0,
855,29359,3,3,,103520217,2153,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
856,29811,4,3,,103520217,2153,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
857,30176,6,2,,103520217,2153,Unspecified,,,,,Water solubility of the compound,Other,12139454.0,
858,30335,5,4,,103520217,2153,Unspecified,,,14125400000.0,IC50,Log IC50 value was determined against adenosine A1 receptor in rat brain membranes,Confirmatory,2991519.0,
859,30347,10,2,,103520217,2153,Active,2827766.0,29290.0,8.47,Ki,Binding affinity towards adenosine A1 receptor in rat whole brain membranes using N6-[3H]cyclohexyladenosine,Confirmatory,1501234.0,
860,30353,7,1,,103520217,2153,Active,,,,,"Affinity constant for inhibition of A1 receptor control of adenylate cyclase in adipocytes, heart and brain cells",Other,6279840.0,
861,30444,8,5,,103520217,2153,Active,231473.0,134.0,6.2,Ki,Binding affinity against human adenosine A1 receptor expressed in CHO cells using [3H]CHA,Confirmatory,15214785.0,
862,30489,9,1,,103520217,2153,Active,,,25.0,Ki,Affinity to A2 adenosine receptor was measured by the displacement of [3H]-CGS- 21680 in bovine brain striatal membrane,Confirmatory,8071944.0,
863,30500,10,1,,103520217,2153,Active,1168253.0,100135473.0,16.6,Ki,Affinity against adenosine A2 receptor in the brain membranes measured by the displacement of [3H]-CPX,Confirmatory,1331453.0,
864,30621,7,6,,103520217,2153,Active,1168253.0,100135473.0,14.0,Ki,Antagonism of cyclic [3H]AMP accumulation in guinea pig cerebral cortical slices (elicited by 15 uM 2-chloroadenosine at adenosine A2 receptor),Confirmatory,2984420.0,
865,30624,9,1,,103520217,2153,Active,,,16.6,Ki,Binding affinity against adenosine A2 receptor of striatal membrane using [3H]CGS-21680 as a radioligand,Confirmatory,8496906.0,
866,30626,7,6,,103520217,2153,Active,1168253.0,100135473.0,14.0,Ki,Compound was evaluated for its ability to antagonise cyclic [3H]AMP accumulation in [3H]adenine-labeled guinea pig cerebral cortical slices.,Confirmatory,3806581.0,
867,30627,6,3,,103520217,2153,Active,,,14.0,Ki,Inhibition of 2-CADO-stimulated adenylate cyclase at Adenosine A2 receptor in guinea pig cerebral cortical slices,Confirmatory,3172141.0,
868,30789,6,8,,103520217,2153,Active,112938.0,136.0,13.8,Ki,In vitro binding affinity to Adenosine A2 receptor of human platelets by inhibition of NECA-stimulated adenylate cyclase,Confirmatory,3172141.0,
869,30789,6,8,,103520217,2153,Active,543740.0,135.0,13.8,Ki,In vitro binding affinity to Adenosine A2 receptor of human platelets by inhibition of NECA-stimulated adenylate cyclase,Confirmatory,3172141.0,
870,30797,9,1,,103520217,2153,Active,,,14.0,Ki,Inhibition of the stimulation by 5'-(N-ethylcarbamoyl) adenosine of adenyl cyclase via adenosine A2 receptor in human platelet membranes.,Confirmatory,2724296.0,
871,30802,3,10,,103520217,2153,Unspecified,112939.0,29316.0,,,Ratio of Ki for adenosine A2 and A1 receptors in rat,Other,2002461.0,
872,30802,3,10,,103520217,2153,Unspecified,2827766.0,29290.0,,,Ratio of Ki for adenosine A2 and A1 receptors in rat,Other,2002461.0,
873,30802,3,10,,103520217,2153,Unspecified,8928539.0,25369.0,,,Ratio of Ki for adenosine A2 and A1 receptors in rat,Other,2002461.0,
874,30807,9,1,,103520217,2153,Active,,,22.0,Ki,Binding affinity against Adenosine A2 receptor in rat striatal membranes using [3H]5'-(N-ethylcarboxamido)-adenosine (NECA) as the ligand,Confirmatory,8230124.0,
875,30810,7,1,,103520217,2153,Active,,,16.0,Ki,"Binding affinity against adenosine A2 receptor from rat striatal membranes, using N-[3H]-ethyladenosin-5''-uronamide as radioligand (in the presence of 50 nM cyclopentyl adenosine).",Confirmatory,1613758.0,
876,30811,7,5,,103520217,2153,Active,112939.0,29316.0,25.3,Ki,Inhibition of N-[3H]-ethyladenosin-5''-uronamide binding to adenosine A2 receptor from rat striatal membranes,Confirmatory,1613758.0,
877,30811,7,5,,103520217,2153,Active,8928539.0,25369.0,25.3,Ki,Inhibition of N-[3H]-ethyladenosin-5''-uronamide binding to adenosine A2 receptor from rat striatal membranes,Confirmatory,1613758.0,
878,31241,3,7,,103520217,2153,Unspecified,,,,,Antagonistic activity expressed as percent displacement of 0.4 nM of [3H]DPCPX from adenosine A1 receptors in rat brain cortex membranes at 10 uM,Other,10479294.0,
879,31270,3,6,,103520217,2153,Unspecified,,,,,"Enhancing activity at 10 uM PD 81,723 (100%) at Adenosine A1 receptor in rat brain cortex membranes",Other,10479294.0,
880,31389,9,2,,103520217,2153,Active,,,28.0,IC50,Antagonism of adenosine A1 receptor assessed from the ability to inhibit binding of [3H]cyclohexyladenosine to rat cerebral cortical membranes,Confirmatory,6090665.0,
881,31390,11,1,,103520217,2153,Active,,,20.0,IC50,Binding affinity against adenosine A1 receptor in rat brain membrane preparations using N6-[3H]cyclohexyladenosine as a radioligand,Confirmatory,3806606.0,
882,31391,10,2,,103520217,2153,Active,160332359.0,282133.0,12.7,IC50,Binding affinity against bovine brain adenosine A1 receptor using N6-[3H]- cyclohexyladenosine,Confirmatory,2991519.0,
883,31418,7,2,,103520217,2153,Unspecified,,,10.0,IC50,Inhibition of binding towards adenosine A1 receptor using [3H]N-cyclohexyladenosine ([3H]CHA) in rat whole brain membranes.,Confirmatory,3361572.0,
884,31539,9,5,,103520217,2153,Active,2827766.0,29290.0,19.0,IC50,Inhibition of adenosine binding to A1 receptor of rat brain homogenates,Confirmatory,8120866.0,
885,31695,6,7,,103520217,2153,Active,2827766.0,29290.0,,,Inhibition against Adenosine A1 receptor of rat fat cell membranes,Other,12139454.0,
886,31709,9,2,,103520217,2153,Active,,,17.0,Ki,Ability to inhibit binding of [3H]CHA to adenosine A1 receptor in rat brain cortical membranes.,Confirmatory,9435909.0,
887,31710,9,2,,103520217,2153,Active,,,14.0,Ki,Ability to inhibit binding of [3H]R-PIA to Adenosine A1 receptor in rat brain cortical membranes,Confirmatory,9435909.0,
888,31714,9,2,,103520217,2153,Active,,,14.0,Ki,Ability to inhibit binding of 1 nM [3H]cyclohexyladenosine to adenosine A1 receptor in rat cerebral cortical membranes,Confirmatory,3806581.0,
889,31831,8,5,,103520217,2153,Active,160332359.0,282133.0,6.0,Ki,Displacement of [3H]CPX from adenosine A1 receptor of calf brain cortical membrane,Confirmatory,2002461.0,
890,31837,10,2,,103520217,2153,Active,160332359.0,282133.0,2.43,IC50,Binding affinity against bovine brain adenosine A1 receptor using N6-[3H]- cyclohexyladenosine,Confirmatory,2991519.0,
891,31838,5,4,,103520217,2153,Unspecified,,,3019950000.0,IC50,Log IC50 value was determined against adenosine A1 receptor in bovine brain membranes,Confirmatory,2991519.0,
892,31856,9,2,,103520217,2153,Active,,,14.0,Ki,Antagonism of binding of 1 nM [3H]cyclohexyladenosine to adenosine A1 receptors on rat cortical membranes,Confirmatory,2984420.0,
893,31860,9,1,,103520217,2153,Active,,,14.0,Ki,Binding affinity for Adenosine A1 receptor from rat brain using [3H]-PIA as radioligand,Confirmatory,2213834.0,
894,31861,11,1,,103520217,2153,Active,,,8.5,Ki,"Binding affinity against Adenosine A1 receptor in rat brain membrane, using [3H]N6-cyclohexyladenosine as the radioligand",Confirmatory,2795597.0,
895,31865,8,5,,103520217,2153,Active,2827766.0,29290.0,8.47,Ki,Binding affinity against Adenosine A1 receptor using N6-[3H]-cyclohexyladenosinene in rat whole brain membranes,Confirmatory,1548682.0,
896,31881,9,2,,103520217,2153,Active,,,14.0,Ki,Binding affinity at Adenosine A1 receptor in rat brain cortical membrane using [3H]N6-R-phenylisopropyladenosine (R-PIA) as radioligand,Confirmatory,8230124.0,
897,31887,9,1,,103520217,2153,Active,,,14.0,Ki,Binding affinity for adenosine A1 receptor from rat brain membranes using [3H]PIA as radioligand,Confirmatory,8410976.0,
898,31980,9,1,,103520217,2153,Active,,,8.5,Ki,Affinity to A1 adenosine receptor was measured by the displacement of [3H]PIA in bovine brain cortical membrane,Confirmatory,8071944.0,
899,31982,7,2,,103520217,2153,Active,,,3.8,Ki,Binding affinity against adenosine A1 receptor in bovine brain membranes by [3H]CHA displacement.,Confirmatory,15214785.0,
900,31991,8,5,,103520217,2153,Active,160332359.0,282133.0,3.8,Ki,Binding affinity towards adenosine A1 receptor of bovine brain membrane using [3H]-CHA at 20 uM,Confirmatory,10737748.0,
901,31999,8,5,,103520217,2153,Active,160332359.0,282133.0,3.8,Ki,Displacement of [3H]CHA from adenosine A1 receptor in bovine brain membranes,Confirmatory,10956220.0,
902,32016,7,1,,103520217,2153,Active,,,6.92,Ki,Binding affinity of specific [3H]R-PIA binding to rat Adenosine A1 receptor in HEK293 cells,Confirmatory,12014951.0,
903,32039,9,1,,103520217,2153,Active,,,14.0,Ki,Binding affinity to A1 adenosine receptor from rat cortical membrane in presence of [3H]R-(phenylisopropyl)-adenosine,Confirmatory,8182711.0,
904,32040,8,5,,103520217,2153,Active,2827766.0,29290.0,9.2,Ki,Displacement of [3H]CPX from adenosine A1 receptor of rat brain cortical membrane,Confirmatory,2002461.0,
905,32155,10,5,,103520217,2153,Active,1351830.0,100135472.0,9.8,Ki,Affinity against adenosine A1 receptor in the brain membranes by the displacement of [3H]CPX.,Confirmatory,1331453.0,
906,32159,10,5,,103520217,2153,Active,1351830.0,100135472.0,9.8,Ki,Binding affinity against adenosine A1 receptor of cerebral cortex using [3H]CPX as a radioligand,Confirmatory,8496906.0,
907,32160,8,5,,103520217,2153,Active,1351830.0,100135472.0,23.0,Ki,Inhibition of N6-[3H]cyclohexyladenosine binding to guinea pig forebrain membrane Adenosine A1 receptor,Confirmatory,1548682.0,
908,32161,8,5,,103520217,2153,Active,1351830.0,100135472.0,13.0,Ki,Binding affinity against Adenosine A1 receptor using N6-[3H]cyclohexyladenosine in guinea pig membranes,Confirmatory,1548682.0,
909,32162,8,5,,103520217,2153,Active,1351830.0,100135472.0,23.0,Ki,"Binding affinity against adenosine A1 receptor from guinea pig forebrain membranes, using N6-[3H]cyclohexyladenosine as radioligand.",Confirmatory,1613758.0,
910,32164,8,5,,103520217,2153,Active,1351830.0,100135472.0,23.0,Ki,Inhibition of [3H]cyclohexyladenosine binding to guinea pig forebrain membranes Adenosine A1 receptor,Confirmatory,1992150.0,
911,32177,7,2,,103520217,2153,Active,,,8.5,Ki,Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand,Confirmatory,1738138.0,
912,32193,8,5,,103520217,2153,Active,2827766.0,29290.0,9.7,Ki,Binding affinity towards adenosine A1 receptor in rat forebrain membranes using N6-[3H]cyclohexyladenosine,Confirmatory,1501234.0,
913,32292,8,5,,103520217,2153,Active,1351830.0,100135472.0,23.0,Ki,Binding affinity against adenosine A1 receptor in guinea pig forebrain membranes using N6-[3H]cyclohexyladenosine as radioligand,Confirmatory,1501234.0,
914,32294,8,5,,103520217,2153,Active,1351830.0,100135472.0,23.0,Ki,Binding affinity against Adenosine A1 receptor from guinea pig forebrain membranes by N6-[3H]- cyclohexyladenosine displacement.,Confirmatory,8355252.0,
915,32323,9,5,,103520217,2153,Active,2827766.0,29290.0,14.0,Ki,Binding of 1 nM [3H]CHA to Adenosine A1 receptor of rat cerebral cortical membranes,Confirmatory,3172141.0,
916,32324,8,5,,103520217,2153,Active,2827766.0,29290.0,0.7,Ki,Inhibition of [3H]-CHA binding to rat brain membrane Adenosine A1 receptor,Confirmatory,2258897.0,
917,32483,9,5,,103520217,2153,Active,2827766.0,29290.0,7.4,Ki,In vitro binding affinity to Adenosine A1 receptor of rat cerebral cortical membranes using 1 nM [3H]PIA,Confirmatory,3172141.0,
918,32485,8,5,,103520217,2153,Active,2827766.0,29290.0,13.0,Ki,Inhibition of (R)-N6-([3H]-phenylisopropyl) adenosine binding to adenosine A1 receptor from rat cortical membranes,Confirmatory,1613758.0,
919,32487,9,2,,103520217,2153,Active,,,8.7,Ki,Inhibition of 1 nM [3H]- N6 -(phenylisopropyl) adenosine binding to Adenosine A1 receptor in rat fat cell membrane,Confirmatory,2724296.0,
920,32491,9,2,,103520217,2153,Active,,,13.0,Ki,Inhibition of 1 nM [3H]- N6-(phenylisopropyl) adenosine binding to Adenosine A1 receptor in rat cerebral cortical membranes,Confirmatory,2724296.0,
921,32494,8,5,,103520217,2153,Active,2827766.0,29290.0,8.47,Ki,Inhibition of N6-[3H]cyclohexyladenosine binding to adenosine A1 receptor from whole brain membranes,Confirmatory,1613758.0,
922,32497,11,2,,103520217,2153,Active,2827766.0,29290.0,8.5,Ki,Inhibition of [3H]CHA binding to Adenosine A1 receptor in rat brain membranes,Confirmatory,2342066.0,
923,32500,7,2,,103520217,2153,Active,,,8.47,Ki,Inhibition of binding of 1 nM [3H]N-6-(phenylisopropyl)adenosine to adenosine A1 receptor in rat cortical membranes,Confirmatory,2754711.0,
924,32508,7,1,,103520217,2153,Active,,,8.47,Ki,"Tested for binding affinity against Adenosine A1 receptor from rat forebrain membranes, using N6-[3H]- cyclohexyladenosine as radioligand",Confirmatory,8355252.0,
925,32514,9,1,,103520217,2153,Active,,,8.5,Ki,Displacement of [3H]PIA from adenosine A1 receptors of rat brain membrane,Confirmatory,7932565.0,
926,32636,3,7,,103520217,2153,Unspecified,,,,,"Binding affinity against adenosine A1 receptor in rat brain membrane preparations using N6-[3H]cyclohexyladenosine as radioligand, PCY = log (100000/IC50).",Other,3806606.0,
927,32642,3,5,,103520217,2153,Unspecified,,,,,Relative affinities for rat Adenosine A1 and Adenosine A2B receptors,Other,12014951.0,
928,32643,3,5,,103520217,2153,Unspecified,,,,,Relative affinities for rat Adenosine A1 and Adenosine A2B receptors,Other,12014951.0,
929,32862,9,1,,103520217,2153,Active,,,8.0,Ki,Binding affinity for adenosine A2A receptor from rat brain membranes using [3H]CGS-21680,Confirmatory,8410976.0,
930,32865,7,2,,103520217,2153,Active,,,6.7,Ki,Binding affinity at rat Adenosine A2A receptor by [3H]-CGS- 21680 displacement.,Confirmatory,12014951.0,
931,33176,7,1,,103520217,2153,Active,,,9.07,Ki,"Binding affinity at human Adenosine A2B receptor expressed in HEK293 cells, using [125I]ABOPX as radioligand",Confirmatory,12014951.0,
932,33407,7,2,,103520217,2153,Unspecified,,,10.0,IC50,Inhibition of binding to Adenosine-2 receptor using [3H]NECA in rat striatum,Confirmatory,3361572.0,
933,33434,9,2,,103520217,2153,Active,,,25.0,Ki,Binding affinity for Adenosine A2 receptor from rat striatum using [3H]NECA as radioligand,Confirmatory,2213834.0,
934,33435,7,1,,103520217,2153,Active,,,25.0,Ki,"Binding affinity against Adenosine A2 receptor in rat brain membrane, using [3H]-NECA as the radioligand.",Confirmatory,2795597.0,
935,33437,7,5,,103520217,2153,Active,112939.0,29316.0,25.3,Ki,Binding affinity against Adenosine A2 receptor using N-[3H]-ethyl adenosine-5-uronamide in rat striatal membranes,Confirmatory,1548682.0,
936,33437,7,5,,103520217,2153,Active,8928539.0,25369.0,25.3,Ki,Binding affinity against Adenosine A2 receptor using N-[3H]-ethyl adenosine-5-uronamide in rat striatal membranes,Confirmatory,1548682.0,
937,33438,7,5,,103520217,2153,Active,112939.0,29316.0,16.0,Ki,Binding affinity against Adenosine A2 receptor using N-[3H]-ethyladenosin-5''-uronamide in rat striatal membranes,Confirmatory,1548682.0,
938,33438,7,5,,103520217,2153,Active,8928539.0,25369.0,16.0,Ki,Binding affinity against Adenosine A2 receptor using N-[3H]-ethyladenosin-5''-uronamide in rat striatal membranes,Confirmatory,1548682.0,
939,33498,3,6,,103520217,2153,Unspecified,,,,,"Tested for the binding affinity, for displacement of [125I]AB-MECA in membranes of CHO cells stably transfected with the rat A3-cDNA at the 10e-4 concentration (M)",Other,7932565.0,
940,33565,7,5,,103520217,2153,Active,112939.0,29316.0,16.0,Ki,Inhibition of [3H]5'-(N-ethylcarbamoyl)-adenosine binding to Adenosine A2 receptor in rat striatal membranes in the presence of 50 nM cyclopentyladenosine,Confirmatory,1992150.0,
941,33565,7,5,,103520217,2153,Active,8928539.0,25369.0,16.0,Ki,Inhibition of [3H]5'-(N-ethylcarbamoyl)-adenosine binding to Adenosine A2 receptor in rat striatal membranes in the presence of 50 nM cyclopentyladenosine,Confirmatory,1992150.0,
942,33579,9,1,,103520217,2153,Active,,,19.0,Ki,Binding affinity to A2 adenosine receptor from rat striatal membrane in presence of [3H]5'-(N-ethylcarboximido)-adenosine,Confirmatory,8182711.0,
943,33580,7,5,,103520217,2153,Active,112939.0,29316.0,25.0,Ki,Binding affinity for adenosine A2 receptor using [3H]NECA in rat striatal membrane,Confirmatory,2002461.0,
944,33580,7,5,,103520217,2153,Active,8928539.0,25369.0,25.0,Ki,Binding affinity for adenosine A2 receptor using [3H]NECA in rat striatal membrane,Confirmatory,2002461.0,
945,33586,7,1,,103520217,2153,Active,,,25.3,Ki,Binding affinity towards adenosine A2 receptor in rat striatal membranes using N-[3H]-ethyladenosin-5''-uronamide as radioligand,Confirmatory,1501234.0,
946,33587,7,1,,103520217,2153,Active,,,16.0,Ki,Binding affinity against adenosine A2 receptor in rat striatal membranes using N-[3H]-ethyladenosin-5''-uronamide as radioligand in the presence of 50 nM cyclopentyladenosine,Confirmatory,1501234.0,
947,33591,7,5,,103520217,2153,Active,112939.0,29316.0,1.31,Ki,Binding of Adenosine A2 receptor in whole rat brain membrane using [3H]CHA as a Radioligand,Confirmatory,2258897.0,
948,33591,7,5,,103520217,2153,Active,8928539.0,25369.0,1.31,Ki,Binding of Adenosine A2 receptor in whole rat brain membrane using [3H]CHA as a Radioligand,Confirmatory,2258897.0,
949,33610,8,5,,103520217,2153,Active,112939.0,29316.0,15.1,Ki,Inhibition of [125I]-APOBX binding to rat Adenosine A2B receptor expressed in HEK cells,Confirmatory,12014951.0,
950,33613,7,1,,103520217,2153,Active,,,21.0,Ki,Displacement of [3H]-CGS- 21680 from adenosine A2a receptor of bovine striatal membranes,Confirmatory,15214785.0,
951,33728,7,2,,103520217,2153,Active,,,25.3,Ki,Inhibition of binding of [3H]5'-(N-ethylcarbamoyl)-adenosine to adenosine A2 receptor in rat striatal membranes,Confirmatory,2754711.0,
952,33734,9,2,,103520217,2153,Active,,,17.0,Ki,Inhibition of the stimulation by 5'-(N-ethylcarbamoyl) adenosine of adenyl cyclase via Adenosine A2 receptor in rat PC12 membranes,Confirmatory,2724296.0,
953,33740,7,1,,103520217,2153,Active,,,16.0,Ki,Binding affinity at Adenosine A2 receptor from rat striatal membranes by N-[3H] ethyladenosin-5'- uronamide displacement.,Confirmatory,8355252.0,
954,33746,3,7,,103520217,2153,Active,,,,,Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand,Other,1738138.0,
955,33752,3,6,,103520217,2153,Unspecified,,,,,Ratio of A2 to A1.,Other,1738138.0,
956,33897,6,4,,103520217,2153,Active,,,17.0,Ki,Antagonism of N-ethylcarboxamido adenosine-stimulated adenylate cyclase associated with stimulation of Adenosine A2 receptor of rat PC12 membranes,Confirmatory,2213834.0,
957,33909,7,1,,103520217,2153,Active,,,,,"Affinity constant for A2 receptor control of adenylate cyclase in adipocytes, heart and brain cells",Other,6279840.0,
958,33921,4,4,,103520217,2153,Unspecified,,,,,Binding affinity towards adenosine A2A receptor of bovine striatal membrane using [3H]-CGS- at 20 uM,Other,10737748.0,
959,33926,7,1,,103520217,2153,Active,,,21.0,Ki,Displacement of [3H]-CGS- 21680 from adenosine A2A receptor in bovine striatal membranes.,Confirmatory,10956220.0,
960,33940,9,1,,103520217,2153,Active,,,25.0,Ki,Displacement of [3H]-CGS- 21680 from adenosine A2a receptors of rat striatal membrane,Confirmatory,7932565.0,
961,34158,7,1,,103520217,2153,Inactive,,,,,Inhibition of adenyl cyclase via P site in adipocytes; Inactive,Other,6279840.0,
962,34160,6,3,,103520217,2153,Active,,,0.94,IC50,Inhibition of Adenylate Cyclase in Rat adipocytes,Confirmatory,2258897.0,
963,34297,3,7,,103520217,2153,Active,,,,,Binding affinity against adenylate cyclase using N-[3H]-ethyl adenosine-5-uronamide as radioligand in human platelet membranes,Other,1548682.0,
964,34298,3,8,,103520217,2153,Active,,,,,Inhibitory activity against adenylate cyclase using (R)-N6-(2-[3H]-phenyl-1-methylethyladenosine as radioligand in rat adipocytes,Other,1548682.0,
965,34304,3,10,,103520217,2153,Active,62512172.0,107.0,,,Inhibition of adenylate cyclase stimulation by N-[3H]-ethyladenosin-5''-uronamide in human platelet membranes,Other,1613758.0,
966,34578,7,2,,103520217,2153,Unspecified,,,86.0,Ki,Binding affinity against human adenosine A3 receptor expressed in CHO cells by [125I]AB-MECA displacement.,Confirmatory,15214785.0,
967,34738,8,5,,103520217,2153,Unspecified,803374855.0,140.0,86.0,Ki,Binding affinity towards human adenosine A3 receptor expressed in HEK293 cells using [125I]AB-MECA at 1 uM,Confirmatory,10737748.0,
968,34889,8,5,,103520217,2153,Unspecified,803374855.0,140.0,86.0,Ki,Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells.,Confirmatory,10956220.0,
969,35013,9,2,,103520217,2153,Active,,,9.4,Ki,Ability to inhibit binding of [3H]-CGS- 21680 to adenosine A2A receptor in rat brain striatal membranes.,Confirmatory,9435909.0,
970,35014,9,2,,103520217,2153,Active,,,19.0,Ki,Ability to inhibit binding of [3H]NECA to Adenosine A2A receptor in rat brain striatal membranes,Confirmatory,9435909.0,
971,42825,12,2,,103520217,2153,Active,160332359.0,282133.0,20.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to bovine brain,Confirmatory,6279840.0,
972,55471,3,3,,103520217,2153,Unspecified,,,,,Binding affinity to DNA intercalator Acridine orange.,Other,11741482.0,
973,73683,8,1,,103520217,2153,Unspecified,,,70.8,ED50,"Relaxation in guinea pig tracheal preparation relative to papaverine, range 63.1-79.4",Confirmatory,3965705.0,
974,73739,6,3,,103520217,2153,Active,,,28.2,EC50,Effective concentration required in vitro for tracheal muscle (from male Hartley guinea pigs) relaxation,Confirmatory,8496906.0,
975,74012,3,3,,103520217,2153,Inactive,,,,,"Compound was evaluated in the guinea pig anaphylaxis test for in vivo activity; Inactive, treated 12/19, control 16/20",Other,2415706.0,
976,74022,6,3,,103520217,2153,Active,,,28.2,EC50,Relaxant activity on the spontaneous tone of isolated guinea pig tracheal ring chains.,Confirmatory,1331453.0,
977,75527,3,3,,103520217,2153,Unspecified,,,,,Percent decrease in bronchodilator activity against acetylcholine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg,Other,2859374.0,
978,75528,3,3,,103520217,2153,Unspecified,,,,,Percent decrease in bronchodilator activity against histamine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg,Other,2859374.0,
979,75529,3,3,,103520217,2153,Unspecified,,,,,Percentage decrease in bronchodilator activity against serotonin-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg,Other,2859374.0,
980,75916,7,1,,103520217,2153,Unspecified,,,,,Effective concentration required in vitro for heart stimulation (right atrium) in guinea pig,Other,8496906.0,
981,75917,7,1,,103520217,2153,Unspecified,1351830.0,100135472.0,,,Positive chronotropic effect on isolated guinea pig right atrium (heart stimulation).,Other,1331453.0,
982,76078,4,4,,103520217,2153,Active,,,3.0,IC50,Inhibition of 2-chloroadenosine-induced relaxation in histamine-contracted guinea pig trachea,Confirmatory,3361572.0,
983,76088,6,3,,103520217,2153,Active,,,6.52,IC50,Inhibition of the Schulz-Dale (SD) reaction-induced contraction in trachea of guinea pig,Confirmatory,1331454.0,
984,76186,3,4,,103520217,2153,Unspecified,,,,,Bronchodilatory activity in vitro by tracheal tone inhibition at 30 ug/mL in guinea pig tracheal muscle.,Other,11063618.0,
985,76315,3,3,,103520217,2153,Unspecified,,,,,Dose that protects 50% of guinea pig from collapse was determined in guinea pig anaphylaxis assay,Other,2342077.0,
986,76612,3,4,,103520217,2153,Unspecified,,,,,Evaluation of bronchodilator activity at dose 60 mg/kg perorally 1 hr prior to histamine aerosol exposure; 20-30,Other,7411545.0,
987,76796,7,4,,103520217,2153,Unspecified,,,,,"In vivo ability to inhibit bronchospasm induced by intravenous doses of histamine on the artificially respired, anesthetized guinea pig",Other,1527785.0,
988,77088,8,1,,103520217,2153,Unspecified,,,,,Evaluation of in vitro bronchodilator activity in isolated guinea pig tracheal spiral preparation,Other,6161252.0,
989,77244,5,1,,103520217,2153,Active,,,0.043,ED50,Inhibition of the bronchospasm induced by histamine in guinea pig,Confirmatory,6319701.0,
990,77586,2,5,,103520217,2153,Unspecified,,,,,"Tested in vitro for its effect on tracheal relaxation in guinea pig trachea, activity expressed as percentage increase in the velocity of the flux of perfusion at concentration 10 ug/mL",Other,,
991,77937,3,4,,103520217,2153,Unspecified,,,,,"Effect on collapse time of antigen-induced bronchospasm in passively sensitized guinea pigs (at 25 mg/kg, po).MCT for untreated animals is 254+/-18.",Other,1331454.0,
992,77939,3,4,,103520217,2153,Unspecified,,,,,"Effect on collapse time of antigen-induced bronchospasm in passively sensitized guinea pigs (at 50 mg/kg, po).MCT for untreated animals is 254+/-18.",Other,1331454.0,
993,77943,3,3,,103520217,2153,Unspecified,,,,,Mean collapse time in antigen induced bronchospasm in passively sensitized guinea pigs at 25 mg/kg peroral dose,Other,1479586.0,
994,77944,3,3,,103520217,2153,Unspecified,,,,,Mean collapse time in antigen induced bronchospasm in passively sensitized guinea pigs at 50 mg/kg peroral dose,Other,1479586.0,
995,77946,3,3,,103520217,2153,Unspecified,,,,,Mean collapse time in antigen induced bronchospasm in passively sensitized guinea pigs at 10 mg/kg peroral dose,Other,1479586.0,
996,78058,6,2,,103520217,2153,Unspecified,,,,,Tracheal relaxing activity expressed as minimum inhibitory concentration required to obtain a inhibitory response by more than 50%,Other,11063618.0,
997,78060,3,3,,103520217,2153,Unspecified,,,,,Acute lethal toxicity in mice on peroral administration,Other,1479586.0,
998,78274,6,2,,103520217,2153,Active,,,6.52,IC50,Schultz-Dale (SD) reaction in tracheal strip isolated from passively sensitized guinea pigs,Confirmatory,1479586.0,
999,78304,4,4,,103520217,2153,Active,,,10.0,IC50,In vitro inhibition of adenylate cyclase activity of synaptoneurosomes from guinea pig cerebral cortex,Confirmatory,3361572.0,
1000,78489,12,2,,103520217,2153,Active,1168253.0,100135473.0,13.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to guinea pig brain,Confirmatory,6279840.0,
1001,78495,6,2,,103520217,2153,Active,,,42.0,IC50,Ability to inhibit 2-chloroadenosine (15 uM)-elicited accumulations of cyclic AMP in guinea pig cerebral cortical membranes,Confirmatory,6090665.0,
1002,79811,2,5,,103520217,2153,Unspecified,,,,,"Tested in vitro for its effect on tracheal relaxation in guinea pig trachea, activity expressed as pD2 (-log of molar concentration which gives a half maximal relaxing effect)",Other,,
1003,79857,5,3,,103520217,2153,Active,,,29.5121,Kd,Negative inotropic response to adenosine in guinea pig left atrium,Confirmatory,9379444.0,
1004,80441,7,1,,103520217,2153,Unspecified,,,,,In vitro positive chronotropic effect,Other,9379444.0,
1005,80462,3,4,,103520217,2153,Unspecified,,,,,Compound was evaluated for the percent of relaxation using isolated guinea pig trachea at a dose of 1 mM,Other,9871602.0,
1006,80623,3,4,,103520217,2153,Unspecified,,,,,Compound was evaluated for the percent of relaxation using isolated guinea pig trachea,Other,9871602.0,
1007,80631,3,3,,103520217,2153,Unspecified,,,,,Percent relaxation of isolated guinea pig trachea.,Other,9871602.0,
1008,89986,6,2,,103520217,2153,Unspecified,,,335.0,IC50,"Inhibitory activity against histamine release from antigen-challenged, sensitized human basophils",Confirmatory,2415706.0,
1009,91836,6,2,,103520217,2153,Unspecified,,,309.0,IC50,Antiasthmatic activity against the immunoglobulin E (IgE) antigen using the human basophil asthma model.,Confirmatory,1969485.0,
1010,91838,6,2,,103520217,2153,Unspecified,,,,,Effective dose (po) evaluated by Passive cutaneous anaphylaxis test (PCA) by injecting IgE serum intradermally in mice,Other,1969485.0,
1011,108716,3,3,,103520217,2153,Unspecified,,,,,Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 0.08 mg/kg,Other,8355252.0,
1012,108719,4,3,,103520217,2153,Unspecified,,,,,Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after p.o. administration of 0.31 mg/kg,Other,8355252.0,
1013,108722,3,3,,103520217,2153,Unspecified,,,,,Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 1.25 mg/kg,Other,8355252.0,
1014,108851,3,3,,103520217,2153,Unspecified,,,,,Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 5 mg/kg,Other,8355252.0,
1015,115112,3,3,,103520217,2153,Unspecified,,,,,Tested for locomotor activity after oral administration of 10 mg/kg for 120 min,Other,8355252.0,
1016,115113,3,3,,103520217,2153,Unspecified,,,,,Tested for locomotor activity after oral administration of 2.5 mg/kg for 120 min,Other,8355252.0,
1017,115115,3,3,,103520217,2153,Unspecified,,,,,Tested for locomotor activity after oral administration of 5 mg/kg for 120 min,Other,8355252.0,
1018,116915,6,2,,103520217,2153,Unspecified,,,,,Compound was tested for it's acute toxicity in mice when given orally.,Other,1527785.0,
1019,118920,3,3,,103520217,2153,Unspecified,,,,,Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 0.08 mg/kg,Other,8355252.0,
1020,118924,4,3,,103520217,2153,Unspecified,,,,,Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 0.31 mg/kg,Other,8355252.0,
1021,118928,3,3,,103520217,2153,Unspecified,,,,,Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 1.25 mg/kg,Other,8355252.0,
1022,118937,3,3,,103520217,2153,Unspecified,,,,,Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 5 mg/kg,Other,8355252.0,
1023,122964,5,2,,103520217,2153,Unspecified,,,,,Locomotor activity (no. light beam crossings in 50 min) in mice by intravenous dose at 166 umol/kg,Other,1527785.0,
1024,122965,3,3,,103520217,2153,Unspecified,,,,,Locomotor activity (no. light beam crossings in 50 min) in mice by intravenous dose at 55 umol/kg,Other,1527785.0,
1025,131684,6,2,,103520217,2153,Unspecified,,,,,Effective dose in mouse PCA test,Other,2415706.0,
1026,133426,3,4,,103520217,2153,Unspecified,,,,,"Acute lethal toxicity (minimum lethal dose; MLD, po) in mice.",Other,1331454.0,
1027,156500,3,6,,103520217,2153,Unspecified,,,,,Calcium release in PC12 cells at 2 mM as percent of 1 mM caffeine effect,Other,10411473.0,
1028,157756,3,7,,103520217,2153,Unspecified,,,,,Inhibition of PDE4 at 200 uM,Other,9873649.0,
1029,157757,3,7,,103520217,2153,Unspecified,,,,,Inhibition of rolipram binding to PDE4 at 100 uM,Other,9873649.0,
1030,158121,3,7,,103520217,2153,Unspecified,,,,,Inhibition of phosphodiesterase 5A at 100 uM,Other,8120866.0,
1031,158288,6,5,,103520217,2153,Unspecified,,,210.0,IC50,Inhibition of cyclic GMP sensitive phosphodiesterase PDE 2 of guinea pig ventricle,Confirmatory,2985781.0,
1032,158302,9,2,,103520217,2153,Unspecified,,,360.0,IC50,Inhibition of low Km cyclic cAMP phosphodiesterase PDE III of guinea pig ventricle,Confirmatory,2985781.0,
1033,158415,12,2,,103520217,2153,Unspecified,,,90.0,IC50,Inhibition of bovine heart phosphodiesterase,Confirmatory,6279846.0,
1034,158416,7,4,,103520217,2153,Unspecified,,,210.0,IC50,Inhibition of bovine heart phosphodiesterase,Confirmatory,6279846.0,
1035,158419,12,2,,103520217,2153,Unspecified,,,77.0,Ki,Inhibition of bovine heart phosphodiesterase,Confirmatory,6279846.0,
1036,158423,6,8,,103520217,2153,Unspecified,544050.0,281969.0,286.0,IC50,Inhibition of bovine heart cAMP-phosphodiesterase with ethanol,Confirmatory,6265635.0,
1037,158423,6,8,,103520217,2153,Unspecified,544051.0,281970.0,286.0,IC50,Inhibition of bovine heart cAMP-phosphodiesterase with ethanol,Confirmatory,6265635.0,
1038,158424,6,8,,103520217,2153,Unspecified,544050.0,281969.0,412.0,IC50,Inhibition of bovine heart cAMP-phosphodiesterase without ethanol,Confirmatory,6265635.0,
1039,158424,6,8,,103520217,2153,Unspecified,544051.0,281970.0,412.0,IC50,Inhibition of bovine heart cAMP-phosphodiesterase without ethanol,Confirmatory,6265635.0,
1040,158425,9,3,,103520217,2153,Unspecified,,,412.0,IC50,Inhibition of cAMP phosphodiesterase in bovine heart,Confirmatory,6265639.0,
1041,158428,3,5,,103520217,2153,Unspecified,,,,,Compound was evaluated for potency against c-AMP phosphodiesterase relative to theophylline,Other,6265635.0,
1042,158432,9,5,,103520217,2153,Unspecified,544050.0,281969.0,92.0,IC50,Inhibition of bovine heart phosphodiesterase,Confirmatory,1527785.0,
1043,158432,9,5,,103520217,2153,Unspecified,544051.0,281970.0,92.0,IC50,Inhibition of bovine heart phosphodiesterase,Confirmatory,1527785.0,
1044,158433,9,2,,103520217,2153,Unspecified,,,1780.0,IC50,Inhibition of bovine heart cAMP-phosphodiesterase,Confirmatory,3965705.0,
1045,158438,8,2,,103520217,2153,Unspecified,,,286.0,IC50,Inhibitory activity against phosphodiesterase using 1 uM cyclic-AMP as substrate in bovine heart,Confirmatory,6273558.0,
1046,158439,6,2,,103520217,2153,Unspecified,,,412.0,IC50,Inhibition of bovine heart phosphodiesterase using 1 uM cyclic-AMP with ethanol,Confirmatory,6273558.0,
1047,158450,8,2,,103520217,2153,Unspecified,1705947.0,25638.0,530.0,Ki,Inhibition of rat lung cAMP-phosphodiesterase,Confirmatory,6161252.0,
1048,158450,8,2,,103520217,2153,Unspecified,1705949.0,290646.0,530.0,Ki,Inhibition of rat lung cAMP-phosphodiesterase,Confirmatory,6161252.0,
1049,158450,8,2,,103520217,2153,Unspecified,57015263.0,24627.0,530.0,Ki,Inhibition of rat lung cAMP-phosphodiesterase,Confirmatory,6161252.0,
1050,158450,8,2,,103520217,2153,Unspecified,152031653.0,24626.0,530.0,Ki,Inhibition of rat lung cAMP-phosphodiesterase,Confirmatory,6161252.0,
1051,158451,8,1,,103520217,2153,Unspecified,,,1150.0,Ki,Inhibition of rat lung cGMP-Phosphodiesterase,Confirmatory,6161252.0,
1052,158452,3,5,,103520217,2153,Unspecified,,,,,Relative inhibition of rat lung phosphodiesterase cGMP and cAMP activity,Other,6161252.0,
1053,158566,3,5,,103520217,2153,Unspecified,,,,,Relative potency of compound to that of theophylline against phosphodiesterase from bovine heart,Other,6273558.0,
1054,158720,8,2,,103520217,2153,Unspecified,,,100.0,IC50,Inhibition of Peak I phosphodiesterase from pig coronary arteries,Confirmatory,6276544.0,
1055,158721,8,2,,103520217,2153,Unspecified,,,190.0,IC50,Inhibition of pig coronary artery cAMP-specific phosphodiesterase,Confirmatory,6276544.0,
1056,158727,8,2,,103520217,2153,Unspecified,,,85.0,IC50,Inhibition of rabbit kidney Phosphodiesterase,Confirmatory,6279846.0,
1057,158732,6,2,,103520217,2153,Unspecified,,,110.0,Ki,Inhibition of rabbit kidney phosphodiesterase,Confirmatory,6279846.0,
1058,158733,6,2,,103520217,2153,Unspecified,,,180.0,Ki,Inhibition of rabbit lung Phosphodiesterase,Confirmatory,6279846.0,
1059,158885,6,4,,103520217,2153,Unspecified,,,320.0,IC50,Inhibition of [Ca(2+)]/calmodulin dependent phosphodiesterase PDE 1 of guinea pig ventricle,Confirmatory,2985781.0,
1060,158910,9,2,,103520217,2153,Unspecified,,,356.0,IC50,Inhibitory activity against PDE1 from cerebral cortex,Confirmatory,9379444.0,
1061,159038,9,5,,103520217,2153,Unspecified,544050.0,281969.0,500.0,IC50,Inhibition of bovine heart Phosphodiesterase 1A,Confirmatory,2547071.0,
1062,159039,3,7,,103520217,2153,Unspecified,,,,,Concentration required to inhibit 50% activity of phosphodiesterase IB isoenzyme at 100 uM.,Other,8120866.0,
1063,159042,3,7,,103520217,2153,Unspecified,,,,,Inhibition of phosphodiesterase Ic isoenzyme,Other,8120866.0,
1064,159048,10,1,,103520217,2153,Unspecified,,,,,Concentration required to inhibit 50% activity of phosphodiesterase II isoenzyme at 100 uM,Other,8120866.0,
1065,159193,3,7,,103520217,2153,Unspecified,,,,,Concentration required to inhibit 50% activity of phosphodiesterase III isoenzyme at 100 uM,Other,8120866.0,
1066,159377,9,2,,103520217,2153,Unspecified,,,240.0,IC50,Inhibitory activity against Phosphodiesterase 3 from heart.,Confirmatory,9379444.0,
1067,159503,3,7,,103520217,2153,Unspecified,,,,,Inhibition of phosphodiesterase 4 at 100 uM,Other,8120866.0,
1068,160138,9,2,,103520217,2153,Unspecified,,,81.0,IC50,Inhibitory activity against Phosphodiesterase 4 from heart.,Confirmatory,9379444.0,
1069,168580,3,3,,103520217,2153,Unspecified,,,,,Antiallergic activity of edema in the active anaphylaxis assay at a peroral dose of 100 mg/kg in rats,Other,3172125.0,
1070,170577,3,3,,103520217,2153,Unspecified,,,,,Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.08 mg/kg,Other,8355252.0,
1071,170581,4,3,,103520217,2153,Unspecified,,,,,Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after p.o. administration of 0.31 mg/kg,Other,8355252.0,
1072,170585,3,3,,103520217,2153,Unspecified,,,,,Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 1.25 mg/kg,Other,8355252.0,
1073,170590,3,3,,103520217,2153,Unspecified,,,,,Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 20 mg/kg,Other,8355252.0,
1074,170592,3,3,,103520217,2153,Unspecified,,,,,Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 5 mg/kg,Other,8355252.0,
1075,173211,3,4,,103520217,2153,Unspecified,,,,,Decrease in blood pressure at 15 mg/kg in rat,Other,6265635.0,
1076,173212,3,4,,103520217,2153,Unspecified,,,,,Decrease in blood pressure at 2.5 mg/kg in rat,Other,6265635.0,
1077,173213,3,4,,103520217,2153,Unspecified,,,,,Decrease in blood pressure at 5 mg/kg in rat,Other,6265635.0,
1078,173539,3,3,,103520217,2153,Unspecified,,,,,Percent decrease in antiallergic activity by antigen/antibody reaction assay in rat by oral administration at a dose of 10 mg/kg,Other,2859374.0,
1079,173540,3,3,,103520217,2153,Unspecified,,,,,"Percentage decrease in antiallergic activity against cutaneous reaction to histamine in rat, by oral administration at a dose of 10 mg/kg",Other,2859374.0,
1080,174527,8,1,,103520217,2153,Unspecified,,,,,Serum creatinine concentration measured after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 5.43+/-0.11),Other,1501234.0,
1081,176666,8,1,,103520217,2153,Unspecified,,,920.0,ED50,Inhibition of carbachol induced tracheal contraction,Confirmatory,1527785.0,
1082,176668,8,1,,103520217,2153,Unspecified,,,900.0,ED50,Inhibition of spontaneous contraction of isolated rat uterus,Confirmatory,1527785.0,
1083,176821,6,2,,103520217,2153,Unspecified,,,,,Tested for anti PCA- activity when compound was administered perorally 60 min before challenge in,Other,6134832.0,
1084,177138,7,2,,103520217,2153,Unspecified,,,,,In vivo bronchodilator activity in methacholine (intravenous) induced bronchospasm in male Harlan-Sprague-Dawley rats when administered intraduodenally,Other,6161252.0,
1085,178097,6,2,,103520217,2153,Unspecified,,,,,Antiallergic activity by passive cutaneous anaphylaxis test in rats by intraduodenal administration,Other,6161252.0,
1086,178098,8,1,,103520217,2153,Unspecified,,,,,Antiallergic activity by passive cutaneous anaphylaxis test in rats by intravenous administration,Other,6161252.0,
1087,178103,7,2,,103520217,2153,Unspecified,,,,,Antiallergic activity was evaluated by inhibition of allergen-induced bronchospasm in male Harlan-Wistar rats when administered intraduodenally 15 min prior to antigen challenge,Other,6161252.0,
1088,178105,6,2,,103520217,2153,Unspecified,,,,,Antiallergic activity by passive cutaneous anaphylaxis test in ovalbumin sensitized male Harlan-Sprague-Dawley rats administered orally,Other,6161252.0,
1089,178992,5,1,,103520217,2153,Active,,,0.0009,ED50,Inhibition of the uterine smooth muscle contraction induced by histamine on the isolated rat uterus.,Confirmatory,6319701.0,
1090,181530,6,2,,103520217,2153,Unspecified,,,2500.0,IC50,Antiallergic activity by passive cutaneous anaphylaxis test in vitro in rats,Confirmatory,6161252.0,
1091,182086,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of PCA reaction in anesthetized rats after 11.7 mg/kg intraduodenal administration for 15 min,Other,6161252.0,
1092,182087,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of PCA reaction in anesthetized rats at 47.6 mg/kg oral administration for 15 min,Other,6161252.0,
1093,182088,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of PCA reaction in anesthetized rats at 47.6 mg/kg oral administration for 24 hr r,Other,6161252.0,
1094,182089,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of PCA reaction in anesthetized rats at 47.6 mg/kg oral administration for 3 hr,Other,6161252.0,
1095,182090,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of PCA reaction in anesthetized rats at 47.6 mg/kg oral administration for 6 hr,Other,6161252.0,
1096,182091,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of PCA reaction in anesthetized rats at 11.7 mg/kg peroral administration for 3 hr,Other,6161252.0,
1097,183466,3,3,,103520217,2153,Unspecified,,,,,Antiallergic activity evaluated as percent inhibition at peroral dose of 100 mg/kg in rats,Other,3172125.0,
1098,186749,3,4,,103520217,2153,Unspecified,,,,,Decrease in arterial blood pressure in anesthetized rats at 15 mg/kg after intravenous femoral injection,Other,6265635.0,
1099,186750,3,4,,103520217,2153,Unspecified,,,,,Decrease in arterial blood pressure in anesthetized rats at 2.5 mg/kg intravenous femoral injection,Other,6265635.0,
1100,186752,3,4,,103520217,2153,Unspecified,,,,,Decrease in arterial blood pressure in anesthetized rats at 5 mg/kg intravenous femoral injection,Other,6265635.0,
1101,187182,6,8,,103520217,2153,Active,112939.0,29316.0,4.8,Ki,Inhibition of adenosine stimulated accumulation of cyclic AMP at Adenosine A2 receptor of VA13 fibroblasts of rat,Confirmatory,3172141.0,
1102,187182,6,8,,103520217,2153,Active,8928539.0,25369.0,4.8,Ki,Inhibition of adenosine stimulated accumulation of cyclic AMP at Adenosine A2 receptor of VA13 fibroblasts of rat,Confirmatory,3172141.0,
1103,187481,3,3,,103520217,2153,Unspecified,,,,,Relative potency is evaluated by in vitro route in rats,Other,6161252.0,
1104,187482,3,3,,103520217,2153,Unspecified,,,,,Relative potency is evaluated by intraduodenal administration in rats,Other,6161252.0,
1105,187483,3,3,,103520217,2153,Unspecified,,,,,Relative potency is evaluated by intravenous administration in rats,Other,6161252.0,
1106,187947,5,1,,103520217,2153,Unspecified,,,,,Effect on urinary excretion potassium and sodium after oral administration of 1.6 mg/kg to rats(potassium and sodium excretion in control rat is 0.079+/-0.007),Other,1501234.0,
1107,188115,5,1,,103520217,2153,Unspecified,,,,,Effect on urinary excretion potassium and sodium after oral administration of 25 mg/kg to rats(potassium and sodium excretion in control rat is 0.193+/-0.016),Other,1501234.0,
1108,188244,5,1,,103520217,2153,Unspecified,,,,,Effect on urinary excretion potassium and sodium after oral administration of 6.25 mg/kg to rats(potassium and sodium excretion in control rat is 0.132+/-0.010),Other,1501234.0,
1109,188280,4,3,,103520217,2153,Unspecified,,,,,"Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg",Other,1501234.0,
1110,188282,4,3,,103520217,2153,Unspecified,,,,,"Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 25 mg/Kg",Other,1501234.0,
1111,188407,4,4,,103520217,2153,Unspecified,,,,,Ratio of sodium ion/potassium ion concentration in urine of rats following 6.25 mg/kg p.o.,Other,1501234.0,
1112,189923,3,3,,103520217,2153,Unspecified,,,,,"Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg",Other,1501234.0,
1113,189925,4,3,,103520217,2153,Unspecified,,,,,"Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg",Other,1501234.0,
1114,189927,4,3,,103520217,2153,Unspecified,,,,,"Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 6.25 mg/Kg",Other,1501234.0,
1115,189935,4,3,,103520217,2153,Unspecified,,,,,"Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg",Other,1501234.0,
1116,189937,4,3,,103520217,2153,Unspecified,,,,,"Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg",Other,1501234.0,
1117,189939,4,3,,103520217,2153,Unspecified,,,,,"Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 6.25 mg/Kg",Other,1501234.0,
1118,190197,8,1,,103520217,2153,Unspecified,,,,,Urea nitrogen concentration measured after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 182.5+/-3.4),Other,1501234.0,
1119,191181,3,3,,103520217,2153,Unspecified,,,,,Oral diuretic activity was measured after oral administration of 1.6 mg/kg to rats(control volume is 0.69+/-0.03),Other,1501234.0,
1120,191336,3,3,,103520217,2153,Unspecified,,,,,Oral diuretic activity was measured after oral administration of 25 mg/kg to rats(control volume is 0.91+/-0.08),Other,1501234.0,
1121,191353,3,3,,103520217,2153,Unspecified,,,,,Oral diuretic activity was measured after oral administration of 6.25 mg/kg to rats(control volume is 0.83+/-0.08),Other,1501234.0,
1122,191550,3,3,,103520217,2153,Unspecified,,,,,Retention time in Scopolamine induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 5 mg/kg,Other,8355252.0,
1123,191556,3,3,,103520217,2153,Unspecified,,,,,Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.08 mg/kg,Other,8355252.0,
1124,191560,4,3,,103520217,2153,Unspecified,,,,,Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after p.o. administration of 0.31 mg/kg,Other,8355252.0,
1125,191564,3,3,,103520217,2153,Unspecified,,,,,Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 1.25 mg/kg,Other,8355252.0,
1126,191566,3,3,,103520217,2153,Unspecified,,,,,Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 20 mg/kg,Other,8355252.0,
1127,192667,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of serum creatinine by the compound given as ratio of Cr value in treated to vehicle treated ones after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 182.5+/-3.4),Other,1501234.0,
1128,194938,3,3,,103520217,2153,Unspecified,,,,,Percent inhibition of Urea nitrogen by the compound given as ratio of UN value in treated to vehicle treated ones after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 182.5+/-3.4),Other,1501234.0,
1129,195542,10,2,,103520217,2153,Active,112939.0,29316.0,4.5,Ki,Antagonist binding of 2-chloro-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1130,195542,10,2,,103520217,2153,Active,2506479.0,25370.0,4.5,Ki,Antagonist binding of 2-chloro-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1131,195542,10,2,,103520217,2153,Active,2827766.0,29290.0,4.5,Ki,Antagonist binding of 2-chloro-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1132,195542,10,2,,103520217,2153,Active,8928539.0,25369.0,4.5,Ki,Antagonist binding of 2-chloro-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1133,195543,10,2,,103520217,2153,Active,112939.0,29316.0,2.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat brain,Confirmatory,6279840.0,
1134,195543,10,2,,103520217,2153,Active,2506479.0,25370.0,2.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat brain,Confirmatory,6279840.0,
1135,195543,10,2,,103520217,2153,Active,2827766.0,29290.0,2.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat brain,Confirmatory,6279840.0,
1136,195543,10,2,,103520217,2153,Active,8928539.0,25369.0,2.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat brain,Confirmatory,6279840.0,
1137,195544,10,2,,103520217,2153,Active,112939.0,29316.0,9.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1138,195544,10,2,,103520217,2153,Active,2506479.0,25370.0,9.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1139,195544,10,2,,103520217,2153,Active,2827766.0,29290.0,9.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1140,195544,10,2,,103520217,2153,Active,8928539.0,25369.0,9.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat brain,Confirmatory,6279840.0,
1141,196738,11,2,,103520217,2153,Active,112939.0,29316.0,22.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat fat,Confirmatory,6279840.0,
1142,196738,11,2,,103520217,2153,Active,2506479.0,25370.0,22.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat fat,Confirmatory,6279840.0,
1143,196738,11,2,,103520217,2153,Active,2827766.0,29290.0,22.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat fat,Confirmatory,6279840.0,
1144,196738,11,2,,103520217,2153,Active,8928539.0,25369.0,22.0,Ki,Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat fat,Confirmatory,6279840.0,
1145,196931,11,2,,103520217,2153,Active,112939.0,29316.0,20.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat testes,Confirmatory,6279840.0,
1146,196931,11,2,,103520217,2153,Active,2506479.0,25370.0,20.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat testes,Confirmatory,6279840.0,
1147,196931,11,2,,103520217,2153,Active,2827766.0,29290.0,20.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat testes,Confirmatory,6279840.0,
1148,196931,11,2,,103520217,2153,Active,8928539.0,25369.0,20.0,Ki,Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat testes,Confirmatory,6279840.0,
1149,197750,6,2,,103520217,2153,Unspecified,,,,,Tested for the antiallergic activity in rat passive cutaneous anaphylaxis (PCA) test; po,Other,7108903.0,
1150,197751,6,2,,103520217,2153,Unspecified,,,,,Tested for the bronchodilator activity by measuring inhibition of methacholine induced bronchospasm in rat intra duodenally,Other,7108903.0,
1151,202405,3,7,,103520217,2153,Unspecified,,,,,Compound was screened for their ability to potentiate [Ca2+] release induced by cADRP(an endogenous modulator of ryanodine receptor) in sea urchin egg homogenates at a concentration of 2 mM,Other,10411473.0,
1152,205268,4,7,,103520217,2153,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
1153,205269,3,7,,103520217,2153,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM,Other,2579237.0,
1154,210768,6,3,,103520217,2153,Active,,,28.0,EC50,In vitro guinea pig tracheal relaxation,Confirmatory,9379444.0,
1155,219684,8,2,,103520217,2153,Unspecified,,,77.0,Ki,Inhibition of bovine heart cAMP Phosphodiesterase,Confirmatory,6279842.0,
1156,219688,8,2,,103520217,2153,Unspecified,,,90.0,IC50,Inhibition of bovine heart cAMP Phosphodiesterase,Confirmatory,6279842.0,
1157,219689,6,2,,103520217,2153,Unspecified,,,190.0,IC50,Inhibition of bovine brain cAMP Phosphodiesterase,Confirmatory,6279842.0,
1158,219690,6,2,,103520217,2153,Unspecified,,,150.0,Ki,Inhibition of bovine brain cAMP Phosphodiesterase,Confirmatory,6279842.0,
1159,219817,6,2,,103520217,2153,Unspecified,,,210.0,IC50,Inhibition of rabbit lung cAMP Phosphodiesterase,Confirmatory,6279842.0,
1160,219818,6,2,,103520217,2153,Unspecified,,,180.0,Ki,Inhibition of rabbit lung cAMP Phosphodiesterase,Confirmatory,6279842.0,
1161,219846,9,5,,103520217,2153,Unspecified,729163.0,5142.0,56.8,Ki,Inhibition of c-AMP phosphodiesterase activity in guinea pig tracheal muscle,Confirmatory,1331453.0,
1162,219846,9,5,,103520217,2153,Unspecified,12644392.0,5144.0,56.8,Ki,Inhibition of c-AMP phosphodiesterase activity in guinea pig tracheal muscle,Confirmatory,1331453.0,
1163,219846,9,5,,103520217,2153,Unspecified,20141263.0,5143.0,56.8,Ki,Inhibition of c-AMP phosphodiesterase activity in guinea pig tracheal muscle,Confirmatory,1331453.0,
1164,219846,9,5,,103520217,2153,Unspecified,116242706.0,5141.0,56.8,Ki,Inhibition of c-AMP phosphodiesterase activity in guinea pig tracheal muscle,Confirmatory,1331453.0,
1165,220054,9,2,,103520217,2153,Unspecified,,,56.8,Ki,Inhibition of cyclic AMP-phosphodiesterase ( PDE) in the supernatant of tracheal muscle homogenate,Confirmatory,8496906.0,
1166,221857,3,3,,103520217,2153,Unspecified,,,,,"Positive chronotropic effect, 15% increase in heart rate of male Hartley guinea pigs on intraduodenal administration (mean of 3-5 animals)",Other,8496906.0,
1167,221859,6,2,,103520217,2153,Unspecified,,,,,"Bronchodilatory effect, 50% inhibition of spasmogen-induced response in male Hartley guinea pigs on intraduodenal administration",Other,8496906.0,
1168,223359,3,4,,103520217,2153,Unspecified,,,,,In vivo positive chronotropic effect on isolated guinea pig right atrium,Other,1331453.0,
1169,223360,6,2,,103520217,2153,Unspecified,,,,,In vivo reduction of acetylcholine-induced bronchospasm in guinea pigs by intraduodenal dose,Other,1331453.0,
1170,227036,3,6,,103520217,2153,Unspecified,,,,,A1 selectivity is the ratio between A2 and A1 receptor,Other,8182711.0,
1171,227877,3,4,,103520217,2153,Unspecified,,,,,Ratio of stimulatory activity in right atrium to relaxant activity in tracheal muscle,Other,1331453.0,
1172,228357,4,6,,103520217,2153,Unspecified,,,,,Ratio of Ki at A2 receptor to that of A1 receptor,Other,1501234.0,
1173,228358,3,5,,103520217,2153,Unspecified,,,,,"Ratio against A1 adenosine receptor to the A2 adenosine receptor (guinea pig forebrain membranes, using N6-[3H]cyclohexyladenosine as radioligand.",Other,1613758.0,
1174,229793,4,6,,103520217,2153,Unspecified,,,,,Ratio of Ki for A2 and A1 adenosine receptors,Other,8355252.0,
1175,229822,3,6,,103520217,2153,Unspecified,,,,,Ratio of antagonism at A2 versus A1 receptors (Ki values),Other,2984420.0,
1176,230229,3,5,,103520217,2153,Unspecified,,,,,Inhibitory selectivity for A2 receptor in rat striatal membranes and A1 receptor in rat cortical membranes,Other,2754711.0,
1177,230247,4,2,,103520217,2153,Unspecified,,,,,Ratio of Na+ to K+ excretion,Other,1992150.0,
1178,230534,3,5,,103520217,2153,Unspecified,,,,,Ratio of selectivity for A3 and A1 receptors at rat brain,Other,7932565.0,
1179,230535,3,6,,103520217,2153,Unspecified,,,,,Ratio of selectivity for A3 and A2a receptors at rat brain,Other,7932565.0,
1180,231907,3,5,,103520217,2153,Unspecified,,,,,Ratio between the Ki values of A2 and A1 receptors,Other,8071944.0,
1181,232062,3,10,,103520217,2153,Unspecified,112939.0,29316.0,,,Selectivity as ratio of Ki for adenosine A2 and A1 adenosine receptors,Other,1548682.0,
1182,232062,3,10,,103520217,2153,Unspecified,2827766.0,29290.0,,,Selectivity as ratio of Ki for adenosine A2 and A1 adenosine receptors,Other,1548682.0,
1183,232062,3,10,,103520217,2153,Unspecified,8928539.0,25369.0,,,Selectivity as ratio of Ki for adenosine A2 and A1 adenosine receptors,Other,1548682.0,
1184,232222,3,3,,103520217,2153,Unspecified,,,,,Selectivity for A2 and A1 receptors was evaluated,Other,2795597.0,
1185,233055,3,4,,103520217,2153,Unspecified,,,,,Bronchoselectivity expressed as ratio of stimulatory activity in the right atrium (EC15) to relaxant activity in the tracheal muscle (EC50),Other,8496906.0,
1186,233904,3,6,,103520217,2153,Unspecified,,,,,Selectivity was expressed as the ratio is Ki of adenosine A1 receptor to that of adenosine A2 receptor,Other,3806581.0,
1187,233916,3,6,,103520217,2153,Unspecified,,,,,Selectivity ratio as adenosine A1 receptor/adenosine A2A receptor.,Other,9435909.0,
1188,234622,3,3,,103520217,2153,Unspecified,,,,,"Bronchoselectivity, ratio of positive chronotropic action (ED15) to bronchodilator action (ED50)",Other,8496906.0,
1189,236904,3,3,,103520217,2153,Unspecified,,,,,Partition coefficient (logP),Other,15925511.0,
1190,237685,4,3,,103520217,2153,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
1191,238055,10,5,,103520217,2153,Active,231473.0,134.0,12.0,Kd,Dissociation constant against Adenosine A1 receptor,Confirmatory,15771445.0,
1192,238114,6,3,,103520217,2153,Active,,,0.4,Kd,Dissociation constant of the compound,Confirmatory,15293991.0,
1193,239444,10,2,,103520217,2153,Active,543740.0,135.0,0.0006,Ki,Binding affinity for adenosine A2a receptor by using as [3H]ZM-241385 radioligand in membranes from HEK-A2A cells,Confirmatory,15664822.0,
1194,239445,10,2,,103520217,2153,Active,112938.0,136.0,7.059,Ki,Binding affinity for adenosine A2b receptor by using as [3H]ZM-241385 radioligand in membranes from HEK-A2B cells,Confirmatory,15664822.0,
1195,239508,10,2,,103520217,2153,Active,231473.0,134.0,0.0006,Ki,Binding affinity for adenosine A1 receptor by using as [3H]CPX iradioligand n membranes from Chinese hamster ovary cells,Confirmatory,15664822.0,
1196,239588,10,2,,103520217,2153,Active,803374855.0,140.0,0.013999999999999999,Ki,Binding affinity for adenosine A3 receptor by displacement of specific binding of [125I]AB-MECA in membranes from CHO-A3 cells,Confirmatory,15664822.0,
1197,243443,3,10,,103520217,2153,Unspecified,231473.0,134.0,,,Dissociation constant against Adenosine A1 receptor,Other,15771445.0,
1198,254330,5,6,,103520217,2153,Active,112938.0,136.0,9.07,Ki,Antagonist activity against human Adenosine A2b receptor,Confirmatory,16250640.0,
1199,256809,8,5,,103520217,2153,Active,160332359.0,282133.0,3.8,Ki,Displacement of [3H]CHA from adenosine A1 receptor in bovine cerebral cortical membranes,Confirmatory,16335918.0,
1200,256813,7,1,,103520217,2153,Active,,,21.0,Ki,Displacement of [3H]CGS 21680 from adenosine A2A receptor in bovine striatal membranes,Confirmatory,16335918.0,
1201,256816,8,5,,103520217,2153,Active,231473.0,134.0,6.2,Ki,Displacement of [3H]CHA from cloned human adenosine A1 receptor expressed in CHO cells,Confirmatory,16335918.0,
1202,256818,8,5,,103520217,2153,Active,543740.0,135.0,7.9,Ki,Displacement of [3H]NECA from cloned human adenosine A2A receptor expressed in CHO cells,Confirmatory,16335918.0,
1203,256820,8,5,,103520217,2153,Unspecified,803374855.0,140.0,86.0,Ki,Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells,Confirmatory,16335918.0,
1204,256822,3,9,,103520217,2153,Unspecified,231473.0,134.0,,,Selectivity for human adenosine A3 receptor over human adenosine A1 receptor,Other,16335918.0,
1205,256822,3,9,,103520217,2153,Unspecified,803374855.0,140.0,,,Selectivity for human adenosine A3 receptor over human adenosine A1 receptor,Other,16335918.0,
1206,256823,3,9,,103520217,2153,Unspecified,231473.0,134.0,,,Selectivity for human adenosine A3 receptor over human adenosine A2A receptor,Other,16335918.0,
1207,256823,3,9,,103520217,2153,Unspecified,803374855.0,140.0,,,Selectivity for human adenosine A3 receptor over human adenosine A2A receptor,Other,16335918.0,
1208,266271,8,5,,103520217,2153,Active,112938.0,136.0,9.07,Ki,Displacement of [3H]ZM241385 from human adenosine A2b receptor expressed in HEK cells,Confirmatory,16759111.0,
1209,266272,8,5,,103520217,2153,Active,231473.0,134.0,6.92,Ki,Displacement of [3H]CPX from human adenosine A3 receptor expressed in CHO cells,Confirmatory,16759111.0,
1210,266273,8,5,,103520217,2153,Active,543740.0,135.0,6.7,Ki,Displacement of [3H]ZM-241385 from human adenosine A2a receptor expressed in HEK cells,Confirmatory,16759111.0,
1211,266274,8,5,,103520217,2153,Active,803374855.0,140.0,22.3,Ki,Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells,Confirmatory,16759111.0,
1212,266823,8,5,,103520217,2153,Unspecified,803374855.0,140.0,86.0,Ki,Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells,Confirmatory,16789747.0,
1213,266825,8,5,,103520217,2153,Active,231473.0,134.0,6.2,Ki,Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells,Confirmatory,16789747.0,
1214,266827,8,5,,103520217,2153,Active,543740.0,135.0,7.9,Ki,Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells,Confirmatory,16789747.0,
1215,266829,8,5,,103520217,2153,Active,160332359.0,282133.0,3.8,Ki,Displacement of [3H]DPCPX from adenosine A1 receptor in bovine brain membranes,Confirmatory,16789747.0,
1216,266831,7,1,,103520217,2153,Active,,,21.0,Ki,Displacement of [3H]CGS 21680 from adenosine A2A receptor in bovine striatal membranes,Confirmatory,16789747.0,
1217,268021,5,2,,103520217,2153,Unspecified,,,,,Aqueous solubility of the compound,Other,16616488.0,
1218,268022,5,2,,103520217,2153,Unspecified,,,,,Solubility in IPM,Other,16616488.0,
1219,268023,3,4,,103520217,2153,Unspecified,,,,,"Ratio for partition coefficient, log K in IPM to buffer at pH 4",Other,16616488.0,
1220,268024,7,1,,103520217,2153,Unspecified,,,,,Permeability across hairless mouse skin,Other,16616488.0,
1221,288184,9,1,,103520217,2153,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
1222,288185,7,1,,103520217,2153,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
1223,288192,3,4,,103520217,2153,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
1224,297166,8,5,,103520217,2153,Unspecified,803374855.0,140.0,86.0,Ki,Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells,Confirmatory,17665891.0,
1225,297168,8,5,,103520217,2153,Active,231473.0,134.0,6.2,Ki,Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells,Confirmatory,17665891.0,
1226,297170,8,5,,103520217,2153,Active,543740.0,135.0,7.9,Ki,Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells,Confirmatory,17665891.0,
1227,300011,3,3,,103520217,2153,Unspecified,,,,,"Effect on 1-methyl-4-phenyl-2,3-dihydropyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 10 uM",Other,17533133.0,
1228,300012,3,3,,103520217,2153,Unspecified,,,,,"Effect on 1-methyl-4-phenyl-2,3-dihydropyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 100 uM",Other,17533133.0,
1229,300013,3,3,,103520217,2153,Unspecified,,,,,"Effect on 1-methyl-4-phenyl-2,3-dihydropyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 500 uM",Other,17533133.0,
1230,300014,3,3,,103520217,2153,Unspecified,,,,,"Effect on 1-methyl-4-phenyl-2,3-dihydropyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 1000 uM",Other,17533133.0,
1231,300015,3,3,,103520217,2153,Unspecified,,,,,Effect on 1-methyl-4-phenylpyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 10 uM,Other,17533133.0,
1232,300016,3,3,,103520217,2153,Unspecified,,,,,Effect on 1-methyl-4-phenylpyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 100 uM,Other,17533133.0,
1233,300017,3,3,,103520217,2153,Unspecified,,,,,Effect on 1-methyl-4-phenylpyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 500 uM,Other,17533133.0,
1234,300018,3,3,,103520217,2153,Unspecified,,,,,Effect on 1-methyl-4-phenylpyridinium-induced mutagenicity in Vibrio harveyi BB7XM assessed as number of neomycin-resistant mutants at 1000 uM,Other,17533133.0,
1235,311524,4,3,,103520217,2153,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
1236,336478,3,7,,103520217,2153,Unspecified,,,,,Inhibition of COX2 at 100 uM by scintillation proximity assay,Other,12444669.0,
1237,363122,3,3,,103520217,2153,Unspecified,,,,,Inhibition of PDE4 at 200 uM,Other,18686943.0,
1238,372137,8,5,,103520217,2153,Active,231473.0,134.0,6.2,Ki,Binding affinity to human adenosine A1 receptor,Confirmatory,19569717.0,
1239,372138,8,5,,103520217,2153,Active,543740.0,135.0,4.2,Ki,Binding affinity to human adenosine A2A receptor,Confirmatory,19569717.0,
1240,372139,8,5,,103520217,2153,Active,112938.0,136.0,7.85,Ki,Binding affinity to human adenosine A2B receptor,Confirmatory,19569717.0,
1241,372140,8,5,,103520217,2153,Unspecified,803374855.0,140.0,52.3,Ki,Binding affinity to human adenosine A3 receptor,Confirmatory,19569717.0,
1242,372141,8,5,,103520217,2153,Active,2827766.0,29290.0,8.5,Ki,Binding affinity to rat adenosine A1 receptor,Confirmatory,19569717.0,
1243,372142,8,5,,103520217,2153,Active,8928539.0,25369.0,25.0,Ki,Binding affinity to rat adenosine A2A receptor,Confirmatory,19569717.0,
1244,372143,8,5,,103520217,2153,Active,112939.0,29316.0,15.1,Ki,Binding affinity to rat adenosine A2B receptor,Confirmatory,19569717.0,
1245,372144,8,5,,103520217,2153,Unspecified,2506479.0,25370.0,100.0,Ki,Binding affinity to rat adenosine A3 receptor,Confirmatory,19569717.0,
1246,373867,6,3,,103520217,2153,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
1247,379301,9,2,,103520217,2153,Active,,,8.5,Ki,Binding affinity to adenosine A1 receptor,Confirmatory,10757709.0,
1248,386623,4,8,,103520217,2153,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
1249,400069,9,5,,103520217,2153,Active,2827766.0,29290.0,26.0,Ki,Displacement of [3H]CHA from adenosine A1 receptor in rat brain cortical membrane,Confirmatory,9514015.0,
1250,400072,9,5,,103520217,2153,Active,8928539.0,25369.0,22.0,Ki,Displacement of [3H]CGS21680 from adenosine A2A receptor in rat brain striatal membrane,Confirmatory,9514015.0,
1251,400077,6,3,,103520217,2153,Unspecified,,,565.0,Ki,Displacement of [3H]diazepam from benzodiazepine binding site of GABAA receptor in rat brain cortical membrane,Confirmatory,9514015.0,
1252,408425,8,5,,103520217,2153,Unspecified,803374855.0,140.0,86.0,Ki,Displacement of [125I]AB-MECA from human cloned adenosine A3 receptor expressed in CHO cells,Confirmatory,18468446.0,
1253,408427,8,5,,103520217,2153,Active,231473.0,134.0,6.2,Ki,Displacement of [125I]DPCPX from human cloned adenosine A1 receptor expressed in CHO cells,Confirmatory,18468446.0,
1254,408429,8,5,,103520217,2153,Active,543740.0,135.0,7.9,Ki,Displacement of [125I]NECA from human cloned adenosine A2A receptor expressed in CHO cells,Confirmatory,18468446.0,
1255,408431,8,5,,103520217,2153,Active,160332359.0,282133.0,3.8,Ki,Displacement of [125I]DPCPX from adenosine A1 receptor in bovine brain membrane,Confirmatory,18468446.0,
1256,408433,4,3,,103520217,2153,Active,,,21.0,Ki,Displacement of [3H]CGS21680 from adenosine A2A receptor in bovine brain membrane,Confirmatory,18468446.0,
1257,409954,4,9,,103520217,2153,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
1258,409956,4,9,,103520217,2153,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
1259,411208,9,2,,103520217,2153,Unspecified,,,,IC50,Inhibition of TNSALP,Confirmatory,19038545.0,
1260,414670,8,5,,103520217,2153,Unspecified,803374855.0,140.0,86.0,Ki,Displacement of [125I]AB-MECA from human cloned adenosine A3 receptor expressed in CHO cells,Confirmatory,19301821.0,
1261,414672,8,5,,103520217,2153,Active,231473.0,134.0,6.2,Ki,Displacement of [3H]DPCPX from human cloned adenosine A1 receptor expressed in CHO cells,Confirmatory,19301821.0,
1262,414674,8,5,,103520217,2153,Active,543740.0,135.0,7.9,Ki,Displacement of [3H]NECA from human cloned adenosine A2A receptor expressed in CHO cells,Confirmatory,19301821.0,
1263,414676,8,5,,103520217,2153,Active,160332359.0,282133.0,3.8,Ki,Displacement of [3H]DPCPX from bovine brain cortical membrane adenosine A1 receptor,Confirmatory,19301821.0,
1264,414678,4,3,,103520217,2153,Active,,,21.0,Ki,Displacement of [3H]CGS 21680 from bovine striatal membrane adenosine A2A receptor,Confirmatory,19301821.0,
1265,425652,7,2,,103520217,2153,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1266,425653,7,2,,103520217,2153,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1267,432063,8,1,,103520217,2153,Unspecified,,,,,Apparent permeability at pH 7.4 after 24 hrs by PAMPA method,Other,19410338.0,
1268,434446,8,1,,103520217,2153,Unspecified,,,,,Passive membrane permeability across the PAMPA using pre coated plate based method,Other,19616948.0,
1269,434955,1,2,,855679,2153,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1270,434959,1,1,,85787353,2153,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1271,434959,1,1,,85789579,2153,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1272,434962,1,2,,855679,2153,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1273,434973,1,3,,855679,2153,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1274,434989,1,1,,855679,2153,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1275,435003,1,3,,855679,2153,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1276,435005,1,1,,855679,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1277,435022,2,2,,855679,2153,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1278,435030,1,2,,855679,2153,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1279,435030,1,2,,855679,2153,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1280,444050,7,1,,103520217,2153,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
1281,444051,6,2,,103520217,2153,Unspecified,,,,,Total clearance in human,Other,20070106.0,
1282,444052,6,2,,103520217,2153,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
1283,444053,6,2,,103520217,2153,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
1284,444054,6,1,,103520217,2153,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
1285,444055,3,3,,103520217,2153,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
1286,444056,3,3,,103520217,2153,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
1287,444057,3,3,,103520217,2153,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1288,444058,6,2,,103520217,2153,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1289,449728,1,2,,855679,2153,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1290,449739,1,2,,855679,2153,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1291,449762,1,2,,855679,2153,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1292,449763,1,3,,855679,2153,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1293,449768,1,1,,855679,2153,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1294,453742,5,2,,103520217,2153,Unspecified,,,550.0,IC50,Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 150 mM NH4Cl,Confirmatory,20004571.0,
1295,453743,5,2,,103520217,2153,Unspecified,,,400.0,IC50,Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 150 mM NH4Cl,Confirmatory,20004571.0,
1296,453745,5,2,,103520217,2153,Unspecified,,,430.0,IC50,Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 10 mM L-glutamine and 0.15 mM GTP,Confirmatory,20004571.0,
1297,453746,5,2,,103520217,2153,Unspecified,,,300.0,IC50,Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 10 mM L-glutamine and 0.15 mM GTP,Confirmatory,20004571.0,
1298,455986,3,5,,103520217,2153,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
1299,459064,8,2,,103520217,2153,Unspecified,,,5.0,IC50,Inhibition of PLAP by analogous luminescence assay,Confirmatory,20031422.0,
1300,459065,8,2,,103520217,2153,Unspecified,,,5.0,IC50,Inhibition of TNAP by analogous luminescence assay,Confirmatory,20031422.0,
1301,459066,8,2,,103520217,2153,Unspecified,,,5.0,IC50,Inhibition of IAP by analogous luminescence assay,Confirmatory,20031422.0,
1302,462282,7,5,,103520217,2153,Active,543740.0,135.0,,IC50,Binding affinity to human adenosine A2A receptor,Confirmatory,20188574.0,
1303,462300,9,2,,103520217,2153,Active,112939.0,29316.0,15.1,Ki,Binding affinity to rat adenosine A2B receptor,Confirmatory,20188574.0,
1304,462301,9,2,,103520217,2153,Unspecified,2506479.0,25370.0,85.0,Ki,Binding affinity to rat adenosine A3 receptor,Confirmatory,20188574.0,
1305,462302,7,5,,103520217,2153,Active,231473.0,134.0,6.77,Ki,Binding affinity to human adenosine A1 receptor,Confirmatory,20188574.0,
1306,462303,7,5,,103520217,2153,Active,112938.0,136.0,,IC50,Binding affinity to human adenosine A2B receptor,Confirmatory,20188574.0,
1307,462304,7,5,,103520217,2153,Active,803374855.0,140.0,22.3,Ki,Binding affinity to human adenosine A3 receptor,Confirmatory,20188574.0,
1308,462305,7,5,,103520217,2153,Active,2827766.0,29290.0,,IC50,Binding affinity to rat adenosine A1 receptor,Confirmatory,20188574.0,
1309,462306,7,5,,103520217,2153,Active,8928539.0,25369.0,,IC50,Binding affinity to rat adenosine A2A receptor,Confirmatory,20188574.0,
1310,462597,10,2,,103520217,2153,Active,231473.0,134.0,10.1,Ki,Displacement of [3H]DPCPX from human recombinant adenosine A1 receptor expressed in CHO-A1 cell membrane,Confirmatory,20202853.0,
1311,462598,10,2,,103520217,2153,Active,543740.0,135.0,18.5,Ki,Displacement of [3H]ZM241385 from human recombinant adenosine A2A receptor expressed in in human HeLa cell membrane,Confirmatory,20202853.0,
1312,462599,10,2,,103520217,2153,Active,112938.0,136.0,2.7,Ki,Displacement of [3H]DPCPX from human recombinant adenosine A2B receptor expressed in HEK293 cell membrane,Confirmatory,20202853.0,
1313,462600,10,2,,103520217,2153,Unspecified,803374855.0,140.0,85.1,Ki,Displacement of [3H]NECA from human recombinant adenosine A3 receptor expressed in human HeLa cell membrane,Confirmatory,20202853.0,
1314,463073,1,2,,855679,2153,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1315,463075,1,1,,855679,2153,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1316,463079,1,2,,855679,2153,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1317,463082,1,1,,855679,2153,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1318,463104,1,2,,855679,2153,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1319,463106,1,2,,90341676,2153,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1320,463111,1,1,,855679,2153,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1321,463115,1,1,,855679,2153,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1322,463141,1,2,,855679,2153,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1323,463165,1,1,,855679,2153,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1324,463187,1,1,,855679,2153,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1325,463189,1,1,,855679,2153,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1326,463190,1,2,,855679,2153,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1327,463193,1,1,,855679,2153,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1328,463195,1,2,,855679,2153,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1329,463210,1,2,,855679,2153,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1330,463212,1,1,,855679,2153,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1331,463254,1,1,,855679,2153,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1332,467612,3,6,,103520217,2153,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
1333,467613,5,3,,103520217,2153,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
1334,476929,3,3,,103520217,2153,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
1335,485270,1,1,,855679,2153,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1336,485272,1,1,,855679,2153,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1337,485273,2,1,,855679,2153,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1338,485275,1,3,,855679,2153,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1339,485281,1,1,,855679,2153,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1340,485290,1,1,,855679,2153,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1341,485290,1,1,,17389715,2153,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1342,485290,1,1,,26746955,2153,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1343,485290,1,1,,26751482,2153,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1344,485290,1,1,,29215004,2153,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1345,485290,1,1,,50103997,2153,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1346,485290,1,1,,50103998,2153,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1347,485294,1,1,,855679,2153,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1348,485295,1,2,,90341676,2153,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1349,485297,1,1,,855679,2153,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1350,485297,1,1,,90341676,2153,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1351,485298,1,1,,855679,2153,Inconclusive,,,7.0795,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1352,485298,1,1,,90341676,2153,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1353,485313,1,2,,855679,2153,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1354,485313,1,2,,90341676,2153,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1355,485314,1,1,,855679,2153,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1356,485341,1,1,,855679,2153,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1357,485342,1,2,,90341676,2153,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1358,485344,1,1,,855679,2153,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1359,485345,1,2,,90341676,2153,Inconclusive,,,6.5131,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1360,485346,1,1,,855679,2153,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1361,485346,1,1,,855679,2153,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1362,485347,1,2,,855679,2153,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1363,485349,1,1,,855679,2153,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1364,485350,1,2,,92124327,2153,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1365,485353,2,1,,855679,2153,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1366,485358,1,1,,855679,2153,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1367,485360,1,1,,855679,2153,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1368,485364,1,1,,855679,2153,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1369,485366,1,2,,90341676,2153,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1370,485367,1,2,,855679,2153,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1371,485368,1,2,,90341676,2153,Inconclusive,72386991.0,3656265.0,0.7569,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1372,488772,1,1,,90341676,2153,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1373,488773,1,2,,90341676,2153,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1374,488806,1,2,,855679,2153,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1375,488816,1,1,,90341676,2153,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1376,488837,1,1,,855679,2153,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1377,488837,1,1,,90341676,2153,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1378,488839,1,1,,56463437,2153,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1379,488839,1,1,,56463437,2153,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1380,488847,1,3,,855679,2153,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1381,488862,1,1,,56463437,2153,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1382,488890,1,2,,855679,2153,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1383,488895,1,2,,56463437,2153,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1384,488896,1,1,,56463437,2153,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1385,488899,1,1,,56463437,2153,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1386,488922,1,2,,855679,2153,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1387,488949,1,2,,90341676,2153,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1388,488953,1,1,,90341676,2153,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1389,488965,1,2,,56463437,2153,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1390,488966,1,1,,56463437,2153,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1391,488975,1,2,,855679,2153,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1392,488977,1,2,,855679,2153,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1393,488978,1,1,,90341676,2153,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1394,488981,1,1,,90341676,2153,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1395,488982,1,1,,90341676,2153,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1396,488983,1,1,,90341676,2153,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1397,489030,2,1,,855679,2153,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1398,489031,2,1,,855679,2153,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1399,492947,1,1,,855679,2153,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1400,492953,1,1,,56463437,2153,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1401,492956,1,1,,56463437,2153,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1402,492967,1,2,,99301291,2153,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1403,492972,1,1,,56463437,2153,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1404,493005,1,1,,56463437,2153,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1405,493008,1,1,,56463437,2153,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1406,493008,1,1,,56463437,2153,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1407,493008,1,1,,56463437,2153,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1408,493008,1,1,,56463437,2153,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1409,493011,1,1,,855679,2153,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1410,493012,1,1,,855679,2153,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1411,493014,1,1,,855679,2153,Inconclusive,,,1.9953,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1412,493027,1,2,,56463437,2153,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1413,493027,1,2,,56463437,2153,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1414,493033,1,2,,92124327,2153,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1415,493035,1,2,,56463437,2153,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1416,493035,1,2,,56463437,2153,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1417,493036,1,2,,855679,2153,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1418,493056,1,1,,855679,2153,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1419,493084,1,1,,855679,2153,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1420,493087,1,1,,56463437,2153,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1421,493091,1,1,,56463437,2153,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1422,493098,1,1,,56463437,2153,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1423,493106,1,1,,90341676,2153,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1424,493107,1,1,,90341676,2153,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1425,493131,1,1,,56463437,2153,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1426,493153,1,1,,90341676,2153,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1427,493153,1,1,,90341676,2153,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1428,493160,1,1,,56463437,2153,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1429,493162,1,2,,99301291,2153,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1430,493164,1,2,,90341676,2153,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1431,493164,1,2,,90341676,2153,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1432,493164,1,2,,90341676,2153,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1433,493187,1,2,,56463437,2153,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1434,493244,1,1,,56463437,2153,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1435,493244,1,1,,56463437,2153,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1436,493244,1,1,,56463437,2153,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1437,493244,1,1,,56463437,2153,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1438,494495,3,6,,103520217,2153,Active,112938.0,136.0,9.07,Ki,Antagonist activity against human adenosine A2B receptor,Confirmatory,20537438.0,
1439,496817,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
1440,496818,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
1441,496819,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
1442,496820,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
1443,496821,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
1444,496823,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
1445,496824,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
1446,496825,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
1447,496826,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
1448,496827,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
1449,496828,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
1450,496829,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
1451,496830,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
1452,496831,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
1453,496832,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
1454,497005,4,2,,103520217,2153,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
1455,504326,1,2,,56463437,2153,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1456,504326,1,2,,56463437,2153,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1457,504327,1,1,,855679,2153,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1458,504327,1,1,,90341676,2153,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1459,504329,1,1,,56463437,2153,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1460,504332,1,1,,855679,2153,Inactive,168985070.0,,0.2818,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1461,504332,1,1,,90341676,2153,Active,168985070.0,,3.3587,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1462,504333,1,1,,855679,2153,Inconclusive,6683500.0,29994.0,2.5119,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1463,504339,1,1,,56463437,2153,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1464,504357,1,1,,56463437,2153,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1465,504357,1,1,,56463437,2153,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1466,504406,1,1,,855679,2153,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1467,504408,2,1,,855679,2153,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1468,504411,1,1,,56463437,2153,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1469,504414,1,1,,56463437,2153,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1470,504414,1,1,,56463437,2153,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1471,504423,1,1,,56463437,2153,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1472,504441,1,1,,56463437,2153,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1473,504444,1,1,,56463437,2153,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1474,504454,1,3,,56463437,2153,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1475,504459,1,3,,855679,2153,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
1476,504462,1,1,,56463437,2153,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1477,504466,1,1,,855679,2153,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1478,504467,1,1,,855679,2153,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1479,504490,1,2,,56463437,2153,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1480,504523,1,1,,56463437,2153,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1481,504523,1,1,,56463437,2153,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1482,504536,1,1,,90341676,2153,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1483,504541,1,1,,855679,2153,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1484,504547,1,1,,90341676,2153,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1485,504548,1,2,,90341676,2153,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1486,504558,1,1,,56463437,2153,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1487,504577,2,2,,56463437,2153,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1488,504582,2,1,,56463437,2153,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1489,504594,1,1,,56463437,2153,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1490,504600,1,2,,855679,2153,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1491,504621,1,1,,56463437,2153,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1492,504634,1,1,,56463437,2153,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1493,504648,1,1,,56463437,2153,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1494,504651,1,1,,855679,2153,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1495,504652,1,1,,855679,2153,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1496,504660,1,1,,855679,2153,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1497,504690,1,3,,56463437,2153,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1498,504692,2,2,,56463437,2153,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1499,504700,1,1,,56463437,2153,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1500,504700,1,1,,56463437,2153,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1501,504706,1,1,,855679,2153,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1502,504707,1,1,,56463437,2153,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1503,504707,1,1,,56463437,2153,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1504,504720,1,1,,56463437,2153,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1505,504734,1,1,,56463437,2153,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1506,504749,1,3,,29215004,2153,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1507,504749,1,3,,104171361,2153,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1508,504749,1,3,1.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1509,504749,1,3,2.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1510,504749,1,3,3.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1511,504749,1,3,4.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1512,504749,1,3,5.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1513,504749,1,3,6.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1514,504749,1,3,7.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1515,504749,1,3,8.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1516,504749,1,3,9.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1517,504749,1,3,10.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1518,504749,1,3,11.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1519,504749,1,3,12.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1520,504749,1,3,13.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1521,504749,1,3,14.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1522,504749,1,3,15.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1523,504749,1,3,16.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1524,504749,1,3,17.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1525,504749,1,3,18.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1526,504749,1,3,19.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1527,504749,1,3,20.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1528,504749,1,3,21.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1529,504749,1,3,22.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1530,504749,1,3,23.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1531,504749,1,3,24.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1532,504749,1,3,25.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1533,504749,1,3,26.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1534,504749,1,3,27.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1535,504749,1,3,28.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1536,504749,1,3,29.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1537,504749,1,3,30.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1538,504749,1,3,31.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1539,504749,1,3,32.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1540,504749,1,3,33.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1541,504749,1,3,34.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1542,504749,1,3,35.0,29215004,2153,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1543,504749,1,3,36.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1544,504749,1,3,37.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1545,504749,1,3,38.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1546,504749,1,3,39.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1547,504749,1,3,40.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1548,504749,1,3,41.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1549,504749,1,3,42.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1550,504749,1,3,43.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1551,504749,1,3,44.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1552,504749,1,3,45.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1553,504749,1,3,46.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1554,504749,1,3,47.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1555,504749,1,3,48.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1556,504749,1,3,49.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1557,504749,1,3,50.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1558,504749,1,3,51.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1559,504749,1,3,52.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1560,504749,1,3,53.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1561,504749,1,3,54.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1562,504749,1,3,55.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1563,504749,1,3,56.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1564,504749,1,3,57.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1565,504749,1,3,58.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1566,504749,1,3,59.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1567,504749,1,3,60.0,104171361,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1568,504749,1,3,61.0,29215004,2153,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1569,504766,2,1,,56463437,2153,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1570,504770,1,2,,92124327,2153,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1571,504775,1,1,,56463437,2153,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1572,504803,1,1,,56463437,2153,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1573,504810,1,2,,855679,2153,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1574,504810,1,2,,90341676,2153,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1575,504812,1,2,,855679,2153,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1576,504812,1,2,,90341676,2153,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1577,504832,1,1,,855679,2153,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1578,504832,1,1,,104171361,2153,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1579,504834,1,1,,855679,2153,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1580,504834,1,1,,104171361,2153,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1581,504836,1,2,,90341676,2153,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1582,504842,1,1,,855679,2153,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1583,504845,1,1,,56463437,2153,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1584,504845,1,1,,90341676,2153,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1585,504847,1,1,,56463437,2153,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1586,504847,1,1,,90341676,2153,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1587,504847,1,1,,104171361,2153,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1588,504865,1,1,,90341676,2153,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1589,504865,1,1,,104171361,2153,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1590,504884,1,2,,56463437,2153,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1591,504891,1,1,,56463437,2153,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1592,504894,1,1,,56463437,2153,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1593,504937,1,2,,56463437,2153,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1594,511376,2,3,,103520217,2153,Unspecified,,,,,"Neurotoxicity in ddY mouse assessed as changes in behavioral activity at 110 nmol/mouse, icv measured for 60 mins",Other,20681583.0,
1595,521220,3,3,,103520217,2153,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1596,540209,4,3,,103520217,2153,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1597,540210,4,3,,103520217,2153,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1598,540211,2,5,,103520217,2153,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1599,540212,4,3,,103520217,2153,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1600,540213,4,3,,103520217,2153,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1601,540253,1,1,,56463437,2153,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1602,540253,1,1,,56463437,2153,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1603,540253,1,1,,56463437,2153,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1604,540256,1,2,,855679,2153,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1605,540256,1,2,,90341676,2153,Inconclusive,,,0.5171,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1606,540263,1,1,,56463437,2153,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1607,540263,1,1,,56463437,2153,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1608,540267,1,1,,56463437,2153,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1609,540275,1,1,,855679,2153,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1610,540276,1,2,,855679,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1611,540276,1,2,,17389715,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1612,540276,1,2,,26746955,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1613,540276,1,2,,26746956,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1614,540276,1,2,,26751482,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1615,540276,1,2,,29215004,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1616,540276,1,2,,50100831,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1617,540276,1,2,,50103996,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1618,540276,1,2,,50103997,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1619,540276,1,2,,50103998,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1620,540276,1,2,,56463437,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1621,540276,1,2,,90341676,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1622,540276,1,2,,104171361,2153,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1623,540277,1,1,,855679,2153,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1624,540295,1,1,,56463437,2153,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1625,540299,1,2,,92124327,2153,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1626,540303,1,1,,56463437,2153,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1627,540303,1,1,,56463437,2153,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1628,540303,1,1,,56463437,2153,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1629,540308,1,1,,56463437,2153,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1630,540317,1,1,,56463437,2153,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1631,540336,1,1,,56463437,2153,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1632,540336,1,1,,56463437,2153,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1633,540364,1,2,,56463437,2153,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1634,588209,2,3,,103520217,2153,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1635,588210,2,4,,103520217,2153,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1636,588211,2,3,,103520217,2153,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1637,588212,2,3,,103520217,2153,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1638,588213,2,3,,103520217,2153,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1639,588214,2,3,,103520217,2153,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1640,588215,2,3,,103520217,2153,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1641,588216,2,3,,103520217,2153,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1642,588217,2,3,,103520217,2153,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1643,588218,2,3,,103520217,2153,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1644,588219,2,3,,103520217,2153,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1645,588334,1,1,,56463437,2153,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1646,588335,1,1,,56463437,2153,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1647,588342,1,1,,855679,2153,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1648,588349,1,1,,90341676,2153,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
1649,588352,1,2,,56463437,2153,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1650,588354,1,1,,56463437,2153,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1651,588358,1,2,,56463437,2153,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1652,588368,1,2,,855679,2153,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
1653,588378,1,1,,90341676,2153,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
1654,588391,1,1,,56463437,2153,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1655,588405,1,1,,56463437,2153,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1656,588413,1,2,,56463437,2153,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1657,588436,1,1,,56463437,2153,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1658,588453,1,1,,56463437,2153,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1659,588453,1,1,,90341676,2153,Inactive,8659577.0,58819.0,14.1254,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1660,588453,1,1,,124883294,2153,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1661,588456,1,1,,56463437,2153,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1662,588456,1,1,,90341676,2153,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1663,588456,1,1,,124883294,2153,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1664,588458,1,1,,56463437,2153,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1665,588459,1,2,,855679,2153,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
1666,588459,1,2,,855679,2153,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
1667,588459,1,2,,855679,2153,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
1668,588460,1,2,,855679,2153,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
1669,588460,1,2,,855679,2153,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
1670,588460,1,2,,855679,2153,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
1671,588461,1,2,,855679,2153,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
1672,588461,1,2,,855679,2153,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
1673,588461,1,2,,855679,2153,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
1674,588473,1,1,,56463437,2153,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1675,588473,1,1,,56463437,2153,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1676,588475,1,2,,56463437,2153,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1677,588475,1,2,,56463437,2153,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1678,588478,1,2,,124800442,2153,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1679,588489,1,1,,56463437,2153,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1680,588492,1,1,,56463437,2153,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1681,588493,1,2,,56463437,2153,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1682,588497,1,2,,56463437,2153,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1683,588497,1,2,,56463437,2153,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1684,588497,1,2,,56463437,2153,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1685,588499,1,3,,56463437,2153,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1686,588499,1,3,,56463437,2153,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1687,588499,1,3,,56463437,2153,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1688,588501,1,2,,56463437,2153,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1689,588501,1,2,,56463437,2153,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1690,588501,1,2,,56463437,2153,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1691,588506,1,2,,855679,2153,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
1692,588511,1,2,,855679,2153,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1693,588513,1,1,,17389715,2153,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1694,588514,1,1,,17389715,2153,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1695,588515,1,1,,17389715,2153,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1696,588516,1,1,,17389715,2153,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1697,588519,1,2,,92124327,2153,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1698,588526,1,1,,17389715,2153,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1699,588527,1,1,,17389715,2153,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1700,588532,1,1,,17389715,2153,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1701,588533,1,1,,17389715,2153,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1702,588534,1,1,,17389715,2153,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1703,588535,1,1,,17389715,2153,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1704,588536,1,1,,17389715,2153,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1705,588537,1,1,,17389715,2153,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1706,588541,1,1,,17389715,2153,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1707,588543,1,1,,17389715,2153,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1708,588544,1,1,,17389715,2153,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1709,588545,1,1,,17389715,2153,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1710,588546,1,1,,17389715,2153,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1711,588547,1,1,,17389715,2153,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1712,588549,1,1,,56463437,2153,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1713,588550,1,1,,855679,2153,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
1714,588579,1,1,,56463437,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1715,588579,1,1,,90341676,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1716,588579,1,1,,104171361,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1717,588579,1,1,,124883291,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1718,588579,1,1,,124883293,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1719,588579,1,1,,124883294,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1720,588579,1,1,,124883295,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1721,588579,1,1,,124883296,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1722,588579,1,1,,124883297,2153,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1723,588590,1,1,,56463437,2153,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1724,588590,1,1,,124883294,2153,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1725,588591,1,1,,56463437,2153,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1726,588621,1,1,,56463437,2153,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1727,588627,1,1,,855679,2153,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1728,588664,1,2,,56463437,2153,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1729,588664,1,2,,56463437,2153,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1730,588674,1,2,,56463437,2153,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1731,588675,1,1,,855679,2153,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1732,588676,1,1,,855679,2153,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1733,588685,1,1,,855679,2153,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
1734,588689,1,1,,56463437,2153,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1735,588692,2,1,,56463437,2153,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1736,588726,1,2,,56463437,2153,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1737,588727,1,1,,56463437,2153,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1738,588795,1,1,,56463437,2153,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1739,588795,1,1,,90341676,2153,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1740,588795,1,1,,124883294,2153,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1741,588814,1,3,,56463437,2153,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1742,588819,1,4,,56463437,2153,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1743,588834,2,1,,17389715,2153,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1744,588834,2,1,,29215004,2153,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1745,588850,1,1,,56463437,2153,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1746,588852,1,3,,56463437,2153,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1747,588855,1,1,,56463437,2153,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1748,588855,1,1,,124883294,2153,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1749,588856,1,1,,56463437,2153,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1750,588856,1,1,,124883294,2153,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1751,589031,1,10,,103520217,2153,Unspecified,117144.0,1544.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP1A2",Other,,
1752,592681,1,4,,103520217,2153,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
1753,602123,1,1,,56463437,2153,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1754,602141,1,1,,56463437,2153,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1755,602162,1,1,,56463437,2153,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1756,602163,1,1,,56463437,2153,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1757,602179,1,2,,56463437,2153,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1758,602229,1,1,,56463437,2153,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1759,602233,1,1,,56463437,2153,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1760,602244,1,2,,56463437,2153,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1761,602247,1,2,,56463437,2153,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1762,602248,1,2,,56463437,2153,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1763,602250,1,2,,56463437,2153,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1764,602252,1,1,,56463437,2153,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1765,602252,1,1,,56463437,2153,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1766,602261,1,1,,56463437,2153,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1767,602274,1,2,,56463437,2153,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1768,602276,1,1,,855679,2153,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
1769,602277,1,1,,855679,2153,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
1770,602281,1,1,,56463437,2153,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1771,602281,1,1,,56463437,2153,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1772,602310,1,2,,56463437,2153,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1773,602310,1,2,,124883294,2153,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1774,602313,1,1,,56463437,2153,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1775,602314,1,2,,92124327,2153,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1776,602329,1,1,,56463437,2153,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1777,602332,1,1,,56463437,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1778,602332,1,1,,90341676,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1779,602332,1,1,,104171361,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1780,602332,1,1,,124883291,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1781,602332,1,1,,124883293,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1782,602332,1,1,,124883294,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1783,602332,1,1,,124883295,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1784,602332,1,1,,124883296,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1785,602332,1,1,,124883297,2153,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1786,602340,1,2,,56463437,2153,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1787,602342,2,1,,56463437,2153,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1788,602346,1,1,,56463437,2153,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1789,602363,1,1,,56463437,2153,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1790,602393,1,1,,56463437,2153,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1791,602396,1,2,,56463437,2153,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1792,602399,1,2,,56463437,2153,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1793,602405,1,1,,56463437,2153,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1794,602410,1,1,,56463437,2153,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1795,602429,1,1,,56463437,2153,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1796,602438,1,1,,56463437,2153,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1797,602440,1,1,,56463437,2153,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1798,602449,1,2,,56463437,2153,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1799,602481,1,1,,56463437,2153,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1800,602756,3,1,,103520217,2153,Unspecified,,,,,Maximum permeability flux through hairless mouse skin applied topically as suspension in propylene glycol,Other,21616664.0,
1801,603953,1,3,,103520217,2153,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
1802,607198,5,6,,103520217,2153,Unspecified,543740.0,135.0,10.0,Ki,Displacement of [3H]ZM241385 from stabilized human adenosine receptor A2a expressed in HEK293 cells followed by receptor capturing on Biocore chips by SPR method,Confirmatory,21661720.0,
1803,607199,1,5,,103520217,2153,Unspecified,,,,,Binding affinity at stabilized human adenosine receptor A2a L85A'3.33 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor,Other,21661720.0,
1804,607200,1,5,,103520217,2153,Unspecified,,,,,Binding affinity at human adenosine receptor A2a L167A'extracellular loop 2 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor,Other,21661720.0,
1805,607201,1,5,,103520217,2153,Inconclusive,,,,,Binding affinity at human adenosine receptor A2a M177A'5.38 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor,Other,21661720.0,
1806,607202,1,5,,103520217,2153,Unspecified,,,,,Binding affinity at human adenosine receptor A2a receptor Y271A'7.36 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor,Other,21661720.0,
1807,607203,1,5,,103520217,2153,Unspecified,,,,,Binding affinity at human adenosine receptor A2a I66A'2.64 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor,Other,21661720.0,
1808,607231,1,5,,103520217,2153,Unspecified,,,,,Binding affinity at human adenosine receptor A2a N181A'5.42 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor,Other,21661720.0,
1809,607232,1,5,,103520217,2153,Unspecified,,,,,Inverse agonist activity at human adenosine receptor A2a S277A'7.42 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor,Other,21661720.0,
1810,623870,1,1,,56463437,2153,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1811,623870,1,1,,56463437,2153,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1812,623877,1,1,,56463437,2153,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1813,623901,1,1,,56463437,2153,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1814,624030,1,2,,104171361,2153,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1815,624031,1,2,,104171361,2153,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1816,624032,1,2,,104171361,2153,Inactive,8393992.0,24660.0,0.0029,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1817,624037,1,3,,56463437,2153,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1818,624038,1,3,,56463437,2153,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1819,624040,1,3,,56463437,2153,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1820,624044,1,2,,104171361,2153,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1821,624101,1,2,,85787353,2153,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1822,624125,1,4,,56463437,2153,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1823,624126,1,3,,56463437,2153,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1824,624127,1,2,,56463437,2153,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1825,624137,1,1,,85787353,2153,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1826,624146,1,1,,90341676,2153,Inconclusive,71051501.0,2744.0,0.1122,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
1827,624147,1,1,,90341676,2153,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
1828,624148,1,2,,90341676,2153,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
1829,624149,1,1,,90341676,2153,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
1830,624156,1,1,,85787353,2153,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1831,624156,1,1,,85789579,2153,Inconclusive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1832,624168,1,1,,56463437,2153,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1833,624169,1,1,,56463437,2153,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1834,624170,1,1,,56463437,2153,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1835,624170,1,1,,104171361,2153,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1836,624171,1,1,,56463437,2153,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1837,624172,1,1,,56463437,2153,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1838,624172,1,1,,104171361,2153,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1839,624173,1,3,,56463437,2153,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1840,624173,1,3,,104171361,2153,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1841,624178,1,1,,56463437,2153,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1842,624178,1,1,,124883294,2153,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1843,624202,1,1,,56463437,2153,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1844,624202,1,1,,124883294,2153,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1845,624204,1,2,,56463437,2153,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1846,624246,1,1,,56463437,2153,Inconclusive,343478176.0,2078.0,7.0795,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1847,624256,1,2,,56463437,2153,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1848,624260,1,1,,85787353,2153,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1849,624263,1,1,,56463437,2153,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1850,624263,1,1,,56463437,2153,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1851,624263,1,1,,124883294,2153,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1852,624263,1,1,,124883294,2153,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1853,624267,1,2,,56463437,2153,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1854,624267,1,2,,56463437,2153,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1855,624268,1,3,,56463437,2153,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1856,624288,1,1,,56463437,2153,Inconclusive,52000961.0,2778.0,11.2202,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1857,624296,1,1,,855679,2153,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1858,624296,1,1,,29215004,2153,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1859,624296,1,1,,56463437,2153,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1860,624296,1,1,,104171361,2153,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1861,624297,1,1,,855679,2153,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1862,624297,1,1,,29215004,2153,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1863,624297,1,1,,56463437,2153,Inactive,7705682.0,51053.0,1.2589,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1864,624297,1,1,,104171361,2153,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1865,624304,1,2,,56463437,2153,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1866,624330,1,2,,56463437,2153,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1867,624349,1,2,,92124327,2153,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1868,624349,1,2,,92307755,2153,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1869,624349,1,2,,92308682,2153,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1870,624349,1,2,,121362606,2153,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1871,624352,1,1,,56463437,2153,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1872,624354,1,1,,56463437,2153,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1873,624377,1,1,,56463437,2153,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1874,624414,1,1,,56463437,2153,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1875,624414,1,1,,124883294,2153,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1876,624415,1,2,,56463437,2153,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1877,624416,1,1,,56463437,2153,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1878,624417,1,1,,56463437,2153,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1879,624418,1,1,,56463437,2153,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1880,624455,1,1,,90341676,2153,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
1881,624463,1,1,,56463437,2153,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1882,624464,1,1,,56463437,2153,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1883,624465,1,1,,56463437,2153,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1884,624466,1,3,,56463437,2153,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1885,624467,1,1,,56463437,2153,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1886,624483,1,1,,56463437,2153,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1887,625144,5,5,,103520217,2153,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1888,625145,4,7,,103520217,2153,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1889,625146,5,5,,103520217,2153,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1890,625147,4,7,,103520217,2153,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1891,625148,4,7,,103520217,2153,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1892,625149,4,7,,103520217,2153,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1893,625150,5,5,,103520217,2153,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1894,625151,4,7,,103520217,2153,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1895,625152,4,7,,103520217,2153,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1896,625153,4,7,,103520217,2153,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1897,625154,4,7,,103520217,2153,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1898,625155,4,7,,103520217,2153,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1899,625156,1,9,,103520217,2153,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1900,625157,6,2,,103520217,2153,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1901,625158,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1902,625159,5,5,,103520217,2153,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1903,625160,1,9,,103520217,2153,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1904,625161,4,7,,103520217,2153,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1905,625162,4,7,,103520217,2153,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1906,625163,4,7,,103520217,2153,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1907,625164,1,6,,103520217,2153,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1908,625165,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1909,625166,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1910,625167,5,5,,103520217,2153,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1911,625168,4,7,,103520217,2153,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1912,625169,1,6,,103520217,2153,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1913,625170,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1914,625171,4,7,,103520217,2153,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1915,625172,4,7,,103520217,2153,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1916,625173,5,5,,103520217,2153,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1917,625174,5,5,,103520217,2153,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1918,625175,5,5,,103520217,2153,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1919,625176,1,9,,103520217,2153,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1920,625177,5,5,,103520217,2153,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1921,625178,5,5,,103520217,2153,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1922,625179,1,9,,103520217,2153,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1923,625180,5,5,,103520217,2153,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1924,625181,5,5,,103520217,2153,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1925,625182,5,5,,103520217,2153,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1926,625183,5,5,,103520217,2153,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1927,625184,5,5,,103520217,2153,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1928,625185,5,5,,103520217,2153,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1929,625186,5,5,,103520217,2153,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1930,625187,5,5,,103520217,2153,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1931,625188,1,9,,103520217,2153,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1932,625189,1,7,,103520217,2153,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1933,625190,4,5,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1934,625191,4,7,,103520217,2153,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1935,625192,4,7,,103520217,2153,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1936,625193,5,5,,103520217,2153,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1937,625194,4,7,,103520217,2153,Active,231473.0,134.0,17.104,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1938,625195,4,7,,103520217,2153,Active,543740.0,135.0,12.007,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1939,625196,5,6,,103520217,2153,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1940,625197,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1941,625198,4,7,,103520217,2153,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1942,625199,4,7,,103520217,2153,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1943,625200,4,7,,103520217,2153,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1944,625201,4,7,,103520217,2153,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1945,625202,4,7,,103520217,2153,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1946,625203,4,7,,103520217,2153,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1947,625204,4,7,,103520217,2153,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1948,625205,4,7,,103520217,2153,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1949,625206,4,7,,103520217,2153,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1950,625207,4,7,,103520217,2153,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1951,625208,5,5,,103520217,2153,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1952,625209,4,7,,103520217,2153,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1953,625210,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1954,625211,1,6,,103520217,2153,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1955,625212,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1956,625213,4,7,,103520217,2153,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1957,625214,1,9,,103520217,2153,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1958,625215,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1959,625216,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1960,625217,4,7,,103520217,2153,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1961,625218,4,7,,103520217,2153,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1962,625219,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1963,625220,4,7,,103520217,2153,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1964,625221,4,7,,103520217,2153,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1965,625222,4,7,,103520217,2153,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1966,625223,4,7,,103520217,2153,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1967,625224,3,4,,103520217,2153,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1968,625225,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1969,625226,4,7,,103520217,2153,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1970,625227,4,7,,103520217,2153,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1971,625228,4,7,,103520217,2153,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1972,625229,5,5,,103520217,2153,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1973,625230,1,6,,103520217,2153,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1974,625231,4,7,,103520217,2153,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1975,625232,1,9,,103520217,2153,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1976,625233,4,7,,103520217,2153,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1977,625234,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1978,625235,4,7,,103520217,2153,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1979,625236,5,5,,103520217,2153,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1980,625237,4,7,,103520217,2153,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1981,625238,4,7,,103520217,2153,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1982,625239,4,7,,103520217,2153,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1983,625240,1,9,,103520217,2153,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1984,625241,4,7,,103520217,2153,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1985,625242,4,7,,103520217,2153,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1986,625243,5,5,,103520217,2153,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1987,625244,5,5,,103520217,2153,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1988,625245,5,5,,103520217,2153,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1989,625246,1,9,,103520217,2153,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1990,625247,5,5,,103520217,2153,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1991,625248,5,5,,103520217,2153,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1992,625249,5,5,,103520217,2153,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1993,625250,5,5,,103520217,2153,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1994,625251,5,5,,103520217,2153,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1995,625252,4,7,,103520217,2153,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1996,625253,4,7,,103520217,2153,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1997,625254,4,7,,103520217,2153,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1998,625255,4,7,,103520217,2153,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1999,625256,4,7,,103520217,2153,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2000,625257,4,7,,103520217,2153,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2001,625258,4,7,,103520217,2153,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2002,625259,4,7,,103520217,2153,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2003,625260,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2004,625261,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2005,625262,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2006,625263,4,7,,103520217,2153,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2007,625264,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2008,625265,1,6,,103520217,2153,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2009,625266,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2010,625267,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2011,625268,4,2,,103520217,2153,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2012,625268,4,2,,103520217,2153,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2013,625268,4,2,,103520217,2153,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2014,625268,4,2,,103520217,2153,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2015,625269,4,7,,103520217,2153,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2016,625270,4,7,,103520217,2153,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2017,625271,5,5,,103520217,2153,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2018,625272,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2019,625273,4,6,,103520217,2153,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2020,625274,1,6,,103520217,2153,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2021,625275,3,4,,103520217,2153,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2022,625279,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2023,625280,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2024,625281,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2025,625282,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2026,625283,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2027,625284,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2028,625285,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2029,625286,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2030,625287,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2031,625288,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2032,625289,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2033,625290,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2034,625291,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2035,625292,1,3,,103520217,2153,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2036,651548,1,1,,85787353,2153,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2037,651550,1,1,,56463437,2153,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2038,651560,1,1,,56463437,2153,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2039,651572,1,2,,56463437,2153,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2040,651582,1,1,,56463437,2153,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2041,651602,1,1,,56463437,2153,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2042,651602,1,1,,56463437,2153,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2043,651602,1,1,,56463437,2153,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2044,651610,2,1,,56463437,2153,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2045,651631,4,1,,144204378,2153,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2046,651631,4,1,,144209573,2153,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2047,651631,4,1,,144210348,2153,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2048,651632,4,1,,144204378,2153,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2049,651632,4,1,,144209573,2153,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2050,651632,4,1,,144210348,2153,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2051,651633,4,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2052,651633,4,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2053,651633,4,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2054,651634,4,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2055,651634,4,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2056,651634,4,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2057,651635,1,3,,56463437,2153,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2058,651635,1,3,,90341676,2153,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2059,651636,1,1,,56463437,2153,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2060,651640,1,1,,56463437,2153,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2061,651644,1,1,,56463437,2153,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2062,651647,1,1,,56463437,2153,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2063,651654,1,1,,56463437,2153,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2064,651658,1,1,,56463437,2153,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2065,651660,1,1,,56463437,2153,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2066,651661,2,1,,56463437,2153,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2067,651687,1,1,,56463437,2153,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2068,651699,1,1,,56463437,2153,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2069,651699,1,1,,56463437,2153,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2070,651702,1,2,,56463437,2153,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2071,651704,2,1,,56463437,2153,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2072,651710,1,1,,56463437,2153,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2073,651711,2,1,,56463437,2153,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2074,651718,1,2,,56463437,2153,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2075,651723,1,1,,56463437,2153,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2076,651724,1,1,,56463437,2153,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2077,651725,1,1,,56463437,2153,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2078,651741,1,1,,17389715,2153,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2079,651743,1,1,,17389715,2153,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2080,651749,1,1,,17389715,2153,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2081,651751,1,1,,17389715,2153,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2082,651754,1,1,,17389715,2153,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2083,651755,1,1,,17389715,2153,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2084,651757,1,1,,17389715,2153,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2085,651758,1,1,,17389715,2153,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2086,651768,1,2,,56463437,2153,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2087,651777,1,1,,17389715,2153,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2088,651778,1,1,,17389715,2153,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2089,651800,1,1,,56463437,2153,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2090,651802,1,1,,17389715,2153,Inactive,49066040.0,6097.0,42.1632,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2091,651803,1,1,,56463437,2153,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction: TR assay against cherry picks,Confirmatory,,
2092,651804,1,1,,56463437,2153,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction: HTRF assay against cherry picks,Confirmatory,,
2093,651819,1,1,,56463437,2153,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2094,651820,1,1,,855679,2153,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2095,651820,1,1,,56463437,2153,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2096,651821,2,4,,56463437,2153,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2097,651828,1,2,,92308682,2153,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2098,651828,1,2,,121362606,2153,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2099,651838,1,1,,17389715,2153,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2100,651838,1,1,1.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2101,651838,1,1,2.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2102,651838,1,1,3.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2103,651838,1,1,4.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2104,651838,1,1,5.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2105,651838,1,1,6.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2106,651838,1,1,7.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2107,651838,1,1,8.0,17389715,2153,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2108,651957,1,1,,56463437,2153,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2109,651958,1,1,,56463437,2153,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2110,651965,1,1,,56463437,2153,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2111,651965,1,1,,124883294,2153,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2112,651999,1,1,,56463437,2153,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2113,652010,1,1,,56463437,2153,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2114,652017,1,1,,56463437,2153,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2115,652025,1,1,,56463437,2153,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2116,652039,1,1,,56463437,2153,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2117,652048,1,2,,56463437,2153,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2118,652048,1,2,,144204378,2153,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2119,652051,1,1,,56463437,2153,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2120,652051,1,1,,144204378,2153,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2121,652054,1,1,,56463437,2153,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2122,652067,1,4,,56463437,2153,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2123,652104,1,1,,56463437,2153,Inconclusive,20140568.0,23435.0,11.2202,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2124,652105,1,1,,56463437,2153,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2125,652106,1,1,,56463437,2153,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2126,652106,1,1,,90341676,2153,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2127,652106,1,1,,124883294,2153,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2128,652115,1,1,,56463437,2153,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2129,652126,1,3,,56463437,2153,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2130,652154,1,1,,56463437,2153,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2131,652162,2,1,,56463437,2153,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2132,652163,1,1,,56463437,2153,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2133,652197,1,1,,56463437,2153,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2134,652257,1,1,,56463437,2153,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2135,678712,1,8,,103520217,2153,Inconclusive,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2136,678713,1,8,,103520217,2153,Inconclusive,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2137,678714,1,8,,103520217,2153,Inconclusive,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2138,678715,1,8,,103520217,2153,Inconclusive,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2139,678716,1,8,,103520217,2153,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2140,678717,1,8,,103520217,2153,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2141,678722,1,5,,103520217,2153,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2142,679509,1,8,,103520217,2153,Unspecified,74753520.0,10864.0,,,TP_TRANSPORTER: uptake in OAT2-expressing oocytes,Other,15708966.0,
2143,680773,1,8,,103520217,2153,Unspecified,74753520.0,10864.0,,,TP_TRANSPORTER: inhibition of erythromycin uptake in OAT2-expressing oocytes,Other,15708966.0,
2144,686940,1,1,,56463437,2153,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2145,686964,1,1,,56463437,2153,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2146,686970,1,2,,56463437,2153,Inconclusive,49168486.0,3417.0,20.5962,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2147,686971,1,2,,56463437,2153,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2148,686977,2,1,,49698738,2153,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2149,686978,1,1,,56463437,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2150,686978,1,1,,124883291,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2151,686978,1,1,,124883294,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2152,686978,1,1,,124883295,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2153,686978,1,1,,124883296,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2154,686978,1,1,,144204378,2153,Inconclusive,79154014.0,55775.0,9.4411,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2155,686979,1,1,,56463437,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2156,686979,1,1,,124883291,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2157,686979,1,1,,124883294,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2158,686979,1,1,,124883295,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2159,686979,1,1,,124883296,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2160,686979,1,1,,144204378,2153,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2161,686992,2,1,,56463437,2153,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2162,686996,1,1,,56463437,2153,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2163,687014,1,1,,56463437,2153,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2164,687016,1,1,,56463437,2153,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2165,699539,1,7,,103520217,2153,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2166,699540,1,7,,103520217,2153,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2167,699541,1,7,,103520217,2153,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2168,711193,3,1,,103520217,2153,Unspecified,,,,,Permeability at 10 uM at pH 7.4 by PAMPA method,Other,23181502.0,
2169,711194,3,1,,103520217,2153,Unspecified,,,,,Permeability at 10 uM at pH 5.0 by PAMPA method,Other,23181502.0,
2170,720504,1,1,,56463437,2153,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2171,720508,1,1,,56463437,2153,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2172,720509,1,1,,56463437,2153,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2173,720511,1,1,,56463437,2153,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2174,720516,2,1,,144204378,2153,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2175,720516,2,1,,144209573,2153,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2176,720516,2,1,,144210348,2153,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2177,720532,1,1,,124883291,2153,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2178,720532,1,1,,124883293,2153,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2179,720532,1,1,,124883295,2153,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2180,720532,1,1,,124883296,2153,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2181,720532,1,1,,124883297,2153,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2182,720532,1,1,,144204378,2153,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2183,720533,1,1,,124883291,2153,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2184,720533,1,1,,124883293,2153,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2185,720533,1,1,,124883295,2153,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2186,720533,1,1,,124883296,2153,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2187,720533,1,1,,124883297,2153,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2188,720533,1,1,,144204378,2153,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2189,720538,1,2,,90341676,2153,Inactive,220983390.0,410.0,37.933,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2190,720542,1,2,,56463437,2153,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2191,720543,1,1,,56463437,2153,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2192,720551,1,2,,56463437,2153,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2193,720552,2,1,,144204378,2153,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2194,720552,2,1,,144209573,2153,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2195,720552,2,1,,144210348,2153,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2196,720553,1,2,,56463437,2153,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2197,720554,1,3,,121362606,2153,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2198,720559,1,2,,90341676,2153,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2199,720572,1,2,,90341676,2153,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2200,720573,1,2,,90341676,2153,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2201,720579,2,1,,56463437,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2202,720579,2,1,,124883291,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2203,720579,2,1,,124883294,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2204,720579,2,1,,124883295,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2205,720579,2,1,,124883296,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2206,720580,1,1,,56463437,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2207,720580,1,1,,124883291,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2208,720580,1,1,,124883294,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2209,720580,1,1,,124883295,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2210,720580,1,1,,124883296,2153,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2211,720582,1,1,,56463437,2153,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2212,720596,1,1,,56463437,2153,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2213,720634,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2214,720634,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2215,720634,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2216,720635,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2217,720635,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2218,720635,2,1,,144210348,2153,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2219,720636,1,1,,17389715,2153,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2220,720637,2,1,,144204378,2153,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2221,720637,2,1,,144209573,2153,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2222,720637,2,1,,144210348,2153,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2223,720641,1,2,,92307755,2153,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2224,720641,1,2,,92308682,2153,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2225,720647,1,2,,56463437,2153,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2226,720648,1,1,,56463437,2153,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2227,720652,1,1,,17389715,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2228,720653,1,1,,17389715,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2229,720659,1,1,,17389715,2153,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2230,720674,2,2,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2231,720674,2,2,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2232,720674,2,2,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2233,720675,2,2,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2234,720675,2,2,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2235,720675,2,2,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2236,720678,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2237,720678,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2238,720678,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2239,720679,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2240,720679,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2241,720679,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2242,720680,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2243,720680,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2244,720680,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2245,720681,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2246,720681,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2247,720681,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2248,720682,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2249,720682,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2250,720682,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2251,720683,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2252,720683,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2253,720683,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2254,720684,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2255,720684,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2256,720684,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2257,720685,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2258,720685,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2259,720685,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2260,720686,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2261,720686,2,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2262,720686,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2263,720687,2,2,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2264,720687,2,2,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2265,720687,2,2,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2266,720691,4,1,,144204378,2153,Inactive,311348376.0,2908.0,2.6832,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2267,720691,4,1,,144209573,2153,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2268,720691,4,1,,144210348,2153,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2269,720692,3,1,,144204378,2153,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2270,720692,3,1,,144209573,2153,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2271,720692,3,1,,144210348,2153,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2272,720693,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2273,720693,3,1,,144209573,2153,Inconclusive,,,62.4754,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2274,720693,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2275,720700,1,4,,56463437,2153,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2276,720702,1,1,,56463437,2153,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2277,720704,1,4,,56463437,2153,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2278,720706,1,2,,56463437,2153,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2279,720707,1,2,,56463437,2153,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2280,720708,1,2,,56463437,2153,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2281,720709,1,2,,56463437,2153,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2282,720711,1,2,,56463437,2153,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2283,720717,1,3,,92124327,2153,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2284,720717,1,3,,92307755,2153,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2285,720717,1,3,,92308682,2153,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2286,720719,2,1,,144204378,2153,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2287,720719,2,1,,144209573,2153,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2288,720719,2,1,,144210348,2153,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2289,720725,2,1,,144204378,2153,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2290,720725,2,1,,144209573,2153,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2291,720725,2,1,,144210348,2153,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2292,743012,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2293,743012,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2294,743012,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2295,743014,3,1,,144204378,2153,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2296,743014,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2297,743014,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2298,743015,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2299,743015,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2300,743015,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2301,743033,3,1,,144204378,2153,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2302,743033,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2303,743033,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2304,743035,2,1,,144204378,2153,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2305,743035,2,1,,144209573,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2306,743035,2,1,,144210348,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2307,743036,2,1,,144204378,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2308,743036,2,1,,144209573,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2309,743036,2,1,,144210348,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2310,743040,3,1,,144204378,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2311,743040,3,1,,144209573,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2312,743040,3,1,,144210348,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2313,743041,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2314,743041,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2315,743041,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2316,743042,3,1,,144204378,2153,Inconclusive,124375976.0,367.0,0.0017,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2317,743042,3,1,,144209573,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2318,743042,3,1,,144210348,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2319,743053,2,1,,144204378,2153,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2320,743053,2,1,,144209573,2153,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2321,743053,2,1,,144210348,2153,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2322,743054,2,1,,144204378,2153,Inconclusive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2323,743054,2,1,,144209573,2153,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2324,743054,2,1,,144210348,2153,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2325,743063,2,1,,144204378,2153,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2326,743063,2,1,,144209573,2153,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2327,743063,2,1,,144210348,2153,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2328,743064,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2329,743064,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2330,743064,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2331,743065,3,1,,144204378,2153,Inactive,399498506.0,24831.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2332,743065,3,1,,144209573,2153,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2333,743065,3,1,,144210348,2153,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2334,743066,3,1,,144204378,2153,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2335,743066,3,1,,144209573,2153,Inconclusive,399498506.0,24831.0,24.6586,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2336,743066,3,1,,144210348,2153,Active,399498506.0,24831.0,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2337,743067,2,1,,144204378,2153,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2338,743067,2,1,,144209573,2153,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2339,743067,2,1,,144210348,2153,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2340,743069,2,1,,144204378,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2341,743069,2,1,,144209573,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2342,743069,2,1,,144210348,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2343,743074,2,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2344,743074,2,1,,144209573,2153,Inconclusive,,,9.9017,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2345,743074,2,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2346,743075,2,1,,144204378,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2347,743075,2,1,,144209573,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2348,743075,2,1,,144210348,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2349,743077,2,1,,144204378,2153,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2350,743077,2,1,,144209573,2153,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2351,743077,2,1,,144210348,2153,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2352,743078,2,1,,144204378,2153,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2353,743078,2,1,,144209573,2153,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2354,743078,2,1,,144210348,2153,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2355,743079,3,1,,144204378,2153,Active,348019627.0,2099.0,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2356,743079,3,1,,144209573,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2357,743079,3,1,,144210348,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2358,743080,3,1,,144204378,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2359,743080,3,1,,144209573,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2360,743080,3,1,,144210348,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2361,743081,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2362,743081,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2363,743081,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2364,743083,3,1,,144204378,2153,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2365,743083,3,1,,144209573,2153,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2366,743083,3,1,,144210348,2153,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2367,743084,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2368,743084,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2369,743084,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2370,743085,3,1,,144204378,2153,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2371,743085,3,1,,144209573,2153,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2372,743085,3,1,,144210348,2153,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2373,743086,3,1,,144204378,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2374,743086,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2375,743086,3,1,,144210348,2153,Inconclusive,,,76.9588,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2376,743091,2,1,,144204378,2153,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2377,743091,2,1,,144209573,2153,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2378,743091,2,1,,144210348,2153,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2379,743094,3,1,,144204378,2153,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2380,743094,3,1,,144209573,2153,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2381,743094,3,1,,144210348,2153,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2382,743122,2,1,,144204378,2153,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2383,743122,2,1,,144209573,2153,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2384,743122,2,1,,144210348,2153,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2385,743126,1,1,,56463437,2153,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2386,743139,2,1,,144204378,2153,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2387,743139,2,1,,144209573,2153,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2388,743139,2,1,,144210348,2153,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2389,743140,2,1,,144204378,2153,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2390,743140,2,1,,144209573,2153,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2391,743140,2,1,,144210348,2153,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2392,743191,3,1,,144209573,2153,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2393,743191,3,1,,144210348,2153,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2394,743191,3,1,,170466874,2153,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2395,743194,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2396,743194,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2397,743194,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2398,743199,2,1,,144209573,2153,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2399,743199,2,1,,144210348,2153,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2400,743199,2,1,,170466874,2153,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2401,743202,4,1,,144209573,2153,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2402,743202,4,1,,144210348,2153,Inconclusive,20149576.0,4780.0,68.5896,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2403,743202,4,1,,170466874,2153,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2404,743203,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2405,743203,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2406,743203,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2407,743205,1,1,,90341676,2153,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2408,743205,1,1,,90341676,2153,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2409,743206,1,1,,90341676,2153,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2410,743206,1,1,,90341676,2153,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2411,743207,1,1,,90341676,2153,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2412,743207,1,1,,90341676,2153,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2413,743209,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2414,743209,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2415,743209,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2416,743210,4,1,,144209573,2153,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2417,743210,4,1,,144210348,2153,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2418,743210,4,1,,170466874,2153,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2419,743211,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2420,743211,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2421,743211,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2422,743212,3,1,,144209573,2153,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2423,743212,3,1,,144210348,2153,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2424,743212,3,1,,170466874,2153,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2425,743213,3,1,,144209573,2153,Inconclusive,,,0.1976,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2426,743213,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2427,743213,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2428,743215,3,1,,144209573,2153,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2429,743215,3,1,,144210348,2153,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2430,743215,3,1,,170466874,2153,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2431,743217,3,1,,144209573,2153,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2432,743217,3,1,,144210348,2153,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2433,743217,3,1,,170466874,2153,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2434,743218,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2435,743218,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2436,743218,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2437,743219,3,1,,144209573,2153,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2438,743219,3,1,,144210348,2153,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2439,743219,3,1,,170466874,2153,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2440,743220,3,1,,144209573,2153,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2441,743220,3,1,,144210348,2153,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2442,743220,3,1,,170466874,2153,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2443,743221,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2444,743221,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2445,743221,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2446,743222,3,1,,144209573,2153,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2447,743222,3,1,,144210348,2153,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2448,743222,3,1,,170466874,2153,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2449,743223,3,1,,144209573,2153,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2450,743223,3,1,,144210348,2153,Inconclusive,216409708.0,7421.0,21.8724,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2451,743223,3,1,,170466874,2153,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2452,743224,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2453,743224,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2454,743224,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2455,743225,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2456,743225,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2457,743225,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2458,743226,2,1,,144209573,2153,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2459,743226,2,1,,144210348,2153,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2460,743226,2,1,,170466874,2153,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2461,743227,2,1,,144209573,2153,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2462,743227,2,1,,144210348,2153,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2463,743227,2,1,,170466874,2153,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2464,743228,3,1,,144209573,2153,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2465,743228,3,1,,144210348,2153,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2466,743228,3,1,,170466874,2153,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2467,743238,1,1,,56463437,2153,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2468,743239,2,1,,144209573,2153,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2469,743239,2,1,,144210348,2153,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2470,743239,2,1,,170466874,2153,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2471,743240,2,1,,144209573,2153,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2472,743240,2,1,,144210348,2153,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2473,743240,2,1,,170466874,2153,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2474,743241,2,1,,144209573,2153,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2475,743241,2,1,,144210348,2153,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2476,743241,2,1,,170466874,2153,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2477,743242,2,1,,144209573,2153,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2478,743242,2,1,,144210348,2153,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2479,743242,2,1,,170466874,2153,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2480,743244,1,1,,90341676,2153,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2481,743244,1,1,,144204378,2153,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2482,743247,1,2,,56463437,2153,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2483,743255,1,1,,56463437,2153,Inconclusive,118600387.0,7398.0,1.2589,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2484,743266,1,2,,56463437,2153,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2485,743268,1,1,,172080665,2153,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2486,743269,1,1,,56463437,2153,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2487,743269,1,1,,56463437,2153,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2488,743270,1,1,,172080665,2153,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2489,743271,1,1,,172080665,2153,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2490,743272,1,1,,172080665,2153,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2491,743279,1,2,,56463437,2153,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2492,743287,1,1,,56463437,2153,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2493,743288,1,1,,17389715,2153,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2494,743292,1,1,,17389715,2153,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2495,743344,1,1,,174007168,2153,Inactive,,,0.0011,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2496,743345,1,1,,174007168,2153,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2497,743346,1,1,,174007168,2153,Inactive,,,0.053,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2498,743347,1,1,,174007168,2153,Inactive,,,0.0053,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2499,743397,1,1,,56463437,2153,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2500,743398,1,1,,56463437,2153,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2501,749315,1,1,,103520217,2153,Active,,,,,Protective effect in Salmonella typhimurium TA98 assessed as decrease in ICR191-induced mutagenic effect at 0.05 to 250 ug/plate after 4 hrs by Ames test,Other,23601817.0,
2502,749318,1,1,,103520217,2153,Unspecified,,,,,Mutagenic activity in Salmonella typhimurium TA98 at 0.4 mg/plate after 4 hrs by Ames test,Other,23601817.0,
2503,763040,2,3,,103520217,2153,Active,803374855.0,140.0,22.3,Ki,Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cells after 90 mins by gamma counting analysis,Confirmatory,23200243.0,
2504,763041,2,3,,103520217,2153,Active,803374855.0,140.0,29.4,Ki,Competitive binding affinity to human adenosine A3 receptor expressed in CHO cells after 90 mins by flow cytometric analysis in presence of MRS5449,Confirmatory,23200243.0,
2505,763042,2,3,,103520217,2153,Active,543740.0,135.0,1.7,Ki,Displacement of [3H]CGS21680 from human adenosine A2A receptor expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,Confirmatory,23200243.0,
2506,763043,2,3,,103520217,2153,Active,543740.0,135.0,2.03,Ki,Competitive binding affinity to human adenosine A2A receptor expressed in HEK293 cells after 60 mins by fluorescence polarization assay in presence of MRS5346,Confirmatory,23200243.0,
2507,858652,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 428/13,Other,,
2508,858653,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 428/13,Other,,
2509,858654,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 428/13,Other,,
2510,858655,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 428/14,Other,,
2511,858656,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 428/14,Other,,
2512,858657,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 428/14,Other,,
2513,858658,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 428/14,Other,,
2514,858659,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 428/14,Other,,
2515,858660,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 428/14,Other,,
2516,858661,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 428/14,Other,,
2517,858662,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 428/14,Other,,
2518,858663,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 428/14,Other,,
2519,858664,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 428/14,Other,,
2520,858665,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 428/14,Other,,
2521,858666,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 428/14,Other,,
2522,858667,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 428/14,Other,,
2523,858668,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 428/14,Other,,
2524,858669,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 428/14,Other,,
2525,858670,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 428/14,Other,,
2526,858671,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 428/14,Other,,
2527,858672,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 428/14,Other,,
2528,858673,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 428/14,Other,,
2529,858674,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 428/14,Other,,
2530,858675,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 428/14,Other,,
2531,858676,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 428/15,Other,,
2532,858677,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 428/15,Other,,
2533,858678,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 428/15,Other,,
2534,858679,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 428/15,Other,,
2535,858680,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 428/15,Other,,
2536,858681,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 428/15,Other,,
2537,858682,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 428/15,Other,,
2538,858683,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 428/15,Other,,
2539,858684,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 428/15,Other,,
2540,858685,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 428/15,Other,,
2541,858686,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 428/15,Other,,
2542,858687,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 428/15,Other,,
2543,858688,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 428/15,Other,,
2544,858689,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 428/15,Other,,
2545,858690,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 428/15,Other,,
2546,858691,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 428/15,Other,,
2547,858692,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 428/15,Other,,
2548,858693,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 428/15,Other,,
2549,858694,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 428/15,Other,,
2550,860022,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 427/9,Other,,
2551,860023,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 427/9,Other,,
2552,860024,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 427/9,Other,,
2553,860025,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 427/10,Other,,
2554,860026,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 427/10,Other,,
2555,860027,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 427/10,Other,,
2556,860028,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 427/10,Other,,
2557,860029,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 427/10,Other,,
2558,860030,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 427/10,Other,,
2559,860031,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 427/10,Other,,
2560,860032,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 427/10,Other,,
2561,860033,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 427/10,Other,,
2562,860034,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 427/10,Other,,
2563,860035,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 427/10,Other,,
2564,860036,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 427/10,Other,,
2565,860037,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 427/10,Other,,
2566,860038,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 427/10,Other,,
2567,860039,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 427/10,Other,,
2568,860040,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 427/10,Other,,
2569,860041,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 427/10,Other,,
2570,860042,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 427/10,Other,,
2571,860043,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 427/10,Other,,
2572,928465,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020429,Other,,
2573,928466,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020429,Other,,
2574,928467,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020429,Other,,
2575,928468,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020429,Other,,
2576,928469,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020429,Other,,
2577,928470,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020429,Other,,
2578,928471,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020429,Other,,
2579,928472,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020429,Other,,
2580,928473,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020429,Other,,
2581,928474,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020429",Other,,
2582,928475,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020429,Other,,
2583,928476,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020429,Other,,
2584,928477,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020429,Other,,
2585,928478,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020429,Other,,
2586,928479,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020429,Other,,
2587,928480,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020429,Other,,
2588,928481,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020429,Other,,
2589,928482,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020429,Other,,
2590,928483,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020429,Other,,
2591,937487,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020429,Other,,
2592,937488,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020429,Other,,
2593,937489,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020429,Other,,
2594,937490,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020429,Other,,
2595,937491,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020429",Other,,
2596,937492,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020429,Other,,
2597,937493,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020429,Other,,
2598,937494,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020429,Other,,
2599,937495,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020429,Other,,
2600,937496,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020429,Other,,
2601,937497,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020429,Other,,
2602,937498,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020429,Other,,
2603,937499,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020429,Other,,
2604,937500,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020429,Other,,
2605,937501,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020429,Other,,
2606,937502,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020429,Other,,
2607,937503,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020429,Other,,
2608,938134,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020429,Other,,
2609,938135,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020429,Other,,
2610,965523,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020429,Other,,
2611,965524,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020429,Other,,
2612,965525,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020429,Other,,
2613,965526,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020429,Other,,
2614,965527,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020429,Other,,
2615,965528,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020429,Other,,
2616,965529,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020429,Other,,
2617,965530,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020429,Other,,
2618,965531,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020429,Other,,
2619,965532,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020429,Other,,
2620,965533,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020429,Other,,
2621,965534,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020429,Other,,
2622,965535,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020429,Other,,
2623,965536,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020429,Other,,
2624,965537,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020429,Other,,
2625,965538,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020429,Other,,
2626,965539,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020429,Other,,
2627,965540,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020429,Other,,
2628,965541,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020429,Other,,
2629,967334,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020429,Other,,
2630,967335,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020429,Other,,
2631,967336,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020429,Other,,
2632,967337,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020429,Other,,
2633,967338,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020429,Other,,
2634,967339,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020429,Other,,
2635,967340,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020429,Other,,
2636,967341,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020429,Other,,
2637,967342,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020429,Other,,
2638,967343,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020429,Other,,
2639,967344,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020429,Other,,
2640,967345,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020429,Other,,
2641,967346,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020429,Other,,
2642,967347,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020429,Other,,
2643,967978,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020429,Other,,
2644,967979,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020429,Other,,
2645,967980,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020429,Other,,
2646,967981,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020429,Other,,
2647,967982,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020429,Other,,
2648,977599,1,1,,103520217,2153,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2649,977602,1,2,,103520217,2153,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2650,977608,3,1,,46393768,2153,Active,78101195.0,,1500.0,IC50,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Other,,
2651,977610,3,1,,170484968,2153,Active,385867924.0,,50.0,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,22879864.0,
2652,1026100,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020429",Other,,
2653,1026101,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020429",Other,,
2654,1026102,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020429",Other,,
2655,1026103,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020429,Other,,
2656,1026104,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020429,Other,,
2657,1026105,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020429",Other,,
2658,1026106,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020429",Other,,
2659,1026689,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020429",Other,,
2660,1026690,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020429,Other,,
2661,1026691,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020429",Other,,
2662,1026692,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020429",Other,,
2663,1026693,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020429",Other,,
2664,1026694,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020429",Other,,
2665,1026695,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020429,Other,,
2666,1026696,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020429",Other,,
2667,1026697,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020429",Other,,
2668,1026698,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020429",Other,,
2669,1026699,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020429",Other,,
2670,1026700,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020429",Other,,
2671,1026701,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020429",Other,,
2672,1026702,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020429",Other,,
2673,1026703,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020429",Other,,
2674,1026704,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020429,Other,,
2675,1026705,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020429",Other,,
2676,1026706,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020429",Other,,
2677,1026707,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020429",Other,,
2678,1026708,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020429,Other,,
2679,1026709,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020429",Other,,
2680,1026710,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020429",Other,,
2681,1026711,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020429",Other,,
2682,1026712,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020429",Other,,
2683,1026713,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020429",Other,,
2684,1026714,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020429",Other,,
2685,1028548,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020429",Other,,
2686,1028549,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020429",Other,,
2687,1028550,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020429",Other,,
2688,1028551,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020429",Other,,
2689,1028552,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020429",Other,,
2690,1028553,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020429",Other,,
2691,1028554,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020429,Other,,
2692,1028555,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020429",Other,,
2693,1029141,1,3,,103520217,2153,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020429,Other,,
2694,1029142,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020429",Other,,
2695,1029143,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020429",Other,,
2696,1029144,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020429",Other,,
2697,1029145,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020429",Other,,
2698,1029146,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020429",Other,,
2699,1029147,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020429",Other,,
2700,1029148,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020429",Other,,
2701,1029149,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020429",Other,,
2702,1029150,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020429",Other,,
2703,1029151,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020429",Other,,
2704,1029152,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020429",Other,,
2705,1029153,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020429",Other,,
2706,1029154,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020429",Other,,
2707,1029155,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020429",Other,,
2708,1029156,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020429",Other,,
2709,1029157,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020429",Other,,
2710,1029158,1,3,,103520217,2153,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020429",Other,,
2711,1035920,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/9,Other,,
2712,1035921,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/10,Other,,
2713,1035922,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/10,Other,,
2714,1035923,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/10,Other,,
2715,1035924,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/10,Other,,
2716,1035925,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/10,Other,,
2717,1035926,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/11,Other,,
2718,1035927,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/11,Other,,
2719,1035928,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/11,Other,,
2720,1035929,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/11,Other,,
2721,1035930,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/11,Other,,
2722,1035931,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/12,Other,,
2723,1035932,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/12,Other,,
2724,1035933,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/12,Other,,
2725,1035934,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/12,Other,,
2726,1035935,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/12,Other,,
2727,1035936,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/13,Other,,
2728,1035937,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/13,Other,,
2729,1035938,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/13,Other,,
2730,1035939,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/13,Other,,
2731,1035940,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/13,Other,,
2732,1035941,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/14,Other,,
2733,1035942,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/14,Other,,
2734,1035943,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/14,Other,,
2735,1035944,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/14,Other,,
2736,1035945,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/14,Other,,
2737,1035946,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/15,Other,,
2738,1035947,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/15,Other,,
2739,1035948,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/15,Other,,
2740,1035949,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/15,Other,,
2741,1035950,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/15,Other,,
2742,1035951,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/16,Other,,
2743,1035952,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/16,Other,,
2744,1035953,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/16,Other,,
2745,1036006,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/5,Other,,
2746,1036007,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/5,Other,,
2747,1036675,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/5,Other,,
2748,1036676,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/5,Other,,
2749,1036677,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/5,Other,,
2750,1036678,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/6,Other,,
2751,1036679,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/6,Other,,
2752,1036680,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/6,Other,,
2753,1036681,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/6,Other,,
2754,1036682,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/6,Other,,
2755,1036683,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/7,Other,,
2756,1036684,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/7,Other,,
2757,1036685,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/7,Other,,
2758,1036686,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/7,Other,,
2759,1036687,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/7,Other,,
2760,1036688,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/8,Other,,
2761,1036689,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/8,Other,,
2762,1036690,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/8,Other,,
2763,1036691,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/8,Other,,
2764,1036692,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/8,Other,,
2765,1036693,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/9,Other,,
2766,1036694,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/9,Other,,
2767,1036695,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/9,Other,,
2768,1036696,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/9,Other,,
2769,1036697,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/9,Other,,
2770,1039712,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/16,Other,,
2771,1039713,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/16,Other,,
2772,1041624,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/10,Other,,
2773,1041625,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/10,Other,,
2774,1041626,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/10,Other,,
2775,1041627,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/10,Other,,
2776,1041628,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/10,Other,,
2777,1041629,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/11,Other,,
2778,1041630,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/11,Other,,
2779,1041631,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/11,Other,,
2780,1041632,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/11,Other,,
2781,1041633,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/11,Other,,
2782,1041634,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/12,Other,,
2783,1041635,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/12,Other,,
2784,1041636,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/12,Other,,
2785,1041637,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/12,Other,,
2786,1041638,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/12,Other,,
2787,1041639,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/13,Other,,
2788,1041640,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/13,Other,,
2789,1041641,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/13,Other,,
2790,1041642,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/13,Other,,
2791,1041643,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/13,Other,,
2792,1041644,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/14,Other,,
2793,1041645,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/14,Other,,
2794,1041646,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/14,Other,,
2795,1041647,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/14,Other,,
2796,1041648,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/14,Other,,
2797,1041649,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/15,Other,,
2798,1041650,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/15,Other,,
2799,1041651,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/15,Other,,
2800,1041652,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/15,Other,,
2801,1041653,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/15,Other,,
2802,1041654,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 427/16,Other,,
2803,1041655,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 427/16,Other,,
2804,1041656,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 427/16,Other,,
2805,1041657,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 427/16,Other,,
2806,1041658,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 427/16,Other,,
2807,1041659,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/5,Other,,
2808,1041660,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/5,Other,,
2809,1041661,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/5,Other,,
2810,1041662,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/5,Other,,
2811,1041663,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/5,Other,,
2812,1041664,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/6,Other,,
2813,1042331,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/6,Other,,
2814,1042332,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/6,Other,,
2815,1042333,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/6,Other,,
2816,1042334,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/6,Other,,
2817,1042335,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/7,Other,,
2818,1042336,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/7,Other,,
2819,1046593,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/7,Other,,
2820,1046594,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/7,Other,,
2821,1046595,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/7,Other,,
2822,1046596,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/8,Other,,
2823,1046597,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/8,Other,,
2824,1046598,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/8,Other,,
2825,1046599,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/8,Other,,
2826,1046600,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 428/8,Other,,
2827,1046601,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 428/9,Other,,
2828,1046602,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 428/9,Other,,
2829,1046603,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 428/9,Other,,
2830,1046604,1,2,,103520217,2153,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 428/9,Other,,
2831,1053175,2,1,,178125809,2153,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2832,1053188,2,1,,56463313,2153,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2833,1053188,2,1,,56463437,2153,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2834,1053197,1,1,,56463437,2153,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2835,1056992,1,1,,103520217,2153,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24128814.0,
2836,1056993,1,1,,103520217,2153,Unspecified,,,,,Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA,Other,24128814.0,
2837,1057059,2,3,,103520217,2153,Active,803374855.0,140.0,22.3,Ki,Binding affinity to human adenosine A3 receptor,Confirmatory,24139167.0,
2838,1057061,2,3,,103520217,2153,Active,8928539.0,25369.0,22.0,Ki,Binding affinity to rat adenosine A2A receptor,Confirmatory,24139167.0,
2839,1057062,2,3,,103520217,2153,Active,2827766.0,29290.0,14.0,Ki,Binding affinity to rat adenosine A1 receptor,Confirmatory,24139167.0,
2840,1057063,2,3,,103520217,2153,Active,231473.0,134.0,6.77,Ki,Binding affinity to human adenosine A1 receptor,Confirmatory,24139167.0,
2841,1057066,2,3,,103520217,2153,Active,543740.0,135.0,6.7,Ki,Binding affinity to human adenosine A2A receptor,Confirmatory,24139167.0,
2842,1057072,2,3,,103520217,2153,Active,112938.0,136.0,9.07,Ki,Binding affinity to human adenosine A2B receptor,Confirmatory,24139167.0,
2843,1062096,1,1,,103520217,2153,Unspecified,,,,,Induction of melanogenesis in mouse B16F10 cells assessed as intracellular melanin level at 125 uM after 72 hrs,Other,24433966.0,
2844,1062097,1,1,,103520217,2153,Unspecified,,,,,Induction of melanogenesis in mouse B16F10 cells assessed as intracellular melanin level at 250 uM after 72 hrs,Other,24433966.0,
2845,1062098,1,1,,103520217,2153,Unspecified,,,,,Induction of melanogenesis in mouse B16F10 cells assessed as intracellular melanin level at 500 uM after 72 hrs,Other,24433966.0,
2846,1062099,1,1,,103520217,2153,Unspecified,,,,,Cytotoxicity against mouse B16F10 cells assessed as cell viability at 125 uM by MTT assay,Other,24433966.0,
2847,1062100,1,1,,103520217,2153,Unspecified,,,,,Cytotoxicity against mouse B16F10 cells assessed as cell viability at 250 uM by MTT assay,Other,24433966.0,
2848,1062101,1,1,,103520217,2153,Unspecified,,,,,Cytotoxicity against mouse B16F10 cells assessed as cell viability at 500 uM by MTT assay,Other,24433966.0,
2849,1071537,2,2,,103520217,2153,Unspecified,,,,,Bronchodilatory activity in Wistar rat trachea assessed as inhibition of carbacol-induced contraction,Other,24445313.0,
2850,1072563,1,1,,103520217,2153,Unspecified,,,,,"Bronchospasmolytic activity in histamine aerosol-induced Dunkin-Hartley guinea pig assessed as survival at 50 mg/kg, po pretreated for 1 hr followed by histamine aerosol-challenge relative to control",Other,24556147.0,
2851,1072565,1,1,,103520217,2153,Unspecified,,,,,"Bronchospasmolytic activity in histamine aerosol-induced Dunkin-Hartley guinea pig assessed as duration of jerks at 50 mg/kg, po pretreated for 1 hr followed by histamine aerosol-challenge (Rvb = 172 +/- 4 seconds)",Other,24556147.0,
2852,1072571,1,1,,103520217,2153,Unspecified,,,,,"Bronchospasmolytic activity in histamine aerosol-induced Dunkin-Hartley guinea pig assessed as time required for onset of bronchospasm at 50 mg/kg, po pretreated for 1 hr followed by histamine aerosol-challenge (Rvb = 67 +/- 2 seconds)",Other,24556147.0,
2853,1079931,1,1,,103520217,2153,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2854,1079932,1,1,,103520217,2153,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2855,1079933,1,1,,103520217,2153,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2856,1079934,1,1,,103520217,2153,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2857,1079935,1,1,,103520217,2153,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2858,1079936,1,1,,103520217,2153,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2859,1079937,1,1,,103520217,2153,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2860,1079938,1,1,,103520217,2153,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2861,1079939,1,1,,103520217,2153,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2862,1079940,1,1,,103520217,2153,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2863,1079941,1,1,,103520217,2153,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2864,1079942,1,1,,103520217,2153,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2865,1079943,1,1,,103520217,2153,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2866,1079944,1,1,,103520217,2153,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2867,1079945,1,1,,103520217,2153,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2868,1079946,1,1,,103520217,2153,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2869,1079947,1,1,,103520217,2153,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2870,1079948,1,1,,103520217,2153,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2871,1079949,1,1,,103520217,2153,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2872,1091955,1,2,,103520217,2153,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
2873,1091956,1,1,,103520217,2153,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
2874,1091957,1,1,,103520217,2153,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
2875,1091958,2,1,,103520217,2153,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
2876,1094464,1,3,,103520217,2153,Unspecified,,,,,Inhibition of Bos taurus (bovine) heart cAMP-dependent phosphodiesterase assessed as inhibition of cyclic AMP to 5' AMP after 20 min by spectrophotometry relative to theophylline,Other,,
2877,1094465,2,2,,103520217,2153,Unspecified,,,1720.0,IC50,Inhibition of Bos taurus (bovine) heart cAMP-dependent phosphodiesterase assessed as inhibition of cyclic AMP to 5' AMP after 20 min by spectrophotometry,Confirmatory,,
2878,1117298,1,2,,170466874,2153,Inactive,,,22.3872,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2879,1117304,1,2,,170466874,2153,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2880,1117305,1,2,,170466874,2153,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2881,1117310,1,1,,170466874,2153,Inactive,,,22.3872,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2882,1117312,1,1,,170466874,2153,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2883,1117314,1,1,,170466874,2153,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2884,1117319,1,2,,855679,2153,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
2885,1117319,1,2,,855679,2153,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
2886,1117326,1,1,,170466874,2153,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2887,1117329,1,1,,170466874,2153,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2888,1117336,1,1,,170466874,2153,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2889,1117340,1,1,,170466874,2153,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2890,1117341,1,1,,170466874,2153,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2891,1117342,1,1,,170466874,2153,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2892,1117343,1,1,,170466874,2153,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2893,1117346,1,1,,170466874,2153,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2894,1120058,3,2,,103520217,2153,Unspecified,1171955.0,5291.0,800.0,IC50,Inhibition of PI3Kbeta (unknown origin),Confirmatory,,
2895,1120059,3,2,,103520217,2153,Unspecified,126302584.0,5290.0,300.0,IC50,Inhibition of PI3Kalpha (unknown origin),Confirmatory,,
2896,1120060,3,2,,103520217,2153,Unspecified,92090623.0,5294.0,800.0,IC50,Inhibition of PI3Kgamma (unknown origin),Confirmatory,,
2897,1120065,3,2,,103520217,2153,Unspecified,67477424.0,5293.0,75.0,IC50,Inhibition of PI3Kdelta (unknown origin),Confirmatory,,
2898,1134134,1,1,,103520217,2153,Unspecified,,,,,"Inhibition of Mongrel dog ventricular muscle cAMP phosphodiesterase using adenosine 3',5' monophosphate as substrate at 100 uM by scintillation counting analysis in presence of [8-14C]adenosine relative to control",Other,85712.0,
2899,1134136,1,1,,103520217,2153,Unspecified,,,,,Antiallergic activity in antiovalbumin serum sensitized guinea pig lung slices assessed as inhibition of ovalbumin-induced histamine release at 1.5 mM preincubated for 5 mins followed by ovalbumin challenge measured after 15 mins by fluorometric analysis relative to control,Other,85712.0,
2900,1136025,1,1,,103520217,2153,Unspecified,,,515.0,IC50,Inhibition of beef heart PDE assessed as cyclic AMP level,Confirmatory,229222.0,
2901,1136026,1,1,,103520217,2153,Unspecified,,,1475.0,IC50,Inhibition of guinea pig lung PDE assessed as cyclic AMP level,Confirmatory,229222.0,
2902,1136029,1,1,,103520217,2153,Unspecified,,,,,Stimulation of guinea pig lung adenylate cyclase activity at 1 x 10'-3 M after 15 mins relative to control,Other,229222.0,
2903,1138021,1,3,,103520217,2153,Inconclusive,112938.0,136.0,,Ki,Inhibition of human recombinant adenosine receptor A2b,Confirmatory,24164628.0,
2904,1138025,1,3,,103520217,2153,Inconclusive,803374855.0,140.0,,Ki,Inhibition of human recombinant adenosine A3 receptor,Confirmatory,24164628.0,
2905,1138031,1,3,,103520217,2153,Active,8928539.0,25369.0,25.0,Ki,Inhibition of rat recombinant adenosine receptor A2a,Confirmatory,24164628.0,
2906,1138032,1,3,,103520217,2153,Active,2827766.0,29290.0,8.5,Ki,Inhibition of rat recombinant adenosine A1 receptor,Confirmatory,24164628.0,
2907,1138893,1,1,,103520217,2153,Unspecified,,,,,Antiasthamic activity in Wistar rat tracheal ring assessed as reversal of carbachol-induced contraction at 0.1 to 500 uM relative to control,Other,24681028.0,
2908,1138894,1,1,,103520217,2153,Unspecified,,,144.0,EC50,Antiasthamic activity in Wistar rat tracheal ring assessed as reversal of carbachol-induced contraction,Confirmatory,24681028.0,
2909,1145606,2,1,,103520217,2153,Unspecified,,,,,"Octanol-aqueous phase partition coefficient, log P of the compound",Other,13215.0,
2910,1145607,1,1,,103520217,2153,Unspecified,,,,,"Octanol-aqueous phase distribution coefficient, log D of the compound",Other,13215.0,
2911,1145612,1,1,,103520217,2153,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 5.3",Other,13215.0,
2912,1145613,1,2,,103520217,2153,Unspecified,,,,,Drug absorption in rat small intestine,Other,13215.0,
2913,1154017,1,1,,103520217,2153,Unspecified,,,,,Intracellular melanogenesis-stimulating activity in mouse B16F0 cells at 500 uM after 72 hrs by spectrophotometry relative to control,Other,24853321.0,
2914,1154018,1,1,,103520217,2153,Unspecified,,,,,Intracellular melanogenesis-stimulating activity in mouse B16F0 cells at 250 uM after 72 hrs by spectrophotometry relative to control,Other,24853321.0,
2915,1154019,1,1,,103520217,2153,Unspecified,,,,,Intracellular melanogenesis-stimulating activity in mouse B16F0 cells at 125 uM after 72 hrs by spectrophotometry relative to control,Other,24853321.0,
2916,1154020,1,1,,103520217,2153,Unspecified,,,,,Extracellular melanogenesis-stimulating activity in mouse B16F0 cells at 500 uM after 72 hrs by spectrophotometry relative to control,Other,24853321.0,
2917,1154021,1,1,,103520217,2153,Unspecified,,,,,Extracellular melanogenesis-stimulating activity in mouse B16F0 cells at 250 uM after 72 hrs by spectrophotometry relative to control,Other,24853321.0,
2918,1154022,1,1,,103520217,2153,Unspecified,,,,,Extracellular melanogenesis-stimulating activity in mouse B16F0 cells at 125 uM after 72 hrs by spectrophotometry relative to control,Other,24853321.0,
2919,1154023,1,1,,103520217,2153,Unspecified,,,,,Cytotoxicity against mouse B16F0 cells assessed as cell viability at 500 uM after 72 hrs by MTT assay,Other,24853321.0,
2920,1154024,1,1,,103520217,2153,Unspecified,,,,,Cytotoxicity against mouse B16F0 cells assessed as cell viability at 250 uM after 72 hrs by MTT assay,Other,24853321.0,
2921,1154025,1,1,,103520217,2153,Unspecified,,,,,Cytotoxicity against mouse B16F0 cells assessed as cell viability at 125 uM after 72 hrs by MTT assay,Other,24853321.0,
2922,1159387,1,2,,103520217,2153,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
2923,1159389,1,2,,103520217,2153,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2924,1159390,1,2,,103520217,2153,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2925,1159391,1,2,,103520217,2153,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2926,1159394,1,2,,103520217,2153,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
2927,1159395,1,2,,103520217,2153,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
2928,1159396,1,2,,103520217,2153,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
2929,1159399,1,2,,103520217,2153,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
2930,1159509,1,1,,144209573,2153,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2931,1159509,1,1,,144210348,2153,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2932,1159509,1,1,,170466874,2153,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2933,1159515,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2934,1159515,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2935,1159515,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2936,1159516,1,1,,144209573,2153,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2937,1159516,1,1,,144210348,2153,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2938,1159516,1,1,,170466874,2153,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2939,1159517,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2940,1159517,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2941,1159517,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2942,1159518,1,1,,144209573,2153,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2943,1159518,1,1,,144210348,2153,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2944,1159518,1,1,,170466874,2153,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2945,1159519,1,1,,144209573,2153,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2946,1159519,1,1,,144210348,2153,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2947,1159519,1,1,,170466874,2153,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2948,1159520,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2949,1159520,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2950,1159520,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2951,1159521,1,1,,144209573,2153,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2952,1159521,1,1,,144210348,2153,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2953,1159521,1,1,,170466874,2153,Inactive,15928672.0,19885.0,0.8413,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2954,1159523,1,1,,144209573,2153,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2955,1159523,1,1,,144210348,2153,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2956,1159523,1,1,,170466874,2153,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2957,1159524,1,1,,56463437,2153,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2958,1159524,1,1,,124883291,2153,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2959,1159524,1,1,,124883295,2153,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2960,1159524,1,1,,124883296,2153,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2961,1159524,1,1,,124883297,2153,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2962,1159525,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2963,1159525,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2964,1159525,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2965,1159526,1,1,,144209573,2153,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2966,1159526,1,1,,144210348,2153,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2967,1159526,1,1,,170466874,2153,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2968,1159527,1,1,,144209573,2153,Inconclusive,325495497.0,6256.0,27.9067,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2969,1159527,1,1,,144210348,2153,Active,325495497.0,6256.0,13.8006,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2970,1159527,1,1,,170466874,2153,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2971,1159528,1,1,,144209573,2153,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2972,1159528,1,1,,144210348,2153,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2973,1159528,1,1,,170466874,2153,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2974,1159529,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2975,1159529,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2976,1159529,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2977,1159531,1,1,,144209573,2153,Active,325495497.0,6256.0,22.1671,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2978,1159531,1,1,,144210348,2153,Active,325495497.0,6256.0,8.70756,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2979,1159531,1,1,,170466874,2153,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2980,1159550,3,1,,252402705,2153,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2981,1159551,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2982,1159551,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2983,1159551,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2984,1159552,1,1,,144209573,2153,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2985,1159552,1,1,,144210348,2153,Inconclusive,325495463.0,5914.0,21.6899,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2986,1159552,1,1,,170466874,2153,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2987,1159553,2,1,,144209573,2153,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2988,1159553,2,1,,144210348,2153,Inconclusive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2989,1159553,2,1,,170466874,2153,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2990,1159555,1,1,,144209573,2153,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2991,1159555,1,1,,144210348,2153,Active,325495463.0,5914.0,40.0798,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2992,1159555,1,1,,170466874,2153,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2993,1159580,2,1,,268734495,2153,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2994,1159583,2,1,,178125809,2153,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
2995,1159606,1,1,,56463437,2153,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2996,1159607,2,1,,312309851,2153,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2997,1159614,1,2,,170466874,2153,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2998,1159620,1,1,,103520217,2153,Active,,,,,Summary of drug indications.,Other,,
2999,1160935,1,1,,103520217,2153,Unspecified,,,,,"Partition coefficient, log D of the compound at pH 7.4",Other,25148516.0,
3000,1165276,1,1,,103520217,2153,Unspecified,,,,,Permeability at pH 7.4 by PAMPA assay,Other,25244572.0,
3001,1167550,1,1,,103520217,2153,Unspecified,,,,,Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay,Other,25282266.0,
3002,1174877,1,2,,103520217,2153,Active,,,19.9,IC50,Bronchodialatory activity in guinea pig trachea assessed as reduction of histamine-induced contracture,Confirmatory,25462283.0,
3003,1185177,1,2,,103520217,2153,Unspecified,92090623.0,5294.0,2904.0,IC50,Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Confirmatory,25050878.0,
3004,1192730,1,1,,103520217,2153,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25614117.0,
3005,1192731,1,1,,103520217,2153,Unspecified,,,,,Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA,Other,25614117.0,
3006,1193161,1,1,,103520217,2153,Unspecified,,,,,Permeability of the compound by PAMPA-BBB assay,Other,25707322.0,
3007,1195137,1,1,,103520217,2153,Unspecified,,,,,Permeability of the compound in DMSO/Prisma HT buffer at 1:200 ratio after 2 hrs by PAMPA-BBB assay,Other,25868744.0,
3008,1199865,1,2,,103520217,2153,Inactive,118495.0,216.0,,,Inhibition of recombinant human ALDH1A1 using propionaldehyde as substrate at 100 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis relative to control,Other,25634381.0,
3009,1199871,1,2,,103520217,2153,Inactive,118504.0,217.0,,,Inhibition of recombinant human ALDH2 using propionaldehyde as substrate at 100 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis,Other,25634381.0,
3010,1199875,1,2,,103520217,2153,Inactive,311033473.0,218.0,,,Inhibition of recombinant human ALDH3A1 using benzaldehyde as substrate at 100 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis,Other,25634381.0,
3011,1199883,1,2,,103520217,2153,Inactive,118495.0,216.0,,,Effect on recombinant human ALDH1A1 using propionaldehyde as substrate up to 250 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis,Other,25634381.0,
3012,1199898,1,2,,103520217,2153,Inactive,52788258.0,220.0,,,Inhibition of recombinant human ALDH1A3 using propionaldehyde as substrate at 100 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis,Other,25634381.0,
3013,1199899,1,2,,103520217,2153,Inactive,90109797.0,8854.0,,,Inhibition of recombinant human ALDH1A2 using propionaldehyde as substrate at 100 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis,Other,25634381.0,
3014,1199900,1,2,,103520217,2153,Inactive,311033472.0,219.0,,,Inhibition of recombinant human ALDH1B1 using propionaldehyde as substrate at 100 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis,Other,25634381.0,
3015,1201374,1,1,,103520217,2153,Unspecified,,,,,In vitro blood-brain barrier permeability at pH 7.4 by UV detection and HPLC based PAMPA method,Other,25768702.0,
3016,1201375,1,2,,103520217,2153,Unspecified,,,,,In vitro blood-brain barrier permeability by PAMPA method,Other,25768702.0,
3017,1201383,1,1,,103520217,2153,Unspecified,,,,,Retention time of the compound by HPLC-UV method,Other,25768702.0,
3018,1211791,1,1,,103520217,2153,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
3019,1211792,1,1,,103520217,2153,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
3020,1211794,1,2,,103520217,2153,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
3021,1211795,1,1,,103520217,2153,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
3022,1211797,1,1,,103520217,2153,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
3023,1211798,1,1,,103520217,2153,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
3024,1223488,1,1,,103520217,2153,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
3025,1223490,1,1,,103520217,2153,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
3026,1224824,1,1,,174007168,2153,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3027,1224825,1,1,,174007168,2153,Inactive,,,18.6548,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3028,1224834,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3029,1224834,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3030,1224834,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3031,1224835,1,1,,144209573,2153,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3032,1224835,1,1,,144210348,2153,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3033,1224835,1,1,,170466874,2153,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3034,1224836,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3035,1224836,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3036,1224836,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3037,1224837,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3038,1224837,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3039,1224837,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3040,1224838,1,1,,144209573,2153,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3041,1224838,1,1,,144210348,2153,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3042,1224838,1,1,,170466874,2153,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3043,1224839,1,1,,144209573,2153,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3044,1224839,1,1,,144210348,2153,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3045,1224839,1,1,,170466874,2153,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3046,1224840,3,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3047,1224840,3,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3048,1224840,3,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3049,1224841,3,1,,144209573,2153,Inconclusive,325495545.0,2101.0,0.2466,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3050,1224841,3,1,,144210348,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3051,1224841,3,1,,170466874,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3052,1224842,3,1,,144209573,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3053,1224842,3,1,,144210348,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3054,1224842,3,1,,170466874,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3055,1224843,1,1,,144209573,2153,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3056,1224843,1,1,,144210348,2153,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3057,1224843,1,1,,170466874,2153,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3058,1224844,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3059,1224844,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3060,1224844,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3061,1224845,1,1,,144209573,2153,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3062,1224845,1,1,,144210348,2153,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3063,1224845,1,1,,170466874,2153,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3064,1224846,1,1,,144209573,2153,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3065,1224846,1,1,,144210348,2153,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3066,1224846,1,1,,170466874,2153,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3067,1224847,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3068,1224847,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3069,1224847,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3070,1224848,3,1,,144209573,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3071,1224848,3,1,,144210348,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3072,1224848,3,1,,170466874,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3073,1224849,3,1,,144209573,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3074,1224849,3,1,,144210348,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3075,1224849,3,1,,170466874,2153,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3076,1224857,2,1,,170466874,2153,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3077,1224857,2,1,,174007168,2153,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3078,1224859,2,1,,90341676,2153,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3079,1224859,2,1,,170466874,2153,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3080,1224859,2,1,,174007168,2153,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3081,1224863,1,1,,176484010,2153,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3082,1224863,1,1,,176485067,2153,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3083,1224863,1,1,,176485089,2153,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3084,1224863,1,1,,316919902,2153,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3085,1224863,1,1,,316920517,2153,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3086,1224864,1,2,,316933619,2153,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3087,1224865,1,2,,56463437,2153,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3088,1224867,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3089,1224867,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3090,1224867,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3091,1224868,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3092,1224868,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3093,1224868,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3094,1224869,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3095,1224869,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3096,1224869,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3097,1224870,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3098,1224870,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3099,1224870,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3100,1224871,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3101,1224871,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3102,1224871,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3103,1224872,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3104,1224872,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3105,1224872,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3106,1224873,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3107,1224873,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3108,1224873,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3109,1224874,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3110,1224874,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3111,1224874,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3112,1224875,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3113,1224875,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3114,1224875,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3115,1224876,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3116,1224876,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3117,1224876,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3118,1224877,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3119,1224877,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3120,1224877,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3121,1224878,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3122,1224878,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3123,1224878,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3124,1224879,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3125,1224879,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3126,1224879,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3127,1224880,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3128,1224880,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3129,1224880,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3130,1224881,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3131,1224881,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3132,1224881,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3133,1224882,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3134,1224882,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3135,1224882,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3136,1224883,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3137,1224883,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3138,1224883,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3139,1224884,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3140,1224884,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3141,1224884,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3142,1224885,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3143,1224885,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3144,1224885,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3145,1224886,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3146,1224886,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3147,1224886,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3148,1224887,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3149,1224887,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3150,1224887,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3151,1224888,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3152,1224888,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3153,1224888,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3154,1224889,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3155,1224889,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3156,1224889,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3157,1224890,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3158,1224890,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3159,1224890,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3160,1224892,1,1,,144209573,2153,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3161,1224892,1,1,,144210348,2153,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3162,1224892,1,1,,170466874,2153,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3163,1224893,1,1,,144209573,2153,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3164,1224893,1,1,,144210348,2153,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3165,1224893,1,1,,170466874,2153,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3166,1224894,1,1,,144209573,2153,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3167,1224894,1,1,,144210348,2153,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3168,1224894,1,1,,170466874,2153,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3169,1224895,1,1,,144209573,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3170,1224895,1,1,,144210348,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3171,1224895,1,1,,170466874,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3172,1224896,1,1,,144209573,2153,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3173,1224896,1,1,,144210348,2153,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3174,1224896,1,1,,170466874,2153,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3175,1224905,2,1,,92308682,2153,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3176,1224905,2,1,,92308682,2153,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3177,1259241,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3178,1259241,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3179,1259241,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3180,1259242,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3181,1259242,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3182,1259242,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3183,1259243,1,1,,144209573,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3184,1259243,1,1,,144210348,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3185,1259243,1,1,,170466874,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3186,1259244,1,1,,144209573,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3187,1259244,1,1,,144210348,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3188,1259244,1,1,,170466874,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3189,1259247,1,1,,144209573,2153,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3190,1259247,1,1,,144210348,2153,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3191,1259247,1,1,,170466874,2153,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3192,1259248,1,1,,144209573,2153,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3193,1259248,1,1,,144210348,2153,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3194,1259248,1,1,,170466874,2153,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3195,1259252,1,1,,174007168,2153,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3196,1259253,1,1,,174007168,2153,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3197,1259255,1,1,,174007168,2153,Inconclusive,169655958.0,,13.2066,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3198,1259256,1,1,,174007168,2153,Inconclusive,169655958.0,,29.5659,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3199,1259309,1,1,,178125809,2153,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3200,1259310,1,1,,104170040,2153,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3201,1259310,1,1,,321941853,2153,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3202,1259310,1,1,,332949783,2153,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3203,1259310,1,1,,332949844,2153,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3204,1259311,1,1,,178125809,2153,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3205,1259313,1,1,,56463437,2153,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3206,1259318,1,1,,56463437,2153,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3207,1259325,1,2,,336954222,2153,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3208,1259344,1,1,,144204378,2153,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3209,1259355,1,1,,29215004,2153,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3210,1259356,1,1,,144204378,2153,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3211,1259364,1,1,,144209573,2153,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3212,1259364,1,1,,144210348,2153,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3213,1259364,1,1,,170466874,2153,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3214,1259365,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3215,1259365,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3216,1259365,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3217,1259366,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3218,1259366,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3219,1259366,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3220,1259367,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3221,1259367,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3222,1259367,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3223,1259368,1,1,,144209573,2153,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3224,1259368,1,1,,144210348,2153,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3225,1259368,1,1,,170466874,2153,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3226,1259369,1,1,,144209573,2153,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3227,1259369,1,1,,144210348,2153,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3228,1259369,1,1,,170466874,2153,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3229,1259370,2,2,,124618217,2153,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3230,1259370,2,2,,124618217,2153,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3231,1259370,2,2,,124618217,2153,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3232,1259377,1,1,,144209573,2153,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3233,1259377,1,1,,144210348,2153,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3234,1259377,1,1,,170466874,2153,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3235,1259378,1,1,,144209573,2153,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3236,1259378,1,1,,144210348,2153,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3237,1259378,1,1,,170466874,2153,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3238,1259379,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3239,1259379,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3240,1259379,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3241,1259380,1,1,,144209573,2153,Inconclusive,,,77.9774,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3242,1259380,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3243,1259380,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3244,1259381,1,1,,144209573,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3245,1259381,1,1,,144210348,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3246,1259381,1,1,,170466874,2153,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3247,1259382,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3248,1259382,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3249,1259382,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3250,1259383,1,1,,144209573,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3251,1259383,1,1,,144210348,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3252,1259383,1,1,,170466874,2153,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3253,1259384,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3254,1259384,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3255,1259384,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3256,1259385,1,1,,144209573,2153,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3257,1259385,1,1,,144210348,2153,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3258,1259385,1,1,,170466874,2153,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3259,1259386,1,1,,144209573,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3260,1259386,1,1,,144210348,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3261,1259386,1,1,,170466874,2153,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3262,1259387,1,1,,144209573,2153,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3263,1259387,1,1,,144210348,2153,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3264,1259387,1,1,,170466874,2153,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3265,1259388,1,1,,144209573,2153,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3266,1259388,1,1,,144210348,2153,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3267,1259388,1,1,,170466874,2153,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3268,1259389,1,1,,124618217,2153,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3269,1259390,1,1,,144209573,2153,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3270,1259390,1,1,,144210348,2153,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3271,1259390,1,1,,170466874,2153,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3272,1259391,1,1,,144209573,2153,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3273,1259391,1,1,,144210348,2153,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3274,1259391,1,1,,170466874,2153,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3275,1259392,1,1,,144209573,2153,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3276,1259392,1,1,,144210348,2153,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3277,1259392,1,1,,170466874,2153,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3278,1259393,1,1,,144209573,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3279,1259393,1,1,,144210348,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3280,1259393,1,1,,170466874,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3281,1259394,1,1,,144209573,2153,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3282,1259394,1,1,,144210348,2153,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3283,1259394,1,1,,170466874,2153,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3284,1259395,1,1,,144209573,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3285,1259395,1,1,,144210348,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3286,1259395,1,1,,170466874,2153,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3287,1259396,1,1,,144209573,2153,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3288,1259396,1,1,,144210348,2153,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3289,1259396,1,1,,170466874,2153,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3290,1259400,1,1,,124883301,2153,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3291,1259401,1,1,,144209573,2153,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3292,1259401,1,1,,144210348,2153,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3293,1259401,1,1,,170466874,2153,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3294,1259402,1,1,,144209573,2153,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3295,1259402,1,1,,144210348,2153,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3296,1259402,1,1,,170466874,2153,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3297,1259403,1,1,,144209573,2153,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3298,1259403,1,1,,144210348,2153,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3299,1259403,1,1,,170466874,2153,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3300,1259404,1,1,,144209573,2153,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3301,1259404,1,1,,144210348,2153,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3302,1259404,1,1,,170466874,2153,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3303,1259406,1,1,,363920467,2153,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3304,1259406,1,1,1.0,363920467,2153,Inactive,26638650.0,3778.0,0.0320503,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3305,1259406,1,1,2.0,363920467,2153,Inactive,4758626.0,3779.0,0.00494012,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3306,1259406,1,1,3.0,363920467,2153,Inactive,5031823.0,10242.0,-0.0513563,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3307,1259406,1,1,4.0,363920467,2153,Inactive,26051275.0,27345.0,-0.00643857,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3308,1259406,1,1,5.0,363920467,2153,Inactive,160410009.0,389816.0,-0.0340527,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3309,1259406,1,1,6.0,363920467,2153,Inactive,26638650.0,3778.0,0.000906728,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3310,1259406,1,1,7.0,363920467,2153,Inactive,4758626.0,3779.0,0.0502947,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3311,1259406,1,1,8.0,363920467,2153,Inactive,5031823.0,10242.0,-0.00244762,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3312,1259406,1,1,9.0,363920467,2153,Inactive,26051275.0,27345.0,0.0293716,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3313,1259406,1,1,10.0,363920467,2153,Inactive,5031823.0,10242.0,0.055397400000000006,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3314,1259407,1,1,,363902679,2153,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3315,1259408,1,1,,363894881,2153,Active,,,,,GENE-TOX mutagenicity studies,Other,,
3316,1259409,1,1,,363902679,2153,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
3317,1259411,1,1,,363902679,2153,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
3318,1259413,1,2,,104170040,2153,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3319,1259415,1,1,,56463437,2153,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3320,1259416,1,2,,56463313,2153,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3321,1259416,1,2,,340079484,2153,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3322,1259416,1,2,,340079486,2153,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3323,1259416,1,2,,375178319,2153,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3324,1259421,1,1,,340079484,2153,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3325,1259421,1,1,,340079486,2153,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3326,1259421,1,1,,375178319,2153,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3327,1259423,1,2,,354771554,2153,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3328,1259423,1,2,,354810039,2153,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3329,1259423,1,2,,354863073,2153,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3330,1259423,1,2,,354935070,2153,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3331,1259423,1,2,,354948943,2153,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3332,1259423,1,2,,354993196,2153,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
